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Abstract 
This thesis concerns the synthesis and characterisation of arene, Cp* and 
functionalised Cp* complexes of ruthenium for their use as transfer hydrogenation 
catalysts and anticancer agents. As catalysts, the compounds have been tested, 
principally, against the redox neutral alkylation of tert-butylamine with phenethyl 
alcohol and the reduction of benzaldehyde. As anticancer agents, the compounds 
have been tested in vitro against the cell lines HT-29 and A2780. 
 
Chapter 1 is a review of transfer hydrogenations using ruthenium, iridium and 
rhodium complexes, immobilisation alternatives and research into metal-containing 
anticancer drugs. 
Chapter 2 describes the synthesis and characterisation of functionalised η6-arene 
complexes of ruthenium and a brief investigation into their immobilisation 
possibilities. 
Chapter 3 describes the synthesis and characterisation of pyridine-containing p-
cymene complexes of ruthenium. 
Chapter 4 describes the synthesis and characterisation of Cp*, functionalised Cp* 
and tetramethylfulvene complexes of ruthenium. 
Chapter 5 describes the homogeneous catalytic testing of the compounds discussed 
in Chapters 2-4 for transfer hydrogenations. 
Chapter 6 describes the in vitro IC50 results obtained for compounds selected among 
those discussed in Chapter 4 against two cell lines. 
Chapter 7 gives the experimental details and the characterisation data for the 
processes and compounds discussed in Chapters 2-6. 
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1.1 Introduction 
This chapter presents an introduction to current and previous research on 
catalytic transfer hydrogenation reactions and chemotherapy with transition metal 
complexes. In the first part, different types of transfer hydrogenation reactions are 
explained and examples given where, principally ruthenium, but also iridium and 
rhodium complexes have been used as catalysts. Some investigations on mechanistic 
aspects of these reactions are introduced, as well as immobilisation techniques that 
have been utilised to adapt the use of the mentioned complexes to heterogeneous 
processes. The second part of this chapter offers a brief summary of metal 
compounds with anticancer activity, including those already in the clinic and others, 
still under study, with the most promising activities. 
1.2 Transfer Hydrogenation Reactions 
1.2.1 Introduction 
Transfer hydrogenation reactions involve the interchange of hydrogen atoms 
between substrates or reactants, that can be either oxidised or reduced during the 
process, and a metal catalyst. A general scheme of this type of reactions is presented 
in Scheme 1.2.1. For instance, alcohols or amines can be oxidised to 
ketones/aldehydes or imines in a dehydrogenation process where the metal catalyst 
takes their hydrogens, generally forming metal hydride species. These hydrogens 
might be then transferred to an organic hydrogen acceptor which, in turn, gets 
reduced. In the reverse reactions or hydrogenations, the metal first binds the 
hydrogens given by a hydrogen donor and then transfers them to the double bond of 
the corresponding substrate. 
 
Scheme 1.2.1 General scheme for transfer hydrogenation reactions 
     Chapter 1 
3 
In contrast to hydrogenations using molecular H2, transfer hydrogenation 
reactions are less hazardous (H2 is very flammable) and avoid the use of the high 
pressures associated with the manipulation of gaseous H2. They are, thus, milder and 
more desirable transformations. 
Despite transition metal complexes being the catalysts most broadly 
employed nowadays for transfer hydrogenations, reactions of this kind were 
traditionally carried out using aluminium alkoxides. These processes with aluminium 
are known as Meerwein-Ponndorf-Verley (MPV) reductions
1-3
 or Oppenauer 
oxidations,
4
 and they are generally thought to proceed through a cyclic six-
membered ring transition state (Scheme 1.2.2).
5
 The major drawback of these 
reactions is that stoichiometric amounts of the metal complex are required, and the 
final alcohols in the case of reductions have to be liberated by aqueous acidification.
5
 
 
Scheme 1.2.2 Mechanism of the MPV reduction of a ketone with aluminium isopropoxide 
This chapter focuses on the utilisation of ruthenium for a series of transfer 
hydrogenations. The first examples of ruthenium-catalysed transfer hydrogenations 
were reported in 1971 by Sasson and Blum, using RuCl2(PPh3)3 at high temperatures 
(180-200ºC),
6, 7
 which were later reduced (82ºC) for reactions performed in the 
presence of NaOH.
8
 
1.2.2 Redox Neutral Alkylations 
Redox neutral alkylations or N-alkylations are reactions between alcohols 
(primary alcohols are the most commonly used) and amines in which, after initial 
oxidation of the alcohol, a condensation of the amine with the generated aldehyde 
     Chapter 1 
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produces an imine, and this is finally reduced to yield an N-alkylated amine. They 
consist, thus, of three parts: oxidation of the alcohol, formation of the imine and 
reduction to an amine. The first and the third parts are aided by a transition metal 
catalyst that “borrows” the hydrogens from the starting alcohol and then transfers 
them to the imine (Scheme 1.2.3). The mechanism is generally referred to as 
“hydrogen borrowing” or “hydrogen autotransfer” process.9, 10 
 
Scheme 1.2.3 General scheme for the N-alkylation of amines with alcohols 
These transformations are good examples of atom economy because the only 
by-product generated is water, from the condensation between the aldehyde and the 
amine. Other traditional methods for the alkylation of amines include the use of toxic 
alkyl halides that, apart from producing salts as by-products, hinder the control of 
mono-alkylations,
11-13
 and the reductive amination of carbonyl compounds.
14, 15
 The 
advantages of using alcohols as alkylating agents are their low toxicity, high 
availability and stability, and low costs. 
Some of the first examples of N-alkylations catalysed by ruthenium 
complexes were reported by Watanabe et al.
16-21
 They investigated the N-alkylation 
of 2-aminopyridine with ethanol (Scheme 1.2.4).
21
 49% yield of 2 was obtained 
selectively with RuCl2(PPh3)3, while [Ru(cod)(cot)] (cod = 1,5-cyclooctadiene; cot = 
1,3,5,7-cyclooctatetraene) produced 79% of 1. In general, it was concluded that the 
ratio of mono-alkylated and di-alkylated products depended on both the molar ratio 
of amine to alcohol and the type of ruthenium complex used, and generally the 
presence of phosphines favoured the di-alkylation. 
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Scheme 1.2.4 N-alkylation of 2-aminopyridine with ethanol 
Watanabe also studied N-heterocyclisations, like the ones summarised in 
Scheme 1.2.5,
17
 to produce quinoline, indole, piperidine, morpholine and piperazine 
derivatives from a variety of amines and alcohols. The most successful catalyst in the 
majority of the trials was RuCl2(PPh3)3, and the importance of phosphine ligands 
was demonstrated, but high temperature conditions were normally required. 
 
Scheme 1.2.5 N-heterocyclisations studied by Watanabe and co-workers 
The synthesis of arylpiperazines (X = NR' and R = aryl in Scheme 1.2.5) was 
also tried with PNP and NN'N (neutral tridentate ligands) complexes of 
ruthenium(II) (Figure 1.2.1) by van Koten et al.,
22
 and they managed comparable or 
better activities than those obtained with RuCl2(PPh3)3. The presence of PPh3 ligands 
in the complexes was essential. In another article, Marsella related a higher PPh3:Ru 
ratio with a higher selectivity towards mono-alkylation in similar reactions.
23
 
The group of Rigo analysed the N-methylation of primary (RNH2) and 
secondary (R2NH) alkylamines by methanol to yield RN(CH3)2 and R2NCH3 species 
respectively.
24
 They used methanol as the solvent, at reflux, and tested several 
ruthenium complexes. The best activities were obtained with [Ru(η5-
C5H5)Cl(PPh3)2] (Figure 1.2.2) and, proving the borrowing hydrogen mechanism, 
both imine and mono-methylated derivatives were detected as intermediates. 
     Chapter 1 
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Figure 1.2.1 Ruthenium complexes studied by van Koten et al. for the synthesis of 
arylpiperazines 
 
Figure 1.2.2 [Ru(η5-C5H5)Cl(PPh3)2] complex employed by Rigo et al. for N-methylation 
More recently, Williams and co-workers discovered the favourable 
combination of [RuCl2(p-cymene)]2 and diphosphines at reflux in toluene for the N-
alkylation of primary or secondary amines.
25, 26
 The optimum conditions were 
obtained with dppf (1,1'-bis(diphenylphosphino)ferrocene) or DPEphos (bis(2-
diphenylphosphinophenyl)ether) as ligands, after reaction times of 24 hours. The 
system was also successful in reactions between primary amines and diols, 
producing N-heterocycles, between secondary alcohols and amines, and between 
primary alcohols and sulfonamides, but in these two last cases, temperatures of 
150ºC in xylene were needed to give complete conversion.
27
 One example of the 
efficient application of [RuCl2(p-cymene)]2 + diphosphine is the synthesis of 
Piribedil, a drug used in the treatment of Parkinson’s disease.27 The compound can 
be obtained in 87% isolated yield with the conditions specified in Scheme 1.2.6. In a 
later article, Williams’ group reported the possibility of carrying out the same 
reactions using microwave heating instead of thermal heating, which largely reduced 
the reaction times and, as an added advantage, removed the need for a solvent.
28
 
Using microwaves, Piribedil can be prepared in 89% yield at 115ºC in 90 minutes, 
using 5 mol% of Ru and DPEphos. 
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Scheme 1.2.6 Williams’ conditions for the synthesis of Piribedil 
According to Xu and co-workers, in contrast to the typical borrowing 
hydrogen reaction conducted under an inert atmosphere, N-alkylations in air work 
more efficiently.
29
 They reported various N-alkylations, including those of 
sulfonamides (Scheme 1.2.7), using simple Ru, Ir or Rh complexes without added 
ligands (e.g. RuCl3, IrCl3 or RhCl3), in air and with no solvent. They proposed that, 
in air (oxygen), the oxidation of the alcohol to an aldehyde is more favourable, and 
that the hydrogen transfer proceeds without the formation of MH or MH2 species. 
 
Scheme 1.2.7 N-alkylation of phenyl sulfonamide in air with Wilkinson’s catalyst 
(RhCl(PPh3)3) 
N-alkylations have also been successful using iridium catalysts, like the ones 
employed by the groups of Williams
30-32
 and Yamaguchi.
33-40
 For instance, Williams 
reported the use of [Ir(cod)Cl]2 with dppf in toluene at reflux for the synthesis of 
tryptamine derivatives (Scheme 1.2.8).
32
 The same group also published the use of 
the SCRAM catalyst [Cp*IrI2]2 (Cp* = pentamethylcyclopentadienyl) for the 
alkylation of amines with alcohols in water (Scheme 1.2.9) or ionic liquids.
31
 The 
use of water was found favourable for the formation of secondary amines, while 
ionic liquids were a better medium for obtaining tertiary amines, probably because 
they ease the iminium reduction step. 
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Scheme 1.2.8 Williams’ conditions for the synthesis of tryptamine derivatives 
 
Scheme 1.2.9 Williams’ conditions for the synthesis of fentanyl 
Yamaguchi and co-workers prepared a highly water soluble and air stable 
ammine complex of iridium (Figure 1.2.3) and used it for the N-alkylation of 
aqueous ammonia with alcohols (Scheme 1.2.10).
40
 This catalyst could be recycled 
two times by addition of dichloromethane at the end of the catalytic reaction, so the 
product could be extracted into the organic phase and the catalyst recovered into the 
aqueous phase. 
 
Figure 1.2.3 Water soluble iridium complex used by Yamaguchi et al. for N-alkylation 
 
Scheme 1.2.10 Yamaguchi’s conditions for the N-alkylation of aqueous ammonia 
An alternative to the normal N-alkylation, entailing an aza-Wittig reaction 
with an iminophosphorane, was also reported by Williams using an iridium catalyst 
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(Scheme 1.2.11).
41
 The combination of [Ir(cod)Cl]2 (2.5 mol%) with dppf (5 mol%) 
and K2CO3 (5 mol%) at 110ºC for 24 hours was found to give quantitative 
conversions. A drawback of this approach is the difficult removal of the 
triphenylphosphine oxide formed during the reaction. 
 
Scheme 1.2.11 General scheme for the N-alkylation using aza-Wittig reactions with 
iminophosphoranes 
1.2.3 Hydrogenations and Dehydrogenations 
Transfer hydrogenations and dehydrogenations need an auxiliary organic 
molecule as hydrogen donor or acceptor respectively. The most commonly used 
hydrogen donor systems are isopropanol and formic acid. 
Isopropanol (IPA) is an effective hydrogen donor that produces acetone 
during catalytic transfer hydrogenations (Scheme 1.2.12).
42, 43
 In this system, the 
product is in equilibrium with the starting materials so, initially, the reaction is 
kinetically controlled, but when the concentrations of product and acetone increase, 
the rate of the reverse reaction also increases and the process becomes 
thermodynamically controlled. This reversibility affects both the yield and the 
optical purity of the product, but can be easily overcome by using IPA in high 
concentrations (as the solvent) or by continuously distilling and removing the 
acetone by-product. The IPA system can be used to reduce aldehydes, ketones and 
iminium salts, and it is a convenient hydrogen donor because it is readily available, 
safe and cheap. While isobutanol is also a good hydrogen donor (but generally less 
active), primary alcohols such as methanol or ethanol produce aldehydes that might 
interfere in the catalytic reaction. Acetone is the hydrogen acceptor normally used 
for the reverse transformations (dehydrogenations). 
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Scheme 1.2.12 Catalytic transfer hydrogenation with isopropanol as hydrogen donor 
The other important hydrogen donor system is the mixture of formic acid 
with triethylamine (Scheme 1.2.13).
44, 45
 Molar mixtures of a 5:2 ratio form an 
azeotrope,
44
 which, at room temperature, is a single phase, soluble in most solvents, 
although other molar ratios may form biphasic solutions.
42, 43
 This triethylammonium 
formate system (TEAF) can be used to reduce aldehydes, ketones, imines and 
iminium salts, and decomposes producing gaseous CO2, which prevents the reverse 
reaction (the process is always kept under kinetic control). The actual hydrogen 
donor in this system is the formate anion, so, in water, hydrogenation reactions only 
take place above pH 3.6 (the aqueous pKa of formic acid). The role of the Et3N in the 
TEAF system is believed to be the buffering of the pH while formic acid is 
consumed. An excess of formic acid over substrate is often used, and the 5:2 TEAF 
system is acidic, which might make it incompatible with some catalysts or 
substrates. In such an acidic medium, imines can get protonated (the pKa of imines is 
approximately 6 in water) forming iminium salts, which are much more reactive. 
This possibly explains why IPA, being a neutral system, cannot reduce imines. In 
aqueous catalytic reactions, the formate salts HCO2Na or HCO2K are commonly 
used, and the CO2 generated ends up trapped as bicarbonate.  
 
Scheme 1.2.13 Catalytic transfer hydrogenation with formic acid-triethylamine as hydrogen 
donor 
1.2.3.1 Ketone and Aldehyde Reductions 
The most notable ruthenium catalytic system for asymmetric transfer 
hydrogenations (ATH) is the one developed by Noyori (Figure 1.2.4),
45
 who won 
the Nobel Prize in 2001 for his work on chirally catalysed hydrogenation reactions. 
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Figure 1.2.4 Noyori’s arene-ruthenium catalysts 
In 1995, Noyori first published the use of N,N-ligand catalysts, prepared in 
situ, for the asymmetric reduction of prochiral aromatic ketones in isopropanol, like 
the example with acetophenone in Scheme 1.2.14.
45
 Due to some reversibility 
observed, to maintain the enantiomeric purity throughout the reaction, the substrate 
concentration had to be low (0.1 M) and long exposures of the product to the catalyst 
had to be avoided. Without the diamine ligand, [RuCl2(mesitylene)]2 gave (S)-1-
phenylethanol in 8% yield. With the addition of TsDPEN (N-(p-toluenesulfonyl)-
1,2-diphenylethylenediamine), the yield reached 95% and 97% e.e. was obtained. 
 
Scheme 1.2.14 Noyori’s conditions for the ATH of acetophenone in IPA with 
[RuCl(mesitylene)(TsDPEN)] (mesitylene = 1,3,5-trimethylbenzene; TsDPEN = N-(p-
toluenesulfonyl)-1,2-diphenylethylenediamine). S/C = 200 
When N,N-ligands are replaced by N,O-ligands, the reaction rates are much 
faster, but the enantioselectivity decreases.
46, 47
 In the model reaction with 
acetophenone (0.1 M) (Scheme 1.2.15), 94% yield was obtained after only 1 hour at 
room temperature in isopropanol, using a catalyst prepared in situ from 
[RuCl2(hexamethylbenzene)]2 and (S,S)-2-methylamino-1,2-diphenylethanol. With 
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both types of N,N- or N,O-ligands, the presence of a primary or secondary amine at 
one end is crucial, and dimethylamino groups have proven inactive. 
 
Scheme 1.2.15 Noyori’s conditions for the ATH of acetophenone in IPA with 
[RuCl(hexamethylbenzene)(aminoalcohol)] (aminoalcohol = 2-methylamino-1,2-
diphenylethanol). S/C = 1000 
To avoid the deterioration of optical purity observed during reactions in 
isopropanol, the same group also tested the N,N-Ru-arene catalytic system using the 
5:2 azeotropic mixture of formic acid and triethylamine.
47, 48
 This allowed a much 
higher substrate concentration, between 2 and 10 M, while maintaining the 
enantioselectivity. In the model reduction of acetophenone (Scheme 1.2.16), using a 
2 M initial concentration of the substrate, complete conversions and very good 
enantioselectivities could be obtained at room temperature. The same reaction at 
60ºC proceeded up to ten times faster, but with 2% decrease in the e.e. This 
acetophenone hydrogenation with [RuCl(mesitylene)(TsDPEN)] also worked with 
10 M solutions and S/C ratios of 1000. With regard to the arene ligands, for all of 
these hydrogenations, the reactivity decreases in the order benzene > p-cymene = 
mesitylene > hexamethylbenzene, probably due to steric reasons, but p-cymene and 
mesitylene give the best enantioselectivities. 
The ATH of benzaldehyde to deuterated benzyl alcohol has also been studied 
by Noyori’s group under the series of different conditions mentioned earlier.49 Table 
1.2.1 gives a summary of the best results. 
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Scheme 1.2.16 Noyori’s conditions for the ATH of acetophenone in formic acid/Et3N with 
[RuCl(mesitylene)(TsDPEN)]. S/C = 200 
 N,N-ligand in IPA N,O-ligand in IPA N,N-ligand in TEAF 
Substrate 
   
[Substrate] (M) 0.1 0.1 0.1 in acetonitrile 
Hydrogen donor Isopropanol Isopropanol DCO2D-Et3N (1:1) 
Catalyst 
   
Base (equiv. to Ru) 
t
BuOK (5) 
t
BuOK (4) None 
S/C 200 200 200 
Temperature (ºC) 22 28 28 
Time (hours) 0.5 1 4 
Product 
   
Conversion (%) 100 49 93 
e.e. (%) 98 45 98 
 
Table 1.2.1 Noyori’s results for the ATH of benzaldehyde to deuterated benzyl alcohol 
Noyori and co-workers also isolated three different species involved in the 
asymmetric transfer hydrogenation catalysis (Figure 1.2.5).
50, 51
 The halogenated 
species (A) acts as a pre-catalyst and needs to lose HCl in order to become the actual 
catalyst (B). This is facilitated in most of the cases with the presence of a base, such 
as KOH or 
t
BuOK. During the catalytic cycle, the sixteen electron complex B is 
transformed into C, which is the active species in the hydrogenation of substrates. C 
can interact with a C=O bond through both the hydride and one N-H, forming a six-
membered ring transition state and promoting the hydrogen transfer (see section 1.3). 
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Both compounds B and C can catalyse dehydrogenations and hydrogenations 
respectively in the absence of a base. 
 
Figure 1.2.5 A) Pre-catalyst; B) catalyst and C) reactive intermediate in Noyori’s ATH 
An increased stability and longevity of Noyori-type catalysts has been 
obtained through the linking of the N,N- or N,O-ligands to the η6-arene moiety, 
giving what are called “tethered” complexes (Figure 1.2.6).52-54 The ligands, thus, 
are attached to the metal at three points, and this locks the free rotation of the arene, 
permitting in most cases a better control over enantioselectivity. For instance, 
complex 6, synthesised by Wills and co-workers, is able to completely reduce 
acetophenone in less than 3 hours at 28ºC in HCO2H-Et3N, giving 96% e.e. (S/C = 
200), or in 100 minutes at 40ºC.
55
 The untethered equivalent, in contrast, needs 
overnight reactions to yield similar results. Moreover, catalyst 6 maintains its 
effectiveness after several new additions of substrate. Later on, the same group 
optimised the length of the tethered chain to four atoms, which further accelerated 
the reductive transformations.
56
 Ether-tethered complexes (such as 7) have also been 
prepared by both Wills’ and Ikariya’s groups with very promising results.57, 58 
 
Figure 1.2.6 Some of the tethered catalysts published by Wills et al. 
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Other ligands employed with ruthenium in transfer hydrogenations with IPA 
include diaminoferrocenyl derivatives
59
 and phosphinites.
60
 In this latter case, the 
phosphinite ligands form dimeric complexes (Figure 1.2.7), which act as pre-
catalysts in the acetophenone reduction in the presence of NaOH, giving good 
conversions and moderate enantioselectivities. These catalysts are believe to operate 
via the formation of a Ru-alkoxide, facilitated by the base. 
 
Figure 1.2.7 Phosphinite-Ru catalyst used for ATH of aromatic ketones in IPA. R = Ph or 
Cy (Cyclohexyl) 
Pentamethylcyclopentadienyl (Cp*) complexes of iridium and rhodium with 
the ligands TsDPEN and TsCYDN (N-(p-toluenesulfonyl)-1,2-cyclohexanediamine) 
have also been tested for ATH of aromatic ketones.
61
 The catalysts can be prepared 
by reacting [Cp*MCl2]2 (M = Ir or Rh) with the ligand and triethylamine at room 
temperature in a molar ratio 1:2:4.2. For the reduction of acetophenone (0.1 M) in 
isopropanol (Scheme 1.2.17), the complexes with TsCYDN give higher reactivities, 
and those with Rh are more active than the Ir analogues. Despite good results, Ru-
TsDPEN provides faster reactions with comparable enantioselectivities. With 
functionalised acetophenones as substrates, electron-withdrawing substituents give 
excellent yields and high optical purities, whereas electron-donating groups slow the 
reactions down, but maintain good enantioselectivities. Bulky alkyl substituents in 
the aromatic ketones both slow the hydrogenations and reduce the final enantiomeric 
excesses. 
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Scheme 1.2.17 Noyori’s conditions for the ATH of acetophenone in IPA with 
[Cp*RhCl(TsCYDN)]. S/C = 200 
Growing interest in greener reactions has driven research towards asymmetric 
transfer hydrogenations in water. In 2001, Williams et al. prepared some water-
soluble ligands based on Noyori’s TsDPEN and Knochel’s TsCYDN by addition of 
a sulfonic acid group (Figure 1.2.8).
62
 The corresponding catalysts were obtained by 
reacting [RuCl2(p-cymene)]2 with each ligand in the presence of a base at 40ºC, and 
used for ATH of aromatic ketones. The model reaction with acetophenone is shown 
in Scheme 1.2.18. Isopropanol was used as co-solvent and hydrogen donor. 
 
Figure 1.2.8 Water-soluble ligands modified with –SO3H from 8) TsDPEN and 9) TsCYDN 
 
Scheme 1.2.18 Williams’ conditions for the ATH of acetophenone in IPA-H2O with water-
soluble TsDPEN- or TsCYDN-derived ligands 
More recently, Xiao’s group demonstrated that Noyori’s catalysts do not need 
to be modified for reactions in water.
63
 They showed that the reduction of 
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acetophenone can proceed in water, using HCO2Na as a hydrogen donor and 
[RuCl(p-cymene)(TsDPEN)] at S/C = 100 or higher. In 1 hour, a complete 
conversion was obtained with 94% e.e., without the need for a co-solvent. When the 
system was compared to the one using HCO2H-Et3N as both solvent and reductant, 
only 2% conversion was managed with the latter in 1 hour. It is believed that, as 
ketones are not soluble in water, in fact the reaction takes place in the substrate 
phase, where the catalyst is more soluble. 
Another useful ligand for water reactions is CsDPEN (N-camphorsulfonyl-
1,2-diphenylethylenediamine), which has been shown to form efficient catalysts with 
Ru, Rh and, mainly, Ir.
64
 In the reduction of acetophenone (Scheme 1.2.19), the 
rhodium and iridium catalysts obtained from [Cp*MCl2]2 (M = Rh or Ir) and 
CsDPEN give faster rates than the one from [RuCl2(p-cymene)]2 and CsDPEN. Ir-
CsDPEN is the best of the three catalysts when the substrate to catalyst ratio is 
increased to 1000. 
 
Scheme 1.2.19 Xiao’s conditions for the ATH of acetophenone in water using Ru-, Rh- or 
Ir-CsDPEN complexes. S/C = 100 
1.2.3.2 Imine Reductions 
In 1996, Noyori reported the reduction of imines with [Ru(p-
cymene)Cl(TsDPEN)], using the 5:2 azeotropic mixture of formic acid-
triethylamine.
65
 An example with 6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline 
is shown in Scheme 1.2.20. This substrate was quantitatively reduced at a substrate 
to catalyst ratio of 200 using acetonitrile as co-solvent. At S/C = 1000, the reaction 
took 12 hours and gave 97% yield and 94% e.e. Isopropanol could not be used as a 
hydrogen source but, with the formic acid azeotrope, imines were much more 
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reactive than ketones, being reduced even in the presence of acetone, which 
remained unchanged. 
 
Scheme 1.2.20 Noyori’s conditions for the ATH of imines in HCO2H-Et3N/CH3CN with 
[Ru(p-cymene)Cl(TsDPEN)]. S/C = 200; HCO2H/substrate = 6 
The use of N'-alkylated TsDPEN complexes of ruthenium for the reduction of 
imines has been investigated by the group of Wills,
66, 67
 and an N'-methylated 
version was discovered to be even more active than the original non-substituted 
complex reported by Noyori. This methylated complex was able to completely 
reduce 6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline with 75% e.e. in less than 2 
hours at 28ºC and S/C = 100. 
It is generally accepted that the mechanism for the reduction of imines differs 
to that of ketones and does not involve a six-membered ring transition state.
68
 
Instead, an ionic hydrogenation is more likely, where the imine is protonated and 
becomes activated and non-coordinative prior to the hydride transfer. This theory is 
supported by Bäckvall’s investigations, which proved that Ru-hydride TsDPEN 
species do not react with imines unless in the presence of an acid.
69
 This explains 
why isopropanol alone cannot be used in these transformations and suggests that a 
concerted pathway does not operate for imines. 
1.2.3.3 Alcohol and Amine Oxidations 
The dehydrogenation of secondary alcohols can be successfully catalysed by 
RuCl2(PPh3)3, using acetone as hydrogen acceptor and solvent, as published by 
Bäckvall.
70, 71
 As an example, the optimised conditions for the oxidation of 1-
phenylethanol are depicted in Scheme 1.2.21. 
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Scheme 1.2.21 Bäckvall’s conditions for the oxidation of 1-phenylethanol in acetone using 
RuCl2(PPh3)3. S/C = 1000 
Despite the good results with secondary alcohols, Bäckvall’s system does not 
work for primary alcohols. However, these other conversions are possible with some 
iridium-Cp* catalysts reported by Yamaguchi and Fujita (Figure 1.2.9).
72-74
 The 
dimer 10 catalyses the oxidation of benzyl alcohol at room temperature in acetone 
(Scheme 1.2.22), whilst 12 performs the same transformation in the absence of 
hydrogen acceptor (Scheme 1.2.23). 
 
Figure 1.2.9 Iridium-Cp* complexes used as oxidation catalysts by Fujita 
 
Scheme 1.2.22 Fujita’s conditions for the oxidation of benzyl alcohol in acetone using 
[Cp*IrCl2]2 
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Scheme 1.2.23 Fujita’s conditions for the oxidant-free dehydrogenation of benzyl alcohol 
A modification of catalyst 11 in Figure 1.2.9 has also been used for the 
dehydrogenation of cyclic amines with good results.
75
 The 5-CF3 substituted 
pyridonate complex is able to oxidise tetrahydroquinolines to quinolines (Scheme 
1.2.24) and, furthermore, the hydrogen generated can be reused for the reverse 
reactions. 
 
Scheme 1.2.24 Fujita’s conditions for the oxidant-free dehydrogenation of 1,2,3,4-
tetrahydroquinoline 
1.2.4 Racemisations and Dynamic Kinetic Resolutions 
In racemisations, an optically pure alcohol or amine is converted into a 
racemic mixture via an intermediate ketone or imine through hydrogen transfer with 
a metal catalyst. Several ruthenium complexes are active for these transformations. 
The racemisation of phenylethanol has been successful with [Ru(η5-
indenyl)Cl(PPh3)2] (Scheme 1.2.25),
76
 with [Cp*RuCl(cod)] and Ph2P(CH2)2NH2 
(Scheme 1.2.26),
77
 or with [Ru(η5-C5Ph5)Cl(CO)2] (Scheme 1.2.27).
78
 
 
Scheme 1.2.25 Park’s conditions for the racemisation of (S)-phenylethanol 
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Scheme 1.2.26 Ikariya’s conditions for the racemisation of (R)-phenylethanol 
 
Scheme 1.2.27 Bäckvall’s conditions for the racemisation of (S)-phenylethanol 
Racemisations play a fundamental part in dynamic kinetic resolutions (DKR), 
which combine the resolution of a racemic mixture by, for example, chemical 
modification using an enzyme or selective crystallisation, with the racemisation of 
the unwanted isomer (Scheme 1.2.28). These processes permit, in theory, a full 
conversion to the isomer of interest, in contrast to the common diastereomeric 
crystallisation, where only a maximum 50% of the desired isomer can be recovered. 
 
Scheme 1.2.28 General scheme for dynamic kinetic resolutions of alcohols or amines 
The ruthenium Shvo-type catalyst in Figure 1.2.10 has been used for the 
DKR of amines with Candida Antarctica lipase B (CALB) as the enzyme and 
isopropyl acetate as acylating agent for resolution (Scheme 1.2.29).
79
 Also 
efficiently, the iridium SCRAM catalyst [Cp*IrI2]2 has been demonstrated to 
catalyse these transformations, such as the one in Scheme 1.2.30,
80
 and has been 
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employed for the preparation of sertraline, the active pharmaceutical ingredient 
(API) in Pfizer’s antidepressant Zoloft.81 
 
Figure 1.2.10 Shvo-type catalyst used for the dynamic kinetic resolution of amines 
 
Scheme 1.2.29 Bäckvall’s conditions for the DKR of racemic methylbenzylamine 
 
Scheme 1.2.30 Page’s conditions for the DKR of racemic 6,7-dimethoxy-1-methyl-1,2,3,4-
tetrahydroisoquinoline 
1.2.5 Other Transfer Hydrogenation Reactions 
1.2.5.1 Reductive Aminations 
Reductive aminations are coupling reactions between ketones or aldehydes 
and amines in the presence of a reducing agent, so the imine formed can be 
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converted into a final amine. They only differ to redox neutral alkylations in that the 
latter start with an alcohol and include one more step. 
Xiao and co-workers have demonstrated the possible use of air stable 
cyclometalated imido iridium complexes (Figure 1.2.11) to carry out non-chiral 
reductive aminations under transfer hydrogenation conditions.
82
 An example is the 
reaction between acetophenone and p-anisidine in Scheme 1.2.31.  
 
Figure 1.2.11 Cyclometalated imido Ir(III) complexes used by Xiao for reductive amination 
 
Scheme 1.2.31 Xiao’s reductive amination between acetophenone and p-anisidine 
A chiral example of intramolecular reductive amination is shown in Scheme 
1.2.32, by Wills et al.
83
 
 
Scheme 1.2.32 Wills’ conditions for intramolecular reductive amination 
     Chapter 1 
24 
1.2.5.2 C-C Bond Forming Reactions 
In a similar process to that of redox neutral alkylations between alcohols and 
amines, Williams developed a hydrogen borrowing system to form C-C bonds from 
alcohols. The alcohol is initially oxidised to a ketone or aldehyde, which then 
undergoes an olefination, and finally the alkene is reduced to an alkane without the 
need of an external hydrogen donor (Scheme 1.2.33). One possible method to obtain 
the intermediate alkene involves the use of active methylene compounds (Scheme 
1.2.34).
84
 A more common method employs indirect Wittig reactions with 
phosphorane ylide nucleophiles (Scheme 1.2.35).
85, 86
 
 
Scheme 1.2.33 General scheme for C-C bond forming reactions from alcohols 
 
Scheme 1.2.34 Williams’ conditions for the C-C bond formation between benzyl alcohol 
and a ketonitrile. Xantphos = 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene 
 
Scheme 1.2.35 Williams’ conditions for the C-C bond formation between benzyl alcohol 
and benzyl(triphenylphosphoranylidene)acetate. dppp = 1,3-bis(diphenylphosphino)propane 
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1.2.6 Reactions Involving H2 
Hydrogenations using molecular H2 and transition metal catalysts are 
extensively employed and constitute a vast area of research. This section only aims 
to, very briefly, present some examples of such reactions with relevant ruthenium, 
rhodium and iridium complexes. 
Several ruthenium systems have served as efficient catalysts for non-
asymmetric hydrogenations. One example is the dimer [RuCl2(p-cymene)]2 which, 
together with I2, is able to facilitate the reduction of quinolines in tetrahydrofuran 
(Scheme 1.2.36).
87
 On publishing their results, Zhou and co-workers stated that the 
presence of I2 was fundamental, and even [RuI2(p-cymene)]2 produced only 48% 
conversion when I2 was not included in the reaction. 
 
Scheme 1.2.36 Zhou’s conditions for the hydrogenation of 2-methylquinoline. S/C = 100 
The use of DPEphos (bis(2-diphenylphosphinophenyl)ether) as ligand for 
cyclopentadienyl or p-cymene complexes of ruthenium (Figure 1.2.12) permits the 
reduction of styrene to ethylbenzene in good yields, as detailed in Scheme 1.2.37.
88
 
However, more common is the utilisation of N-NH2 or P-NH2 ligands, for which 
Ikariya has found a wide range of applications, such as the hydrogenation of 
carboxylic esters (Scheme 1.2.38)
89
 or imides (Scheme 1.2.39).
90
 
 
Figure 1.2.12 DPEphos complexes of ruthenium used for the hydrogenation of styrene 
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Scheme 1.2.37 Balakrishna’s conditions for the hydrogenation of styrene 
 
Scheme 1.2.38 Ikariya’s conditions for the hydrogenation of phthalide 
 
Scheme 1.2.39 Ikariya’s conditions for the hydrogenation of N-benzylphthalimide 
Ikariya’s group has also worked on asymmetric hydrogenations, initially with 
similar systems to the ones employed in the non-asymmetric reactions, but including 
chiral ligands (Scheme 1.2.40).
91
 Later on, this group developed triflylamide (NTf)-
tethered metal-(DPEN) complexes of Ru
92
 and Rh or Ir,
93
 all performing well in the 
asymmetric hydrogenation of acetophenone. Under identical conditions (H2 pressure 
= 30 atm, MeOH, 30ºC, 24 hours, S/C = 100), the three complexes in Figure 1.2.13 
yielded 1-phenylethanol in >94% conversions and 93% enantiomeric excesses. In all 
of these latest examples where the solvent utilised was an alcohol, it was 
demonstrated that the reactions did not proceed without a specified H2 pressure, so 
the role of isopropanol or methanol was not that of a hydrogen donor. In the Noyori-
type catalysts 18, 19 and 20, the NTf tether somehow switches the catalytic activity 
from asymmetric transfer hydrogenation to asymmetric hydrogenation. 
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Scheme 1.2.40 Ikariya’s conditions for the hydrogenation of acetophenone using 
[Cp*RuCl(cod)] and a chiral N-NH2 ligand 
 
Figure 1.2.13 Triflylamide (NTf)-tethered complexes used by Ikariya for asymmetric 
hydrogenations 
1.3 Mechanistic Investigations 
The different possible mechanisms for transfer hydrogenations have been 
reviewed by Brandt et al.
94
 Initially, they can be divided into two main categories: 
direct hydrogen transfer mechanism or hydridic mechanism. A direct hydrogen 
transfer does not involve metal hydride intermediates and typically operates in 
reactions catalysed by main group metals, such as the Meerwein-Ponndorf-Verley 
(MPV) reduction (see above, Scheme 1.2.2). The hydridic route is associated with 
transition metals and entails the formation of hydride intermediates. It can be further 
classified into either a dihydride or a monohydride pathway. In a dihydride 
mechanism, the two hydrogens from an alcohol or amine become equivalent, both 
behave as hydrides during the metal-catalysed process (Scheme 1.3.1). In a 
     Chapter 1 
28 
monohydride mechanism, only the C–H from the donor forms a hydride with the 
metal, whilst the proton in –OH or –NRH keeps its identity (Scheme 1.3.2). 
 
Scheme 1.3.1 Dihydride route in the dehydrogenation of a monodeuterated alcohol and later 
hydrogenation of the resultant ketone 
 
Scheme 1.3.2 Monohydride route in the dehydrogenation of a monodeuterated alcohol and 
later hydrogenation of the resultant ketone 
Dihydride mechanisms are common with ruthenium dichloride complexes, 
such as RuCl2(PPh3)3.
95
 In the presence of a base and isopropanol, RuCl2(PPh3)3 first 
gives RuHCl(PPh3)3 and then RuH2(PPh3)3 in two consecutive steps through 
alkoxide formation and β-elimination. The latter is the active species in hydrogen 
transfer reactions, which follow the mechanism depicted in Scheme 1.3.3.
96
  
 
Scheme 1.3.3 Mechanism for transfer hydrogenation with RuCl2(PPh3)3 
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Monohydride mechanisms generally operate in rhodium- or iridium-catalysed 
reactions, and also with ruthenium monochloride species.
94
 They proceed by either 
inner sphere or outer sphere pathways. 
1.3.1 Inner Sphere Mechanisms 
These processes involve the formation of an alkoxide with the transition 
metal, followed by  β-elimination to produce the metal hydride. Scheme 1.3.4 shows 
the inner sphere mechanism originally proposed for transfer hydrogenations with 
transition metals in isopropanol.
51
 
 
Scheme 1.3.4 Inner sphere mechanism for transfer hydrogenations with transition metals in 
isopropanol 
A particular example of a monohydride inner sphere mechanism is the one 
proposed by Fujita for his oxidant-free oxidation of alcohols with a 2-
hydroxypyridine Cp*Ir complex (Scheme 1.3.5).
73
 This mechanism has been 
supported by the detection of the H2 formed during the reaction and the fact that 
species 11 has been isolated and shows high catalytic activity. 
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Scheme 1.3.5 Mechanism proposed by Fujita for the oxidant-free oxidation of alcohols with 
a 2-hydroxypyridine Cp*Ir complex 
1.3.2 Outer Sphere Mechanisms 
In these mechanisms, there is no direct coordination of any substrate to the 
metal and, with help from a ligand, the hydrogen transfer can take place either in a 
concerted or stepwise manner. 
1.3.2.1 Concerted Mechanisms 
A concerted mechanism has been proposed for the transfer hydrogenation 
with the dimeric Shvo catalyst, which is in equilibrium with two monomers 21 and 
22 (Scheme 1.3.6).
94
 21 can hydrogenate double bonds in hydrogen acceptors 
(Scheme 1.3.7), while 22 is able to dehydrogenate a hydrogen donor, so the two 
monomers interconvert. 
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Scheme 1.3.6 Shvo’s catalyst equilibrium with monomers 21 and 22 
 
Scheme 1.3.7 Transfer hydrogenation with the monomer 21 from the Shvo catalyst 
The metal ligand bifunctional catalysis, as Noyori denominated those transfer 
hydrogenations with [Ru(η6-arene)Cl(N,N- or N,O-ligand)] complexes, is another 
example of a concerted process.
51, 94
 The chelating ligands involved contain an NH2 
or NRH group, which interacts through a hydrogen bond with the carbonyl oxygen 
in ketones. This assists the formation of an ordered six-membered transition state, 
from where the hydride and proton transfers occur simultaneously (Scheme 1.3.8). A 
strong base is needed, firstly to generate the catalyst in situ from [RuCl2(η
6
-arene)]2 
and the chelating ligand, and also to generate the 16 electron species B from the pre-
catalyst A. Both species B and C have been isolated and characterised by X-ray 
crystallography,
50, 51
 but also similar intermediates in reactions with aminoindanol 
ligands have been detected by electrospray ionisation mass spectroscopy.
97
 Not only 
experimental but also computational methods provide evidence for this 
mechanism.
51, 98-100
 With aryl ketones, a transition state in which the aromatic 
substituent is close to the η6-arene ligand of the complex is favoured due to CH/π 
attractive interactions, and greatly contributes to an enrichment of the 
enantioselectivity (Figure 1.3.1).
100, 101
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Scheme 1.3.8 Noyori’s metal ligand bifunctional catalysis mechanism 
 
Figure 1.3.1 CH/π interaction between the η6-arene ligand and the aryl substituent of a 
ketone 
Xiao and co-workers have provided a modified version of Noyori’s 
mechanism for reactions that proceed in water with HCO2Na, where H2O is the 
proton donor and HCO2
-
 is the hydride donor.
102
 Under these conditions, H2O can 
behave as hydrogen-bond donor and interact with the carbonyl oxygen of a ketone 
during hydrogen transfer, which greatly improves the rate of the reaction. However, 
in aqueous media, the transformation depends largely on the pH. In acidic medium, 
TsDPEN can get protonated and de-coordinate, reducing the catalytic activity, and in 
basic medium, H2O can coordinate to Ru and deactivate the catalyst (Scheme 1.3.9). 
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Scheme 1.3.9 Xiao’s mechanism for transfer hydrogenation in water at different pH conditions
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1.3.2.2 Stepwise Mechanisms 
In a stepwise mechanism, the transfer of the proton and that of the hydride 
occur in separate steps. For example, this happens in ionic hydrogenations, where a 
rapid and reversible protonation of the substrate precedes and facilitates the hydride 
transfer from the metal. This mechanism is the one believed to operate in the 
hydrogenation of imines.
69, 94, 103
  
1.4 Immobilisation Techniques 
1.4.1 Introduction 
The main advantage of heterogeneous catalytic processes is the ease of 
recovery of the metal catalysts employed. This is very important when the metals 
used are expensive and limited and recycling becomes a priority for the industry in 
order to reduce economic costs and unnecessary pollutant residues. Besides, in 
specific cases such as the production of pharmaceuticals, the removal of the catalysts 
is essential to avoid or minimise the metal content in the final products. In spite of 
these conveniences, heterogeneous catalysts are still, generally, less active and less 
selective than homogeneous ones. This is explained by the fact that homogeneous 
catalysts dissolve in the reaction media, facilitating the access of the substrates to the 
catalyst. On the other hand, in heterogeneous systems, the access to catalytically 
active sites is commonly restricted, and maximising the surface-area-to-volume ratio 
of the catalysts is a fundamental need. A desirable combination of both types of 
catalysis might be obtained through the immobilisation of homogeneous complexes, 
which can be carried out by either covalent or non-covalent interactions with the 
chosen support. This way, the catalysts can be recovered and recycled by, for 
example, simple filtration or decantation or, more efficiently, adapted for flow 
chemistry. 
1.4.2 Covalent Immobilisation 
Covalent tethering of metal complexes to a solid support through coordinated 
ligands is one of the most common and favoured immobilisation techniques (Figure 
1.4.1). It has the advantage of generating more stable and stronger interactions, but 
generally requires previous modification of the ligands/complexes and/or supports.  
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Figure 1.4.1 Covalent bond between a functionalised metal catalyst and a support 
Both organic and inorganic matrices have been used for covalent 
immobilisation, including silica, alumina, polymers, dendrimers, etc.
104-106
 Organic 
supports might be soluble (linear polymers, dendrimers) or insoluble (cross-linked 
polymers). Soluble polymer-attached complexes allow catalytic reactions to proceed 
under homogeneous conditions and, when the reaction is complete, can be separated 
by, for example, solvent precipitation or membrane filtration. In the case of insoluble 
polymers, an important characteristic is their swellability in organic solvents, which 
may be beneficial and favour a more homogeneous-like behaviour or detrimental and 
incite aggregation and deactivation of the catalysts. Inorganic oxides, on the other 
hand, are always insoluble and present very high thermal and mechanical stabilities, 
large surface areas and a rigid structure that prevents the aggregation of active 
catalysts. Probably the most widely utilised inorganic oxide is silica, principally in 
the form of mesoporous silica (e.g. MCM-41), with well defined pore structures and 
pore diameters between 2 and 50 nm. Silica and alumina contain silanol groups on 
their surfaces which ease the covalent attachment of potential ligands (Scheme 
1.4.1). 
 
Scheme 1.4.1 Typical covalent bonding to silanol groups 
To avoid metal leaching, both the covalent bond between the ligand and the 
support and the coordinative bond between the ligand and the metal have to be stable 
enough under catalytic conditions. To this end, the immobilisation through an arene 
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or cyclopentadienyl ligand is an attractive approach, because these ligands 
coordinate to the metal centre with several carbon atoms and this is expected to offer 
very high stabilities against dissociation. ηx-Coordinated rings (x = 5 or 6) are π-acid 
ligands which, apart from donating electron density to the metal, also receive certain 
back-bonding into their π* empty orbitals.107, 108 One example of this technique is the 
immobilised version of the SCRAM catalyst [Ir(η5-C5Me5)I2]2 where one of the 
methyl groups in each ring has been functionalised with a (CH2)5OH chain and this, 
in turn, immobilised onto poly(ethyleneglycol) (Figure 1.4.2).
109
 This heterogeneous 
catalyst has been used in transfer hydrogenation reactions such as the racemic 
resolution of sertraline, and survived three recycles.
81
 
 
Figure 1.4.2 SCRAM catalyst immobilised onto poly(ethyleneglycol) 
1.4.3 Non-Covalent Immobilisation 
The different non-covalent methods employed for the immobilisation of 
metal complexes generally involve weak interactions with the supports. 
Consequently, the choice of reaction conditions and solvents play an important role 
in guaranteeing the stability and recovery of the catalysts. These methods represent a 
more straightforward approach than covalent immobilisation, with no or less 
previous modifications of the catalysts or supports needed. The four principal 
techniques for non-covalent immobilisation are adsorption, entrapment and 
electronic or coordinative interactions.
104, 106, 110
 
1.4.3.1 Immobilisation by Adsorption 
In the case of adsorption, the metal complex stays attached to the support 
relying on weak van der Waals interactions. The success of this method tends to be 
very limited, but improved approaches use the formation of hydrogen bonds with the 
matrix (e.g. silanol groups on silica) (Figure 1.4.3). These hydrogen bonds might 
     Chapter 1 
37 
form between the surface of the support and a suitable ligand of the metal complex 
or a counterion of a charged catalyst.
104, 106, 110
 Another version of adsorption is that 
of supported liquid phases (SLP). This involves a biphasic system in which a polar 
solvent adheres to a hydrophilic support and dissolves a hydrophilic catalyst, whilst 
the catalytic reaction takes place in an organic apolar solvent in contact with the 
polar one.
106, 110
 
 
Figure 1.4.3 Adsorption of a catalyst through hydrogen bond formation with groups on the 
support 
An example of SLP was reported by Wan and Davis in 1994.
111, 112
 They 
presented a system in which [Ru(BINAP-4SO3Na)(benzene)Cl][Cl] (BINAP = 2,2'-
bis(diphenylphosphino)-1,1'-binaphthyl) was dissolved in highly polar ethylene 
glycol as the hydrophilic phase, supported on a controlled-pore glass (CPG) with an 
average pore size of 242 Å. A non-polar mixture of 1:1 cyclohexane/chloroform was 
used as the hydrophobic phase, where the reactants and products dissolved (Figure 
1.4.4). The heterogeneous catalyst was tested in the hydrogenation of 2-(6'-methoxy-
2'-naphthyl)acrylic acid (Scheme 1.4.2) under 94-101 MPa of H2 and at 276 K. 
100% conversion was obtained with an enantiomeric excess of 96%. The results 
were similar to those of the analogous homogeneous system in methanol, whereas 
the two-phase system without CPG gave a low conversion of < 2%. For the 
heterogeneous SLP system, recycling was successful without loss of 
enantioselectivity and with no leaching of ruthenium into the organic phase 
observed. 
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Figure 1.4.4 [Ru(BINAP-4SO3Na)(benzene)Cl][Cl] in ethylene glycol supported on a 
controlled-pore glass 
 
Scheme 1.4.2 Hydrogenation of 2-(6'-methoxy-2'-naphthyl)acrylic acid to (S)-naproxen 
1.4.3.2 Immobilisation by Entrapment 
The method of entrapment or encapsulation encloses the catalyst inside the 
pores of a support, which makes unnecessary the presence of additional complex-
support interactions.
104, 106, 110
 For this method to be successful, the apertures of the 
pores in the matrix have to be smaller than the size of the complex inside them, so 
the metal catalyst stays entrapped and leaching is avoided. The two techniques 
employed for this aim are either the assembling of parts of the catalyst together once 
inside the cages of the support or the assembling of the support around the pre-
formed catalyst. The first case is known as the “ship-in-a-bottle” approach, and it is 
schematically depicted in Figure 1.4.5. The second case is achieved, normally, by 
polymerising the support around the catalyst, which tends to generate poorly defined 
pore openings and sizes. Depending on the technique of choice, the stabilities of 
either the support or the catalyst under the synthesis conditions need to be 
considered. 
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Figure 1.4.5 “Ship-in-a-bottle” entrapment by formation of the catalyst inside the pores of a 
support 
Blum and co-workers managed to entrap the catalyst [Ru(p-
cymene)Cl(BINAP)][Cl] inside a porous silica obtained by the sol-gel method of 
polymerising Si(OMe)4.
113
 This system was used for the hydrogenation of itaconic 
acid (R = H in Scheme 1.4.3) with a substrate/catalyst molar ratio of 30 at 80ºC and 
10 atm. of H2 in water, in the presence of NEt3. The catalyst was recycled, with 
yields of 100, 98, 95 and 90% in the first four runs and optical purities of 52, 50, 46 
and 41%, and no leaching was observed. The analogous homogeneous system was 
not active for this transformation due to insolubility in water. 
 
Scheme 1.4.3 Hydrogenation of itaconic acid (R = H) or dimethyl itaconate (R = CH3) 
1.4.3.3 Immobilisation by Electronic Interactions 
This method relies on the ionic exchange capabilities of some inorganic 
materials (clays, zeolites, etc.) and polymeric resins. The most common case is that 
in which the support presents anionic charges that allow the interaction with cationic 
complexes by exchange with the initial counterion of the positively charged catalyst 
(Figure 1.4.6).
104, 106, 110
 As a drawback, this immobilisation technique can only be 
applied if the catalyst is known to remain charged during the complete catalytic 
cycle. Natural or synthetic clays are the preferred supports. They are aluminosilicates 
where isomorphic substitutions among cations (Al/Si, Mg/Al, etc.) generate charge 
defaults and the subsequent anionic nature. 
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Figure 1.4.6 Electrostatic interaction between an anionic support and a cationic metal 
complex 
One of the first examples of electrostatic immobilisation of rhodium 
complexes on clays was published by Uematsu and co-workers.
114
 They reported the 
cationic exchange of [Rh(BINAP)(cod)][ClO4] with sodium hectorites (clays) by 
intercalation of the complex between the clay sheets in a mixture of acetonitrile and 
water (Figure 1.4.7). The system was tested for the hydrogenation of itaconates 
(Scheme 1.4.3) and gave complete conversions in methanol in 2 hours, but with very 
poor enantioselectivities. The recycling of this catalyst was not reported. 
 
Figure 1.4.7  [Rh(BINAP)(cod)]
+
 complex immobilised by electrostatic interaction with an 
anionic clay 
1.4.3.4 Immobilisation by Coordinative Interactions 
In this type of immobilisation, a group from the support coordinates to the 
metal centre of the catalyst (Figure 1.4.8).
110
 This coordination can be direct or 
through a previous modification of the support with covalently grafted small 
molecules, e.g. aminopropyl silica. 
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Figure 1.4.8 Coordinative interaction between a functionalised support and a metal catalyst 
One example of this approach was the immobilisation of rhodium 
hydrogenation catalysts onto basic carbon by Stevenson et al.
115
 Complexes of the 
type [Rh(nbd)(diphosphine)][BF4] (nbd = norbornadiene) were anchored to 
unmodified carbon surfaces via Rh-O coordinative bonds (Figure 1.4.9) and tested 
in the hydrogenation of prochiral C=C bonds like that of dimethyl itaconate (R = 
CH3 in Scheme 1.4.3). The results showed similar activities to those obtained with 
the homogeneous analogues (complete conversions reached within minutes) and 
improved enantioselectivities. When the diphosphine used was 2,4-
bis(diphenylphosphino)pentane (bdpp), the enantiomeric excess was 78% (70% in 
the homogeneous system), with no leaching observed by ICP analysis after three 
reuses. 
 
Figure 1.4.9 [Rh(nbd)(bdpp)]
+
 complex immobilised on basic carbon through a Rh-O 
coordinative interaction 
1.4.4 Examples of Immobilised Ruthenium Complexes 
The Noyori-type TsDPEN ligand or derived ligands are probably the most 
frequently used for transfer hydrogenations with ruthenium, and numerous examples 
have been published where the Ru-TsDPEN moiety has been, to a higher or lower 
extent, successfully immobilised. For instance, Wang and co-workers studied the 
performance of complexes of ruthenium with the silica-supported TsDPEN ligand 
(Figure 1.4.10).
116
 The complexes were prepared in situ by addition of [RuCl2(p-
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cymene)]2 to the corresponding supported ligand, and the reduction of acetophenone 
was tested in water with HCO2Na as the hydrogen donor (Scheme 1.4.4). The 
mixture of Ru-23 (1 mol%) and tetrabutylammonium bromide (TBAB) as an 
additive gave > 99% yield with 96% e.e. after 2 hours for the first three runs, and the 
catalyst could be reused six times with maintained enantioselectivities and still 
quantitative yields. Various other ketones could be reduced with the same method, in 
some cases achieving eleven possible reuses, but no leaching information was 
reported. Ligands 24 and 25 (MCM-41 and SBA-15) gave worse results. 
 
Figure 1.4.10 TsDPEN ligand supported on different types of silica 
 
Scheme 1.4.4 Wang’s conditions for the reduction of acetophenone. S/C = 100 
In the same year, Xiao et al. reported the immobilisation of Ru-TsDPEN on 
poly(ethyleneglycol) (Figure 1.4.11).
117
 The catalyst was tested in the asymmetric 
transfer hydrogenation of acetophenone in water with HCO2Na (Scheme 1.4.5). 99% 
conversion was obtained after 1 hour, with 92% enantiomeric excess. Compared 
with the immobilised system in HCO2H-Et3N, the reaction in HCO2Na-H2O gave a 
much faster rate. At the end of each reduction, a solvent of low polarity such as 
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diethyl ether could be added to precipitate the PEG-supported Ru-TsDPEN, and the 
catalyst could be reused more than ten times with no loss in enantioselectivity, 
although 0.4% of leached Ru was detected by ICP analysis. 
 
Figure 1.4.11 Poly(ethyleneglycol)-supported Ru-TsDPEN 
 
Scheme 1.4.5 Xiao’s conditions for the reduction of acetophenone. S/C = 100 
The group of Li developed a strategy to anchor Ru-TsDPEN to a mesoporous 
silica which had been previously modified with the introduction of magnetic 
nanoparticles, so the catalyst could be recovered with the aid of an external 
magnet.
118
 After immobilisation of the ligand (Figure 1.4.12), the complex was 
generated in situ by addition of [RuCl2(p-cymene)]2. The system was tested in the 
asymmetric reduction of substituted dihydroisoquinoline (Scheme 1.4.6), giving 
98% yield and 94% e.e. in 1.5 hours, very similar results to those obtained with the 
corresponding homogeneous analogue. The supported catalyst could be reused nine 
times with enantioselectivities ranging from 90 to 94% and increasing reaction times 
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of 1.5-7 hours. A leaching of 11 mol% Ru was detected by ICP analysis after the 
nine runs.  
 
Figure 1.4.12 TsDPEN ligand immobilised onto magnetic mesoporous silica 
 
Scheme 1.4.6 Li’s conditions for the reduction of substituted dihydroisoquinoline. S/C = 100 
The same group also published an interesting example of encapsulated Ru-
TsDPEN in SBA-16 silica.
119
 They used silylating agents containing organic groups 
with different hydrophobic or hydrophilic properties in order to tune the 
microenvironment of the silica nanocages and enhance the diffusion rates of 
substrates and products. The two silylating agents that they tested are shown in 
Figure 1.4.13. Different systems with varied ratios of the two silylating agents were 
used in the asymmetric transfer hydrogenation of acetophenone and other substrates 
in HCO2Na-H2O. The best results were always obtained when the nanocages had 
been exclusively modified with amphiphilic groups. 
 
     Chapter 1 
45 
 
Figure 1.4.13 a) lipophilic propyltrimethoxysilane and b) amphiphilic N-
trimethoxysilylpropyl-N,N,N-tri-n-butylammonium 
Another example involving magnetic nanoparticles was that of Fan and co-
workers.
120
 They modified the arene in Ru-TsDPEN to include an ammonium salt 
(Figure 1.4.14), suitable to form a pseudorotaxane complex with dibenzo-24-crown-
8-functionalised magnetic nanoparticles. In this case, the hydrogenation of 2-
methylquinoline was examined (Scheme 1.4.7), which could take place 
homogeneously. Upon completion of the reaction, the functionalised magnetic 
nanoparticles could be added to form the insoluble pseudorotaxane, later separated 
from the product by decantation with the aid of an external magnet. The catalyst 
could be then disassembled and reused. A total of five runs were performed, with 2 
mol% Ru, giving constant 89% e.e. and activities in the range 95-99%. 
 
Figure 1.4.14 Ru-TsDPEN complex modified with a dialkylammonium salt in the arene 
 
Scheme 1.4.7 Fan’s conditions for the hydrogenation of 2-methylquinoline. S/C = 50 
More recently, Liu et al. have reported the immobilisation of chiral N'-
alkylated TsDPEN complexes of ruthenium, forming double-stranded hydrophobic 
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linear polystyrene, on zirconium phosphonate layers (Figure 1.4.15).
121
 The 
heterogeneous catalysts were obtained by radical polymerisation of a TsDPEN-
derived system, subsequent coordination with [RuCl2(p-cymene)]2 and, finally, co-
precipitation of the [P(O)(OH)2] functionalised polymer with NaH2PO4 and ZrOCl2. 
This system gave, in the asymmetric transfer hydrogenation of acetophenone with 
HCO2H-Et3N, > 99% conversion with 94.9% e.e. in 16 hours, with a substrate to 
catalyst ratio of 100 and a temperature of 50ºC. Using only the polystyrene chains, 
abundant leaching of Ru was observed, but the further anchoring to the rigid porous 
backbone of the zirconium layers allowed five recycles of the catalyst. 
 
Figure 1.4.15 Polymeric Ru-TsDPEN complexes supported onto inorganic zirconium layers 
1.5 Cancer 
Cancer is the common name for a group of diseases that are characterised by 
excessive cell proliferation due to the loss of growth control by certain cells. 
Whereas most adult cells reach senescence and cease dividing, tumour cells are 
immortal and might divide without limit. There are two types of tumours: benign 
tumours, which rarely threaten life, and malignant tumours, which may become 
invasive and are life-threatening. The latter are those properly known as cancers. The 
causes of cancer are varied, but generally involve agents that damage DNA, such as 
chemical carcinogens, radiation or some viruses.
122
 Such a cellular stress as DNA 
damage, in healthy cells, is normally dealt with by genes like the p53 transcription 
factor, whose function is to trigger biological responses for cellular suicide, 
including cell cycle arrest or cell death by apoptosis. However, in tumour cells, the 
p53 function is frequently inactivated, allowing the uncontrolled cell propagation.
123, 
124
 Besides the formation of primary tumours, most cancerous cells have the ability 
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to migrate, invading nearby or distant secondary sites where they can proliferate in a 
process called metastasis, probably the most lethal consequence of cancers.
125
 
Within the United Kingdom, the most commonly diagnosed cancers are 
breast cancer in women and prostate cancer in men, with five-year survival rates of 
84.3 and 80.2% respectively, according to data from 2010.
126
 These two, together 
with lung and colorectal cancers, made up to 53% of the 268,758 cases of malignant 
tumours registered in England in 2010. The lowest five-year survival among both 
women and men (3.4 and 4.4%) is found in people diagnosed with pancreatic cancer. 
Universal treatments against cancer include surgery, radiotherapy (use of radiation, 
normally X-rays), hormone therapy (in some hormone sensitive cases like breast, 
prostate, ovarian or kidney cancers that grow in response to hormones, medicines are 
used to block the effects of these) or chemotherapy, used by themselves or in 
combinations.
127
 The latter is the utilisation of cell killing or cytotoxic drugs for the 
treatment of the disease, and, among more than 100 compounds available, 
metallodrugs show promising prospects and are under continuous study, with a few 
examples already in the market and the clinic. 
1.6 Platinum-Based Anticancer Drugs 
1.6.1 Cisplatin 
Cisplatin or cis-diamminedichloroplatinum(II) (Figure 1.6.1) was the first 
anticancer metal complex introduced in the clinic and is still broadly used in the 
treatment of, for example, testicular, head and neck, bladder and cervical cancers.
127
 
Its anticancer properties were discovered by Rosenberg in 1965 during an 
investigation of the effect of electrical fields on the growth of bacteria using 
platinum electrodes. These platinum electrodes were thought to be inert, but in fact 
gave rise to electrolysis products such as cisplatin, responsible for the observed 
elongation of the cells.
128
 The drug was first tested in vivo with mice in 1969,
129
 and 
used with patients in 1971,
130
 but it did not obtain the approval of the US Food and 
Drug Administration (FDA) until 1978.
130
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Figure 1.6.1 Structure of cisplatin 
The primary target of cisplatin is commonly considered to be the 
chromosomal DNA. The drug can enter the cells either by passive diffusion or with 
the help of transporters like the copper transporter-1 (CTR1). Once inside the cell, 
cisplatin is activated by aquation (replacement of one or the two chlorides by water 
molecules), which is possible due to the low chloride concentrations in the 
cytoplasm (23 mM). Binding to DNA occurs predominantly at the N7 position of 
guanine (G) (Figure 1.6.2) and, occasionally, adenine (A), generating a series of 
different Pt-DNA adducts (Scheme 1.6.1)
130-132
 that prevent DNA replication and 
transcription. 
 
Figure 1.6.2 N7 position in guanine 
 
Scheme 1.6.1 Mechanism of action of cisplatin 
Among the Pt-DNA adducts that might be formed, the more abundant one 
corresponds to a bifunctional intrastrand (on the same strand) crosslink between two 
     Chapter 1 
49 
adjacent guanines (60-65%), considered to be the responsible factor for the 
antitumour activity of cisplatin. Other adducts include intrastrand crosslinks between 
guanine and adenine, between two guanines separated by a third base, 
monofunctional adducts on guanines or interstrand crosslinks on opposite DNA 
strands.
130, 133-135
 
The three major problems derived from the use of cisplatin are its severe 
toxicity, mainly in the form of nephrotoxicity (damage to the kidneys), its lack of 
solubility, which prevents oral administration, and the acquired or intrinsic resistance 
to the drug observed in some tumours. The latter may be due to successful repair or 
tolerance after Pt-DNA adduct formation, or scarce DNA binding, this one derived 
from the loss of membrane transporters or the cytoplasmic detoxification via 
reactions with thiol-containing species.
130, 132
 Platinum(II) is a soft Lewis acid and 
tends to bind sulfur atoms,
136
 present in the amino acids cysteine and methionine. 
Since the discovery of cisplatin, research into new platinum- and, in general, metal-
based anticancer drugs has tried to overcome the aforementioned drawbacks, and 
find improved physicochemical properties (stability and solubility in water) and 
therapeutic advantages (reduced toxicity and higher spectrum of activity). 
1.6.2 Carboplatin 
Carboplatin or cis-diammine-[1,1-cyclobutane-dicarboxylato]platinum(II) 
(Figure 1.6.3) was first administered to patients in 1982 and approved in 1989.
130
 It 
was developed by substituting the very labile chloride groups in cisplatin with a 
bidentate dicarboxylate, a more stable leaving group, which provides it with a lower 
rate of aquation and, consequently, lower toxicity. Once carboplatin has been 
monoaquated, the dicarboxylate group becomes more labile, so, initially, the drug 
binds monofunctionally to DNA. Equal binding of cisplatin and carboplatin to DNA 
(which requires a 20- to 40-fold larger dose of the latter) results in similar lesions 
and, thus, cytotoxicity.
137
 Carboplatin is used to treat ovarian and lung cancers,
127
 
showing no nephrotoxicity, but myelosuppression (reduced production of blood 
cells) as the dose-limiting side effect.
137
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Figure 1.6.3 Structure of carboplatin 
1.6.3 Oxaliplatin 
Oxaliplatin or cis-(1R,2R)-diamminecyclohexane oxalatoplatinum(II) 
(Figure 1.6.4) was the third and last platinum drug to be approved by the FDA in 
2002.
130
 It was discovered by Kuretani and co-workers in 1978
138
 and it introduces 
the advantages of a greater solubility than that of cisplatin,
138
 and a broader spectrum 
of activity in comparison to cisplatin or carboplatin, being active against some 
cisplatin-resistant cells and colorectal cancers, principally in combination with 5-
fluorouracil (5-FU).
139
 While cisplatin adducts interact with some damage 
recognition proteins producing a signal transduction pathway that leads to cell cycle 
arrest and/or apoptosis, oxaliplatin adducts seem to be poorly recognised by these 
proteins. The mechanism of action and resistance of oxaliplatin is, thus, different, 
and this is believed to result from the type of DNA lesions induced by the 
diamminecyclohexane ligand.
139
 
 
Figure 1.6.4 Structure of oxaliplatin 
1.7 Metallocenes 
The antitumour properties of Cp2TiCl2 or titanocene dichloride (Figure 1.7.1) 
were discovered in 1979 by Köpf and Köpf-Maier after in vivo studies on mice with 
transplanted Ehrlich ascites tumour (EAT) cells.
140
 Subsequently, other metallocene 
dichlorides were tested against the same cancer type. Cp2ZrCl2 and Cp2HfCl2  
showed no activity in vivo, which was initially considered a result of the larger 
distance between the chlorides in these complexes compared with the titanium 
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analogue.
141
 The complexes Cp2VCl2 and Cp2MoCl2, on the other hand, proved 
active against EAT in mice, and this led to an investigation of the possible 
differences in the behaviour of all of the mentioned metallocenes against EAT cells 
in vitro.
142
 While Cp2VCl2 is able to inhibit cellular growth in vitro at concentrations 
of 5 × 10
-6
 M, Cp2TiCl2 and Cp2MoCl2 are only active at concentrations 100 times 
those of vanadocene dichloride, and Cp2ZrCl2 or Cp2HfCl2 require concentrations of 
5 × 10
-3
 M to kill in vitro-cultured cells.
142
 
 
Figure 1.7.1 Structure of titanocene dichloride 
Metallocene dihalides resemble cisplatin in that they share a cis-MX2 
structure where the halides can be hydrolysed to generate the active species that 
eventually binds to DNA. However, the chloride hydrolysis steps of Cp2MCl2 
complexes are much faster than those of cisplatin.
143
 This is probably due to the 
increased preference for H2O (hard base) of hard metals such as Ti(IV) in 
comparison to the soft Pt(II).
136
 Another feature of metallocene complexes is that 
they might suffer hydrolytic displacement of the η5-cyclopentadienyl ligands, 
depending principally on the metal and the solution pH.
143
 At physiological pH, the 
η5-C5H5 hydrolysis of Cp2ZrCl2 is rapid and that of Cp2TiCl2 is also noticeable. Only 
Cp2VCl2 seems stable under the same conditions,
143
 which relates to its higher in 
vitro activity (see above). For this reason and a poor solubility in water, Cp2TiCl2 
was generally administered in 10% DMSO/90% saline solutions at low pH, despite a 
slightly faster rate of η5-C5H5 hydrolysis in DMSO than in pure water (30% of the 
Cp rings hydrolyse in 100% DMSO solutions after 24 hours).
144
 
Titanocene dichloride is 100 times less cytotoxic than cisplatin and 2 times 
less cytotoxic than carboplatin against A2780 ovarian tumour cells, but presents 
different side effects, hepatic toxicity being the most important one, while for 
cisplatin and carboplatin the dose-limiting side effects are nephrotoxicity and 
myelotoxocity respectively.
145
 Cp2TiCl2 maintains its activity against cisplatin-
     Chapter 1 
52 
resistant A2780cis ovarian cancer cells: this cell line is 1.5-fold more resistant to 
Cp2TiCl2 than A2780, but the resistance increases to 12.7-fold in the case of 
cisplatin.
145
  
Extensive studies and promising in vitro and in vivo results with mice made 
titanocene dichloride enter clinical trials. Rübben and co-workers, for example, 
analysed the responses to Cp2TiCl2 of a number of patients with renal-cell carcinoma 
(RCC) in a Phase II study, but none of them showed positive results at the end of the 
treatment.
146
 Cp2TiCl2 was eventually discarded as an anticancer drug, but opened 
the way to the more recent evaluation of diverse metallocene derivatives that intend 
to increase the anticancer activity of the parent complex. 
The most common modifications of Cp2MCl2 complexes involve substitution 
on the cyclopentadienyl rings, in order to improve factors such as solubility or rate of 
hydrolysis. The group of Tacke has reported, for instance, the synthesis of a series of 
bridged and unbridged titanocenes with methoxy-phenyl or benzodioxole 
substituents that exceed the cytotoxicity of the unsubstituted titanocene dichloride.
147
 
Within the McGowan group, a number of Cp2MCl2 compounds with ionised amino 
pendant arm substituents in one or the two η5-C5H5 rings have been synthesised and 
published (Figure 1.7.2). These salts are soluble in polar solvents such as methanol 
or water, and are generally more potent than Cp2TiCl2 and cytotoxic against 
cisplatin-resistant cell lines.
148-150
 
 
Figure 1.7.2 Examples of modified metallocenes published by the McGowan group 
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1.8 Ruthenium Complexes 
1.8.1 NAMI-A 
Imidazolium trans-[imidazoledimethylsulfoxide-tetrachlororuthenate(III)] or 
NAMI-A (Figure 1.8.1) is one of the two ruthenium complexes with anticancer 
properties that has entered clinical trials. It was originally synthesised by the group 
of Sava as an improvement to NAMI, which is the same complex with Na
+
 as the 
cation instead of the protonated imidazole. NAMI, despite showing good antitumour 
and antimetastatic activity, co-crystallises with solvent molecules and degrades in 
air, while NAMI-A is stable and can be obtained in high purity.
151
  
 
Figure 1.8.1 Structure of NAMI-A 
The most singular characteristic of NAMI-A is its lack of direct cytotoxicity, 
observed in a number of studies with different cell lines in vitro.
152
 Nevertheless, 
preclinical investigations in vivo showed that NAMI-A increased the lifetime 
expectancy of tumour-bearing mice due to its antimetastatic capabilities. Unlike, for 
example, cisplatin, NAMI-A did not reduce the growth of primary tumours, but once 
these had been surgically removed, the animals treated with NAMI-A presented 
better survival prospects.
153
 The mechanism of action of NAMI-A has not been 
completely elucidated, but its antimetastatic behaviour responds to several factors: 
this complex salt has anti-angiogenic properties (reduces the formation of new blood 
vessels); it exerts a cytostatic effect (inhibition of cell growth and multiplication) by 
reversible arrest of cells in the premitotic phase, instead of a cytotoxic effect (cell 
killing); and prevents the invasion of the extracellular matrix by tumour cells.
154, 155
 
NAMI-A, like the other anticancer drugs discussed here, seems to coordinate 
to DNA through the N7 atom of guanine or adenine, which has been proven in 
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studies with the 9-methyladenine model.
156
 The hydrolysis of NAMI-A is pH and 
[Cl
−
] dependent and, in the hypoxic environment of tumours (pH = 6.0-7.0), the aqua 
replacement of the DMSO moiety is favoured over the hydrolysis of one chloride. 
This means that, in water, the coordination site to DNA bases is the DMSO site of 
the parent compound.
156
 The pharmacokinetics, toxicity and maximum tolerated 
dose of NAMI-A in patients have been investigated during Phase I clinical trials, and 
no severe toxicity has been found.
157
 This advantage over platinum-based drugs is 
considered the result of the poor cytotoxicity of NAMI-A. 
1.8.2 KP1019 
Indazolium trans-[tetrachlorobis(indazole)ruthenate(III)] or KP1019 (Figure 
1.8.2) was the second ruthenium-based anticancer agent to be considered for clinical 
trials. This complex is stable in the solid state but only moderately soluble in water, 
so, generally, it is prepared in situ from the corresponding sodium salt during clinical 
testing. The main advantages that KP1019 introduces with respect to cisplatin are its 
activity against colon carcinomas, which are not treatable with the platinum drug, 
and scarce levels of acquired resistance, apart from the absence of serious side 
effects that was concluded from Phase I clinical trials.
158
 
 
Figure 1.8.2 Structure of KP1019 
KP1019 is transformed into the aqua species at physiological conditions, with 
a decomposition rate of less than 0.9% per hour and a half-life of 74.3 hours.
159
 In 
the blood plasma, the drug reacts to a large extent with serum proteins such as 
albumin (80-90%) and transferrin (approx. 2%), which are thought to act as 
“reservoir” and transporter into cells respectively.160 KP1019 is activated by 
reduction to ruthenium(II) species, which coordinate faster to biomolecules, in the 
hypoxic environments of tumours.
161
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1.9 Project Aims 
The aims of this project were to: 
 Synthesise and characterise novel complexes of ruthenium with arene or 
pentamethylcyclopentadienyl (Cp*) ligands (Figure 1.9.1). 
 
Figure 1.9.1 Summary of the synthetic strategies employed 
 Investigate the alternatives for the immobilisation of functionalised arene- or 
Cp*-Ru complexes through covalent bonding to solid supports, so they can be used 
as heterogeneous catalysts (Scheme 1.9.1). 
 
Scheme 1.9.1 General structures of the complexes synthesised and the intended 
immobilisation strategy 
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 Test the complexes as catalysts for homogeneous transfer hydrogenation 
reactions. 
 Test the complexes as anticancer agents against the HT-29 and A2780 cell 
lines. 
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2.1 Introduction 
This chapter presents the synthesis of a library of functionalised η6-arene 
ruthenium complexes which try to mimic the performance of the p-cymene 
ruthenium dimer, which is catalytically active towards hydrogen transfer reactions in 
the presence of diphosphine or diamine chelating ligands.
1-3
 The functionalised 
dimers (2.3 to 2.9) have a similar general structure to the p-cymene dimer (Figure 
2.1.1), but they include groups that, in principle, could be covalently attached to 
functionalised supports. The starting materials for the preparation of these complexes 
were two different 2,5-dihydrophenyl carboxy compounds (2.1 and 2.2). These have 
the same general structure but differ in their chain lengths: 2,5-dihydrophenylacetic 
acid (one carbon length chain) and 2,5-dihydro-4-phenylbutyric acid (three carbon 
length chain). 2.10 is a functionalised η6-arene ruthenium monomer with a 
coordinated pyridine. 
 
Figure 2.1.1 Ruthenium p-cymene dimer [RuX2C6H4(CH3)(CH(CH3)2)]2. X = Cl or I 
The routes to the two ligands (compounds 2.1 and 2.2) had been previously 
developed,
4, 5
 as well as those to the complexes 2.3, 2.5 and 2.6.
4, 5
  The syntheses 
and characterisations of five novel compounds (2.4 and 2.7 to 2.10) are reported. All 
of the species discussed in this chapter are shown in Figure 2.1.2. 
The functionalised η6-arene ruthenium dimers were originally prepared to be 
immobilised through the arene ligand and used as heterogeneous catalysts for 
hydrogen transfer reactions. Their different functional groups (acids and esters) 
could give various possibilities when binding covalently to modified supports and 
the different chain lengths could be tested to see if dimers with longer pendant arms 
(more flexible) resembled the commonly more active homogeneous catalysts. The 
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variation of the halides used responded to an interest in analysing possible different 
activities. 
 
Figure 2.1.2 General structures of the complexes discussed in Chapter 2 
2.2 2,5-Dihydrophenyl Carboxy Ligands 
The general process for the synthesis of ligands 2.1 and 2.2 was a Birch 
reduction starting from phenylacetic acid (n = 1) or 4-phenylbutyric acid (n = 3) 
respectively, using sodium, liquid ammonia and ethanol at -78°C under a nitrogen 
atmosphere (Scheme 2.2.1). This procedure had been reported previously by 
Sheldrick et al.
4
 and it had also been used within the McGowan group.
5
  
 
Scheme 2.2.1 General scheme for the synthesis of 2,5-dihydrophenyl carboxy ligands 
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Both compounds were obtained in high yields above 80% and, as they had 
been previously characterised in the literature,
4
 only 
1
H NMR analyses were 
recorded to confirm the formation of the products. Even with incomplete reactions 
the final mixtures were used in subsequent transformations because ruthenium 
sources of the type RuX3 only react with the dihydrophenyl (reduced) compounds. 
2.3 Functionalised η6-Arene Ruthenium Complexes 
2.3.1 Synthesis of [RuX2C6H5(CH2)nCOOR]2 (X = Cl, Br) (2.3−2.8) 
The 2,5-dihydrophenyl carboxy ligands 2.1 and 2.2, together with ruthenium 
sources, RuCl3 ∙ 3H2O or RuBr3, were the starting materials used for the synthesis of 
the complexes presented in this section (2.3 to 2.8). The general process taking place 
was a redox reaction in which ruthenium(III) was reduced to ruthenium(II) and the 
dihydrophenyl carboxy ligand was oxidised to its aromatic form, giving η6-
coordination to the metal (Scheme 2.3.1), as shown by Bennett and Smith.
6
 The 
solvent varied depending on the functional group required in the final complex; a 5:1 
mixture of acetone/water was employed to prepare acids while the use of ethanol 
resulted in the formation of esters. 
 
Scheme 2.3.1 General scheme for the synthesis of functionalised η6-arene ruthenium dimers 
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Compounds 2.3, 2.5 and 2.6 had been previously synthesised by Sheldrick et 
al. and analysed for both η6- and N-terminal labelling of amino acids and peptides. In 
the first case, they tested the labelling of aromatic amino acids by formation of [(η6-
arene)2Ru
II
] sandwich complexes. The N-terminal coupling reactions were 
performed by a carbodiimide method.
4
 Compounds 2.3 and 2.6 had also been 
prepared within the McGowan group as starting materials to possible anticancer 
ruthenium drugs.
5
  
All of these functionalised η6-arene dimers were obtained as orange or red 
powders in yields ranging from 5 to 87%, and they exhibited poor solubilities in non-
coordinating solvents (particularly the acids 2.3 to 2.5). 
2.3.1.1 NMR Data for Compound 2.8 
A labelled diagram of complex 2.8 is given in Figure 2.3.1. The assignment 
shown in Table 2.3.1 corresponds to the data from the 
1
H and 
13
C{
1
H} NMR spectra 
presented in Figure 2.3.2 and Figure 2.3.3 respectively. The 
1
H NMR spectrum of 
this complex contains chemical shifts for the aromatic protons between 5.0 and 6.0 
ppm, shifted upfield from the normal aromatic region due to coordination to 
ruthenium. This is a common factor for all of the arene and cyclopentadienyl 
complexes synthesised in this project. 
1
J 
1
H-
13
C{
1
H} HMQC (Figure 2.3.4) and 
2,3
J 
1
H-
13
C{
1
H} HMBC (Figure 2.3.5) NMR spectra for compound 2.8 are also given, 
and helped in the assignment of the aromatics and the CH2 protons “e”, “f” and “g”. 
 
Figure 2.3.1 Labelled diagram of complex 2.8 
 
     Chapter 2 
71 
7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
5.984.043.994.034.004.032.083.87
1
.2
4
1
.2
6
1
.2
7
1
.8
8
1
.9
0
1
.9
2
1
.9
4
1
.9
6
2
.3
6
2
.3
7
2
.3
9
2
.5
8
2
.6
0
2
.6
2
4
.0
9
4
.1
1
4
.1
3
4
.1
5
5
.3
9
5
.4
0
5
.5
9
5
.6
1
5
.6
2
5
.6
5
5
.6
6
5
.6
8
5.6 5.5 5.4
Chemical Shift (ppm)
5
.6
8
5
.6
6
5
.6
5
5
.6
2
5
.6
1
5
.5
9
5
.4
0
5
.3
9
2.5 2.0 1.5
Chemical Shift (ppm)
2
.6
0
2
.5
8
2
.3
9 2
.3
7
2
.3
6
1
.9
6
1
.9
4
1
.9
2
1
.9
0
1
.8
8
1
.2
7
1
.2
6
1
.2
4
 
Figure 2.3.2 
1
H NMR spectrum of 2.8 in CDCl3 at 400.13 MHz and 300.0 K. 
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Figure 2.3.3 
13
C{
1
H} NMR spectrum of 2.8 in CDCl3 at 100.61 MHz and 300.0 K 
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Figure 2.3.4 
1
J 
1
H-
13
C{
1
H} HMQC spectrum of 2.8 in CDCl3 at 300.0 K 
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Figure 2.3.5 
2,3
J 
1
H-
13
C{
1
H} HMBC spectrum of 2.8 in CDCl3 at 300.0 K 
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1H Chemical Shift, δ (ppm) Assignment 
5.66 (t, 
3
J(H-H) = 5.4 Hz, 4H) b 
5.61 (t, 
3
J(H-H) = 5.3 Hz, 2H) c 
5.39 (d, 
3
J(H-H) = 5.6 Hz, 4H) a 
4.12 (q, 
3
J(H-H) = 7.1 Hz, 4H) i 
2.60 (m, 4H) e 
2.37 (t, 
3
J(H-H) = 7.3 Hz, 4H) g 
1.92 (quintet, 
3
J(H-H) = 7.5 Hz, 4H) f 
1.26 (t, 
3
J(H-H) = 7.0 Hz, 6H) j 
13
C{
1
H} Chemical Shift, δ (ppm) Assignment 
172.7 (Q) h 
100.5 (Q) d 
84.1 (CH) b 
80.5 (CH) a 
80.0 (CH) c 
60.6 (CH2) i 
33.5 (CH2) g 
32.9 (CH2) e 
24.8 (CH2) f 
14.3 (CH3) j 
 
Table 2.3.1 
1
H and 
13
C{
1
H} chemical shift assignment for complex 2.8 
2.3.2 Synthesis of [RuI2C6H5CH2COOCH2CH3]2 (2.9) 
Complex 2.9 was synthesised by halide exchange from complex 2.6 with NaI 
in chloroform (Scheme 2.3.2). This method was adapted from a similar procedure 
presented in the literature by Keppler et al.
7
 and some previous work with iridium by 
one of the partner companies of this project.
8
 The compound was obtained in 14% 
yield as a red solid. 
 
Scheme 2.3.2 Synthesis of complex 2.9 [RuI2C6H5CH2COOEt]2 
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2.3.2.1 NMR Data for Compound 2.9 
A labelled diagram of complex 2.9 is presented in Figure 2.3.6. The 
1
H NMR 
spectrum of this compound is shown in Figure 2.3.7. Table 2.3.2 gives the 
1
H and 
13
C{
1
H} NMR data assignments. 
 
Figure 2.3.6 Labelled diagram of complex 2.9 
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Figure 2.3.7 
1
H NMR spectrum of 2.9 in CDCl3 at 500.23 MHz and 298.4 K. 
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1H Chemical Shift, δ (ppm) Assignment 
5.84 (t, 
3
J(H-H) = 5.4 Hz, 2H) c 
5.67 (t, 
3
J(H-H) = 5.6 Hz, 4H) b 
5.61 (d, 
3
J(H-H) = 5.6 Hz, 4H) a 
4.16 (q, 
3
J(H-H) = 7.2 Hz, 4H) g 
3.69 (s, 4H) e 
1.27 (t, 
3
J(H-H) = 7.2 Hz, 6H) h 
13
C{
1H} Chemical Shift, δ (ppm) Assignment 
170.0 (Q) f 
96.8 (Q) d 
86.1 (CH) a 
84.0 (CH) c 
83.0 (CH) b 
61.7 (CH2) g 
40.6 (CH2) e 
14.1 (CH3) h 
 
Table 2.3.2 
1
H and 
13
C{
1
H} chemical shift assignment for complex 2.9 
2.3.2.2 X-Ray Crystallographic Analysis of Compound 2.9 
Red crystals of complex 2.9 suitable for X-ray crystallography were obtained 
by vapour diffusion of pentane into a saturated solution of the complex in 
dichloromethane. Complex 2.9 crystallised in a monoclinic cell, and structural 
solution was performed in the space group P21/c. The asymmetric unit is formed by 
half of the dimer, and there are 2 molecules in the unit cell. The molecular structure 
of compound 2.9 is shown in Figure 2.3.8 and selected bond lengths and angles are 
given in Table 2.3.3. 
 
Figure 2.3.8 Molecular structure of complex 2.9. Displacement ellipsoids are at the 50% 
probability level. Hydrogen atoms are omitted for clarity 
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Bond Distance (Å) Bond Distance (Å) 
I(1)-Ru(1) 2.7470(4) C(8)-O(1) 1.204(4) 
I(2)-Ru(1) 2.7402(4) O(2)-C(8) 1.344(5) 
C(1)-C(7) 1.512(5) O(2)-C(9) 1.461(4) 
C(7)-C(8) 1.527(4) C(9)-C(10) 1.507(6) 
Ru(1)-Ring 
Centroid 
1.680 Ru(1)-C(arene) 2.202 
Bond Angle (°) Bond Angle (°) 
I(2)-Ru(1)-I(1) 87.474(12) C(1)-C(7)-C(8) 113.9(3) 
Ru(1)*-I(2)-Ru(1) 96.899(10) O(2)-C(8)-C(7) 108.7(3) 
I(2)*-Ru(1)-I(2) 83.101(10) C(8)-O(2)-C(9) 116.5(3) 
C(1)-Ru(1)-I(2) 91.06(9) O(2)-C(9)-C(10) 107.5(3) 
C(6)-Ru(1)-C(1) 37.45(12) O(1)-C(8)-O(2) 125.4(3) 
 
Table 2.3.3 Selected interatomic distances and angles for compound 2.9 with s.u.s. shown in 
parenthesis. * = Symmetry generated atoms 
The distances Ru-I(1) and Ru-I(2), which are around 2.74 Å are, as expected, 
longer than the Ru-Cl distances (around 2.45 Å) in other complexes presented in this 
document. The average distance from ruthenium to the carbon atoms in the arene 
ring is 2.202 Å, and the ring centroid is 1.680 Å away from the metal centre. These 
two values are in accordance with those observed in the other arene complexes 
reported here. When packed in the solid state, complex 2.9 does not present any 
classic hydrogen bond or other type of significant interaction. 
2.3.3 Synthesis of [RuCl2(C6H5CH2COOCH2CH3)(NC5H5)] (2.10) 
Compound 2.10 was prepared by stirring complex 2.6 and pyridine in 
dichloromethane at room temperature overnight (Scheme 2.3.3). It was isolated as an 
orange/yellow product in 71% yield. 
 
Scheme 2.3.3 Synthesis of complex 2.10 [RuCl2(C6H5CH2COOEt)(NC5H5)] 
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2.3.3.1 NMR Data for Compound 2.10 
Figure 2.3.9 shows the labelled diagram of complex 2.10. The 
1
H and 
13
C{
1
H} NMR spectra of this compound are shown in Figure 2.3.10 and Figure 
2.3.11. Table 2.3.4 gives the spectral assignments for this complex. 
 
Figure 2.3.9 Labelled diagram of complex 2.10 
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Figure 2.3.10 
1
H NMR spectrum of 2.10 in CDCl3 at 500.23 MHz and 298.6 K 
     Chapter 2 
78 
170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
1
4
.1
9
3
8
.8
0
6
1
.6
8
8
2
.0
7
8
3
.8
3
8
5
.9
3
9
4
.7
8
1
2
4
.8
6
1
3
8
.0
3
1
5
5
.2
7
1
6
9
.5
9
 
Figure 2.3.11 
13
C{
1
H} NMR spectrum of 2.10 in CDCl3 at 75.47 MHz and 300.0 K 
1H Chemical Shift, δ (ppm) Assignment 
9.05 (d, 
3
J(H-H) = 5.2 Hz, 2H) i 
7.77 (t, 
3
J(H-H) = 7.4 Hz, 1H) k 
7.33 (t, 
3
J(H-H) = 6.8 Hz, 2H) j 
5.64 (t, 
3
J(H-H) = 5.4 Hz, 2H) b 
5.58 (t, 
3
J(H-H) = 5.2 Hz, 1H) c 
5.54 (d, 
3
J(H-H) = 5.6 Hz, 2H) a 
4.20 (q, 
3
J(H-H) = 7.2 Hz, 2H) g 
3.67 (s, 2H) e 
1.29 (t, 
3
J(H-H) = 7.2 Hz, 3H) h 
13
C{
1
H} Chemical Shift, δ (ppm) Assignment 
169.6 (Q) f 
155.3 (CH) i 
138.0 (CH) k 
124.9 (CH) j 
94.8 (Q) d 
85.9 (CH) b 
83.8 (CH) a 
82.1 (CH) c 
61.7 (CH2) g 
38.8 (CH2) e 
14.2 (CH3) h 
 
Table 2.3.4 
1
H and 
13
C{
1
H} chemical shift assignment for complex 2.10 
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2.3.3.2 X-Ray Crystallographic Analysis of Compound 2.10 
Orange crystals of complex 2.10 suitable for X-ray crystallography were 
obtained by vapour diffusion of diethyl ether into a saturated solution of the complex 
in chloroform. Compound 2.10 crystallised in a triclinic cell and structural solution 
was performed in the space group P  . This compound and, in general, all of the 
ruthenium complexes synthesised and analysed by X-ray crystallography in this 
project exhibit the characteristic pseudo-tetrahedral geometry of η6-arene or η5-
cyclopentadienyl ruthenium complexes (“piano stool” or “half sandwich” structure). 
The η6 π-bonded arene occupies one vertex of the tetrahedron, with the other three 
ligands in the remaining three sites. The molecular structure of complex 2.10 is 
shown in Figure 2.3.12, and selected bond lengths and angles are given in  
Table 2.3.5. The average Ru-C(arene) bond distance is 2.209 Å, and the ring centroid 
is at 1.683 Å from the ruthenium atom, both comparable with previous ruthenium 
compounds.
9, 10
 No classic hydrogen bonds have been found, but there are some π-π 
stacking interactions (3.622 Å) between the pyridine rings (Figure 2.3.13). 
 
Figure 2.3.12 Molecular structure of complex 2.10. Displacement ellipsoids are at the 50% 
probability level. Hydrogen atoms are omitted for clarity 
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Bond Distance (Å) Bond Distance (Å) 
Ru(1)-N(1) 2.156(3) C(8)-O(1) 1.213(4) 
Ru(1)-Cl(1) 2.4438(8) C(8)-O(2) 1.344(4) 
Ru(1)-Cl(2) 2.4308(8) O(2)-C(9) 1.483(4) 
C(1)-C(2) 1.439(4) C(9)-C(10) 1.520(5) 
C(1)-C(7) 1.519(4) N(1)-C(11) 1.362(4) 
C(7)-C(8) 1.527(4) C(11)-C(12) 1.394(5) 
Ru(1)-Ring 
Centroid 
1.683 Ru(1)-C(arene) 2.209 
Bond Angle (°) Bond Angle (°) 
Cl(2)-Ru(1)-Cl(1) 86.47(3) C(1)-Ru(1)-C(6) 37.54(11) 
N(1)-C(11)-C(12) 122.9(3) C(1)-C(7)-C(8) 114.9(2) 
C(11)-N(1)-Ru(1) 119.2(2) O(1)-C(8)-C(7) 122.1(3) 
N(1)-Ru(1)-Cl(1) 84.75(7) O(1)-C(8)-O(2) 124.5(3) 
N(1)-Ru(1)-Cl(2) 87.00(7) O(2)-C(9)-C(10) 110.4(3) 
 
Table 2.3.5 Selected interatomic distances and angles for compound 2.10 with s.u.s. shown 
in parenthesis 
 
Figure 2.3.13 Compound 2.10 viewed along the c axis showing π-π stacking interactions 
(3.622 Å) between molecules. Hydrogen atoms omitted for clarity 
2.4 General Observations and Comments 
The functionalised η6-arene ruthenium complexes synthesised in this chapter 
react in solutions of strongly nucleophilic coordinating solvents, despite being air 
stable. This is in accordance with previous observations reported in the literature.
11-15
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These reactions are photochemical, although they could be thermal with more 
unstable and reactive polycyclic aromatic ligands (with more delocalised π-
electrons).
16
 The result is the displacement of the arene, which can be proven by 
1
H 
NMR with the appearance of peaks at around 7 ppm (non-coordinated aromatics).  
Valerga and co-workers studied these reactions for dimers with bridging 
ligands with the general formula [{RuCl2(η
6
-arene)}2(-L)], and suggested that the 
first mechanistic step is the cleavage of the dimer to give a monomer with a 
coordinated arene, two chlorides and the ligand L. This then reacts with a molecule 
of solvent, which replaces the ligand L, and finally, three other molecules of solvent 
displace the arene completely, resulting in the final product, with the general formula 
RuCl2(sol)4 (sol = coordinating solvent) (Scheme 2.4.1).
11
 This product has already 
been characterised and displays tetragonal symmetry with trans linear chlorides.
15
 
Although the complexes presented in this chapter differ slightly in structure, the 
mechanism in which their reactions with coordinating solvents proceed could be 
similar to the one proposed by Valerga, but this has not been investigated further. 
 
Scheme 2.4.1 Sequence suggested by Valerga et al. for the reaction with coordinating 
solvents
11
 
The decomposition in solution of coordinating solvents is accelerated by 
exposing freshly prepared samples to UV lamps, which proves that these reactions 
are photochemical. With p-cymene ligands, these types of reactions have not been 
noticed during this project, which may indicate that electron withdrawing groups 
such as carboxylic acids and esters in the functionalised complexes make them less 
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stable. Arene exchange reactions in aromatic solvents have not been observed, 
although they are also suggested in the literature.
17
 
The acid dimers 2.3, 2.4 and 2.5 are only soluble in coordinating solvents 
such as acetonitrile or methanol, which ends up producing the above mentioned 
photochemical reactions with the solvents. However, the esters are generally more 
soluble, and also dissolve in non-coordinating solvents like chloroform, 
dichloromethane or toluene at its boiling point. 
2.5 Immobilisation Attempts 
The η6-arene complexes presented in this chapter contain functionalities 
suitable, in principle, to react covalently with modified surfaces and give 
immobilised metal compounds that could be tested as heterogeneous hydrogen 
transfer catalysts. However, when different nucleophilic groups, mainly amines, 
were reacted with the carboxy dimers, the final mixtures were complex. This 
possibly indicates that both reactions with the carboxylic carbons and the ruthenium 
centres were taking place. 
In a different attempt, instead of starting from a dimeric complex, ligand 2.1 
was immobilised onto aminopropyl silica (amine loading of 2 mmol/g and moisture 
content of approx. 5%) (Figure 2.5.1), which was provided by an industrial partner 
to this project, Yorkshire Process Technology Ltd. (spin out of Reaxa Ltd.). A 
peptide coupling reagent, N,N'-diisopropylcarbodiimide (DIC) (Figure 2.5.2), was 
used for the formation of the corresponding amide. 
 
Figure 2.5.1 Aminopropyl silica 
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Figure 2.5.2 N,N'-Diisopropylcarbodiimide (DIC) 
The resulting immobilised ligand was analysed by elemental analysis, with 
imprecise results, and solid state infrared spectroscopy, after drying it in a vacuum 
oven at 50-60°C to eliminate the infrared bands at 3400 and 1600 cm
-1
 from the 
silica support, assigned to the stretching and deformation vibrations of adsorbed 
water molecules.
18
 The appearance of an intense peak at 1628 cm
-1
 indicated the 
formation of an amide (Figure 2.5.3). 
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                                  a)                                                        b) 
Figure 2.5.3 Infrared spectra (Transmittance % vs. cm
-1
) of a) aminopropyl silica, b) 
immobilised ligand 2.1 
The immobilised ligand was then mixed with RuCl3 ∙ 3H2O in refluxing 
ethanol. The resulting dark green powder has not been analysed, but was proven to 
be inactive against the N-alkylation of tert-butylamine with phenethyl alcohol. The 
loading of ruthenium within the supported material was believed to be very low. 
2.6 Conclusions 
Two 2,5-dihydrophenyl carboxy ligands and seven functionalised η6-arene 
ruthenium complexes have been successfully synthesised. The aim was to investigate 
the possibilities for covalent immobilisation onto modified supports through pendant 
1628 cm-1 
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chains in the arene ligands and utilisation of the heterogeneous complexes as 
catalysts for hydrogen transfer reactions. The arene coordination to ruthenium in all 
of these complexes has proven poorly stable, contrary to expectations, preventing the 
immobilisation objective. 
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3.1 Introduction 
This chapter introduces the synthesis and characterisation of a library of 
pyridine η6-p-cymene ruthenium monomers with general structure [RuX2(p-
cymene)(NC5H4R)] (R = different substituting groups in the pyridine ring) as 
potential hydrogen transfer catalysts (3.4 to 3.13). A tert-butylamine monomer (3.3) 
was also synthesised following the same general method, and the preparation of a 
complex with two pyridine ligands (3.14) is presented as well. The starting materials 
used for all of these syntheses were the ruthenium dimers with general structure 
[RuX2(p-cymene)]2 (X = Cl for complex 3.1 and X = I for complex 3.2), also 
reported in this chapter. Six of the complexes described had been previously 
synthesised (3.1 to 3.4, 3.6 and 3.12) by different methods. All of the species 
discussed in this chapter are shown in Figure 3.1.1. 
 
Figure 3.1.1 General structures of the complexes discussed in Chapter 3 
The η6-p-cymene ruthenium dimers 3.1 and 3.2 are commercially available. 
Nevertheless, during this project, they were synthesised because it was easy and 
cheap. Some methods previously published for their synthesis include those of 
Bennett and Smith,
1
 Jensen et al.
2
 and Keppler et al.
3
 These two complexes have 
previously proven good pre-catalysts for the hydrogen transfer reactions of interest 
under homogeneous conditions. They generally need the presence of a nucleophilic 
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ligand to cleave the dimer and form the proposed active species, and this 
nucleophilic ligand is commonly a chelating diphosphine or diamine.
4-6
 The 
monomers (3.3 to 3.14) presented in this chapter contain monodentate ligands 
instead, such as pyridines and tert-butylamine. The different functional groups in 
positions 2, 3 and 4 of the pyridines could influence the lability of the pyridine as 
coordinating ligand and, thus, the activity of the catalyst. Fujita and co-workers have 
already used some iridium pyridine (2-hydroxypyridine) complexes as catalysts for 
dehydrogenations of alcohols.
7
  
3.2 η6-p-Cymene Ruthenium Dimers 
3.2.1 Synthesis of [RuCl2(C10H14)]2 (3.1) 
Compound 3.1 was obtained as a red microcrystalline powder in 89% yield 
from the reaction of α-terpinene with RuCl3 ∙ 3H2O in refluxing ethanol (Scheme 
3.2.1). This complex had already been synthesised within the McGowan group using 
the same procedure,
8
 adapted from the publications mentioned above.  
 
Scheme 3.2.1 Synthesis of complex 3.1 [RuCl2(p-cymene)]2 
3.2.2 Synthesis of [RuI2(C10H14)]2 (3.2) 
Compound 3.2 was obtained in 86% yield from the reaction of 3.1 with 
sodium iodide in chloroform/water (Scheme 3.2.2), which was a modification of 
previously published work
1, 3
 and a method utilised for halide exchange reactions 
with iridium complexes that was personally communicated to the author.
9
 It is a dark 
red microcrystalline powder, soluble in most common solvents. Characterisation data 
was compared with the literature to confirm product formation.
3
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Scheme 3.2.2 Synthesis of complex 3.2 [RuI2(p-cymene)]2 
When compound 3.1 was mixed with bromide salts in an attempt to prepare 
[RuBr2(p-cymene)]2 using this method, the result was always a mixture of both the 
chloride and the bromide dimers that could not be separated. The bromide dimer is 
not commercially available. 
3.3 η6-p-Cymene Ruthenium Monomers 
3.3.1 Synthesis of [RuCl2(C10H14)(NH2C(CH3)3)] (3.3) 
Complex 3.3 was produced in 74% yield as an orange solid from compound 
3.1 and tert-butylamine in dichloromethane (Scheme 3.3.1). It is an air and moisture 
stable, neutral, 18 electron complex. The characterisation data matched that 
previously reported by Wright et al., who synthesised this compound using 
ultrasound.
10
 
 
Scheme 3.3.1 Synthesis of complex 3.3 [RuCl2(C10H14)(NH2C(CH3)3)] 
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3.3.1.1 X-Ray Crystallographic Analysis of Compound 3.3 
Orange crystals of complex 3.3 suitable for X-ray crystallography were 
obtained by vapour diffusion of pentane into a saturated solution of the complex in 
chloroform. Complex 3.3 crystallised in a monoclinic cell, and structural solution 
was performed in the space group P21/c. The asymmetric unit comprises one 
molecule of compound 3.3 and one molecule of disordered chloroform. This 
molecule of chloroform is disordered over two positions with an occupancy of 0.5. 
Some atoms in the molecule of the complex seemed also disordered, but the structure 
was solved without considering multiple occupancy in these cases. The molecular 
structure is shown in Figure 3.3.1 and selected bond lengths and angles are shown in 
Table 3.3.1. 
 
Figure 3.3.1 Molecular structure of complex 3.3. Displacement ellipsoids are at the 50% 
probability level. Hydrogen atoms and the molecule of chloroform are omitted for clarity 
The distance between the ruthenium centre and the arene ring centroid is 
1.688 Å. The bond length Ru(1)-N(1) is 2.207(3) Å, and the average Ru-C(arene) is 
2.202 Å, all comparable with previously published values.
11
 Compound 3.3 shows 
intermolecular hydrogen bonding between N(1)-H and Cl(2) with an N...Cl distance 
of 3.602 Å and between C(3)-H and Cl(2) with a C...Cl distance of 3.616 Å. Each 
molecule interacts doubly with two neighbouring molecules in the solid state 
(Figure 3.3.2). 
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Bond Distance (Å) Bond Distance (Å) 
Ru(1)-N(1) 2.207(3) C(4)-C(8) 1.422(11) 
Ru(1)-Cl(1) 2.4483(12) C(8)-C(9) 1.566(10) 
Ru(1)-Cl(2) 2.4704(12) C(8)-C(10) 1.555(5) 
C(1)-C(2) 1.411(15) N(1)-C(11) 1.516(6) 
C(1)-C(7) 1.547(14) C(11)-C(12) 1.539(7) 
Ru(1)-Ring 
Centroid 
1.688 Ru(1)-C(arene) 2.202 
Bond Angle (°) Bond Angle (°) 
Cl(1)-Ru(1)-Cl(2) 86.09(4) C(6)-Ru(1)-C(1) 37.1(3) 
N(1)-C(11)-C(12) 108.4(4) C(6)-C(1)-C(2) 188.8(8) 
C(11)-N(1)-Ru(1) 130.4(3) C(5)-C(4)-C(8) 129.7(8) 
N(1)-Ru(1)-Cl(1) 83.13(9) C(4)-C(8)-C(9) 112.3(8) 
N(1)-Ru(1)-Cl(2) 78.20(10) C(10)-C(8)-C(9) 109.2(9) 
 
Table 3.3.1 Selected interatomic distances and angles for compound 3.3 with s.u.s. shown in 
parenthesis 
 
Figure 3.3.2 Compound 3.3 viewed along the c axis showing hydrogen bonding 
interactions. Only the hydrogen atoms involved in these interactions are shown. The 
molecules of chloroform are omitted for clarity 
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3.3.2 Synthesis of [RuX2(C10H14)(NC5H4R)] (X = Cl, I) (3.4−3.13) 
The general method for the synthesis of these pyridine complexes (3.4 to 
3.13) is given in Scheme 3.3.2. They were all prepared as yellow, orange or brown 
solids under mild conditions from compounds 3.1 or 3.2 and the corresponding 
ligand in dichloromethane at room temperature, in yields above 70%. Some of these 
compounds had been previously synthesised and characterised; the pyridine 
monomer with chlorides (3.4) was prepared by Bennett and Smith,
1
 the 2-
aminopyridine complex (3.6) was reported by Aronson et al. and was characterised 
by X-ray crystallography,
11
 and the 4-dimethylaminopyridine compound (3.12) was 
obtained by Köytepe and co-workers.
12
 These published syntheses, though, involved 
high temperatures. All of the other pyridine monomers (3.5, 3.7 to 3.11 and 3.13) are 
novel to the best knowledge of the author. 
 
Scheme 3.3.2 General scheme for the synthesis of the pyridine η6-p-cymene ruthenium 
monomers 
3.3.2.1 X-Ray Crystallographic Analysis of Compound 3.4 
Orange crystals of complex 3.4 suitable for X-ray crystallography were 
obtained by vapour diffusion of pentane into a saturated solution of the complex in 
chloroform. Compound 3.4 crystallised in a monoclinic cell, and structural solution 
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was performed in the space group P21/c. The complex exhibits the typical “half-
sandwich” structure of η6-arene ruthenium complexes. The molecular structure of 
compound 3.4 is shown in Figure 3.3.3. 
 
Figure 3.3.3 Molecular structure of complex 3.4. Displacement ellipsoids are at the 50% 
probability level. Hydrogen atoms are omitted for clarity 
Bond Distance (Å) Bond Distance (Å) 
Ru(1)-N(1) 2.1720(15) C(4)-C(8) 1.537(2) 
Ru(1)-Cl(1) 2.4382(5) C(8)-C(9) 1.562(3) 
Ru(1)-Cl(2) 2.4514(5) C(8)-C(10) 1.546(3) 
C(1)-C(2) 1.448(3) N(1)-C(11) 1.372(2) 
C(1)-C(7) 1.526(3) C(11)-C(12) 1.407(3) 
Ru(1)-Ring 
Centroid 
1.686 Ru(1)-C(arene) 2.219 
Bond Angle (°) Bond Angle (°) 
Cl(1)-Ru(1)-Cl(2) 87.446(18) C(6)-Ru(1)-C(1) 38.13(7) 
N(1)-C(11)-C(12) 122.27(18) C(6)-C(1)-C(2) 117.16(15) 
C(11)-N(1)-Ru(1) 122.46(12) C(5)-C(4)-C(8) 123.22(15) 
N(1)-Ru(1)-Cl(1) 86.84(4) C(4)-C(8)-C(9) 108.58(14) 
N(1)-Ru(1)-Cl(2) 85.89(4) C(10)-C(8)-C(9) 110.89(16) 
 
Table 3.3.2 Selected interatomic distances and angles for compound 3.4 with s.u.s. shown in 
parenthesis 
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Table 3.3.2 gives selected bond lengths and angles of complex 3.4. The 
average Ru-C(arene) distance for this complex is 2.219 Å, similar to other η
6
-arene 
ruthenium complexes.
11
 The distance between the metal atom and the arene ring 
centroid is 1.686 Å, also comparable with previously reported data. 
3.3.2.2 NMR Data for Compound 3.7 
The structure of complex 3.7 is represented and labelled in Figure 3.3.4. 
Figure 3.3.5 shows the 
1
H NMR spectrum of this complex together with those of 
free 3-hydroxypyridine, [RuCl2(p-cymene)]2 (3.1) and free p-cymene. The region 
between 1.0 and 3.3 ppm includes the aliphatic p-cymene peaks, which are very 
distinctive and allow easy identification of the different compounds. The pyridine 
region between 6.7 and 8.8 ppm shows how the peaks of coordinated 3-
hydroxypyridine in complex 3.7 differ from those of the free ligand; when 
coordinated, 3-hydroxypyridine presents four well separated and differentiable 
peaks. 
13
C{
1
H} (Figure 3.3.6), 
1
H-
1
H COSY (Figure 3.3.7), 
1
J 
1
H-
13
C{
1
H} HMQC 
(Figure 3.3.8) and 
2,3
J 
1
H-
13
C{
1
H} HMBC (Figure 3.3.9) NMR spectra are also 
given. The chemical shift assignment is shown in Table 3.3.3.  
The 
1
H-
1
H COSY and 
1
J
 1
H-
13
C{
1
H} HMQC spectra obtained for complex 
3.7 are analogous to those of the rest of the 3-substituted pyridine complexes in this 
chapter, and, accordingly, similar assignments have been made. 
 
Figure 3.3.4 Labelled diagram of complex 3.7 
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Figure 3.3.5 
1
H NMR spectra of 3.7 (yellow), free 3-hydroxypyridine (green), 3.1 (blue) and 
free p-cymene (red) in CDCl3 
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Figure 3.3.6 
13
C{
1
H} NMR spectrum of 3.7 in CDCl3 at 125.77 MHz and 299.2 K 
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Figure 3.3.7 
1
H-
1
H COSY spectrum of 3.7 in CDCl3 at 300.0 K 
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Figure 3.3.8 
1
J 
1
H-
13
C{
1
H} HMQC spectrum of 3.7 in CDCl3 at 300.1 K 
From the 
1
J 
1
H-
13
C{
1
H} HMQC spectrum of compound 3.7, it can be 
observed that carbon “h” is at a higher field than “l” in the 13C{1H} NMR spectrum 
of this complex. This is maintained in complex 3.8, but reversed in complexes 3.9, 
3.10 and 3.11. The quaternary carbon “i” gradually shifts from a lower to a higher 
field in the series 3.8 < 3.7 < 3.9 < 3.10 < 3.11, which corresponds to the decreasing 
electronegativities of the substituents (F > O > Cl > Br > I). 
 
   Chapter 3 
97 
9 8 7 6 5 4 3 2 1
F2 Chemical Shif t (ppm)
0
50
100
150
200
F
1
 C
h
e
m
ic
a
l 
S
h
if
t 
(p
p
m
)
 
Figure 3.3.9 
2,3
J 
1
H-
13
C{
1
H} HMBC spectrum of 3.7 in CDCl3 at 300.0 K 
1
H Chemical Shift, δ (ppm) Assignment 
8.63 (m, 1H) h 
8.34 (d, 
3
J(H-H) = 5.1 Hz, 1H) l 
7.02 (dd, 
3
J(H-H) = 8.3, 1.5 Hz, 1H) j 
6.89 (dd, 
3
J(H-H) = 8.1, 5.6 Hz, 1H) k 
5.47 (d, 
3
J(H-H) = 5.1 Hz, 2H) e 
5.23 (d, 
3
J(H-H) = 6.0 Hz, 2H) f 
2.98 (m, 1H) b 
2.04 (s, 3H) a 
1.31 (d, 
3
J(H-H) = 6.8 Hz, 6H) c 
13
C{
1
H} Chemical Shift, δ (ppm) Assignment 
153.3 (Q) i 
146.1 (CH) l 
144.2 (CH) h 
126.3 (CH) j 
124.6 (CH) k 
103.5 (Q) d 
97.4 (Q) g 
83.1 (CH) e 
82.1 (CH) f 
30.7 (CH) b 
22.3 (CH3) c 
18.2 (CH3) a 
 
Table 3.3.3 
1
H and 
13
C{
1
H} chemical shift assignment for complex 3.7 
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3.3.2.3 X-Ray Crystallographic Analysis of Compound 3.7 
Orange crystals of compound 3.7 suitable for X-ray crystallography were 
obtained by vapour diffusion of pentane into a saturated solution of the complex in 
dichloromethane. Compound 3.7 crystallised in a monoclinic cell, and structural 
solution was performed in the space group P21/c. The molecular structure of this 
complex is shown in Figure 3.3.10. 
 
Figure 3.3.10 Molecular structure of complex 3.7. Displacement ellipsoids are at the 50% 
probability level. Hydrogen atoms are omitted for clarity 
Selected bond lengths and angles for complex 3.7 are given in Table 3.3.4. 
The average Ru-C(arene) distance for this complex is 2.201 Å and the distance 
between the metal atom and the arene ring centroid is 1.675 Å. The distance Ru-N(1) 
is 2.1505(17) Å. 
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Bond Distance (Å) Bond Distance (Å) 
Ru(1)-N(1) 2.1505(17) C(4)-C(8) 1.525(3) 
Ru(1)-Cl(1) 2.4389(5) C(8)-C(9) 1.543(3) 
Ru(1)-Cl(2) 2.4313(6) C(8)-C(10) 1.531(3) 
C(1)-C(2) 1.441(3) N(1)-C(11) 1.349(3) 
C(2)-C(3) 1.410(3) C(11)-C(12) 1.410(3) 
C(1)-C(7) 1.513(3) O(1)-C(12) 1.369(3) 
Ru(1)-Ring 
Centroid 
1.675 Ru(1)-C(arene) 2.201 
Bond Angle (°) Bond Angle (°) 
Cl(2)-Ru(1)-Cl(1) 87.07(2) C(6)-Ru(1)-C(1) 37.82(8) 
N(1)-C(11)-C(12) 122.5(2) C(6)-C(1)-C(2) 117.39(18) 
C(11)-N(1)-Ru(1) 120.78(14) C(5)-C(4)-C(8) 123.69(18) 
N(1)-Ru(1)-Cl(1) 87.26(5) C(10)-C(8)-C(9) 110.63(18) 
N(1)-Ru(1)-Cl(2) 85.16(5) O(1)-C(12)-C(11) 116.77(19) 
 
Table 3.3.4 Selected interatomic distances and angles for compound 3.7 with s.u.s. shown in 
parenthesis 
Compound 3.7 shows intermolecular hydrogen bonding between O(1)-H and 
Cl(1) with a O...Cl distance of 3.178 Å and between C(3)-H and Cl(1) with a C...Cl 
distance of 3.683 Å in the solid state. Each molecule interacts doubly with two 
neighbouring molecules (Figure 3.3.11).  
 
Figure 3.3.11 Compound 3.7 viewed along the a axis showing hydrogen bonding 
interactions. Only the hydrogen atoms involved in these interactions are shown 
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3.3.2.4 NMR Data for Compound 3.8 
A labelled diagram of complex 3.8 is shown in Figure 3.3.12 and its 
chemical shift assignment is given in Table 3.3.5. 
13
C-
19
F coupling can be observed 
for the pyridine carbons in the 
13
C{
1
H} NMR spectrum (Figure 3.3.13), but the 
corresponding 
1
H-
19
F coupling is not well resolved in the 
1
H NMR spectrum. 
 
Figure 3.3.12 Labelled diagram of complex 3.8 
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Figure 3.3.13 
13
C{
1
H} NMR spectrum of 3.8 in CDCl3 at 75.47 MHz and 300.1 K 
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1
H Chemical Shift, δ (ppm) Assignment 
8.99 (br. s, 1H) h 
8.90 (d, 
3
J(H-H) = 4.8 Hz, 1H) l 
7.50 (m, 1H) j 
7.33 (m, 1H) k 
5.46 (d, 
3
J(H-H) = 5.2 Hz, 2H) e 
5.25 (d, 
3
J(H-H) = 5.2 Hz, 2H) f 
2.98 (m, 1H) b 
2.10 (s, 3H) a 
1.31 (d, 
3
J(H-H) = 6.8 Hz, 6H) c 
13
C{
1
H} Chemical Shift, δ (ppm) Assignment 
158.7 (d, 
1
J(C-F) = 254.3 Hz, Q) i 
151.3 (d, 
4
J(C-F) = 3.8 Hz, CH) l 
143.9 (d, 
2
J(C-F) = 31.7 Hz, CH) h 
124.9 (m, CH) j & k 
103.7 (s, Q) d 
97.3 (s, Q) g 
82.8 (s, CH) e 
82.3 (s, CH) f 
30.7 (s, CH) b 
22.3 (s, CH3) c 
18.2 (s, CH3) a 
 
Table 3.3.5 
1
H and 
13
C{
1
H} chemical shift assignment for complex 3.8 
3.3.2.5 X-Ray Crystallographic Analysis of Compound 3.8 
Orange prisms of complex 3.8 suitable for X-ray crystallography were 
obtained by vapour diffusion of pentane into a saturated solution of the complex in 
chloroform. Compound 3.8 crystallised in a monoclinic cell, and structural solution 
was performed in the space group P21/c. The molecular structure of this complex is 
shown in Figure 3.3.14 and selected bond lengths and angles are given in Table 
3.3.6. The average Ru-C(arene) distance for this complex is 2.187 Å and the distance 
between the metal atom and the arene ring centroid is 1.662 Å. The distance Ru-N(1) 
is 2.1397(13) Å. 
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Figure 3.3.14 Molecular structure of complex 3.8. Displacement ellipsoids are at the 50% 
probability level. Hydrogen atoms are omitted for clarity 
Bond Distance (Å) Bond Distance (Å) 
Ru(1)-N(1) 2.1397(13) C(4)-C(8) 1.514(2) 
Ru(1)-Cl(1) 2.4174(4) C(8)-C(9) 1.536(2) 
Ru(1)-Cl(2) 2.4009(4) C(8)-C(10) 1.523(2) 
C(1)-C(2) 1.426(2) N(1)-C(11) 1.345(2) 
C(2)-C(3) 1.411(2) C(11)-C(12) 1.383(2) 
C(1)-C(7) 1.502(2) F(1)-C(12) 1.350(2) 
Ru(1)-Ring 
Centroid 
1.662 Ru(1)-C(arene) 2.187 
Bond Angle (°) Bond Angle (°) 
Cl(2)-Ru(1)-Cl(1) 87.344(15) C(6)-Ru(1)-C(1) 37.96(6) 
N(1)-C(11)-C(12) 120.50(16) C(6)-C(1)-C(2) 117.24(13) 
C(11)-N(1)-Ru(1) 118.96(11) C(5)-C(4)-C(8) 123.11(13) 
N(1)-Ru(1)-Cl(1) 85.70(4) C(10)-C(8)-C(9) 110.91(15) 
N(1)-Ru(1)-Cl(2) 86.33(4) F(1)-C(12)-C(11) 117.92(16) 
 
Table 3.3.6 Selected interatomic distances and angles for compound 3.8 with s.u.s. shown in 
parenthesis 
3.3.2.6 X-Ray Crystallographic Analysis of Compound 3.10 
Orange needles of complex 3.10 suitable for X-ray crystallography were 
obtained by vapour diffusion of pentane into a saturated solution of the complex in 
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dichloromethane. Compound 3.10 crystallised in a monoclinic cell, and structural 
solution was performed in the space group P21/c. The molecular structure of this 
complex is shown in Figure 3.3.15. Selected bond lengths and angles are given in 
Table 3.3.7. The average Ru-C(arene) distance for this complex is 2.189 Å and the 
separation from the metal atom to the arene ring centroid is 1.670 Å. The distance 
Ru-N(1) is 2.1371(17) Å. 
 
Figure 3.3.15 Molecular structure of complex 3.10. Displacement ellipsoids are at the 50% 
probability level. Hydrogen atoms are omitted for clarity 
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Bond Distance (Å) Bond Distance (Å) 
Ru(1)-N(1) 2.1371(17) C(4)-C(8) 1.510(4) 
Ru(1)-Cl(1) 2.4165(5) C(8)-C(9) 1.540(4) 
Ru(1)-Cl(2) 2.4083(5) C(8)-C(10) 1.522(5) 
C(1)-C(2) 1.425(4) N(1)-C(11) 1.346(3) 
C(2)-C(3) 1.394(4) C(11)-C(12) 1.385(3) 
C(1)-C(7) 1.506(3) Br(1)-C(12) 1.895(2) 
Ru(1)-Ring 
Centroid 
1.670 Ru(1)-C(arene) 2.189 
Bond Angle (°) Bond Angle (°) 
Cl(2)-Ru(1)-Cl(1) 87.97(2) C(6)-Ru(1)-C(1) 37.19(8) 
N(1)-C(11)-C(12) 121.3(2) C(6)-C(1)-C(2) 118.7(2) 
C(11)-N(1)-Ru(1) 122.34(14) C(5)-C(4)-C(8) 123.9(3) 
N(1)-Ru(1)-Cl(1) 86.34(5) C(10)-C(8)-C(9) 110.9(3) 
N(1)-Ru(1)-Cl(2) 84.99(5) C(11)-C(12)-Br(1) 118.05(17) 
 
Table 3.3.7 Selected interatomic distances and angles for compound 3.10 with s.u.s. shown 
in parenthesis 
3.3.2.7 X-Ray Crystallographic Analysis of Compound 3.12 
Orange crystals of complex 3.12 suitable for X-ray crystallography were 
obtained by vapour diffusion of diethyl ether into a saturated solution of the complex 
in dichloromethane. Compound 3.12 crystallised in a monoclinic cell, and structural 
solution was performed in the space group P21/n. The molecular structure of this 
complex is shown in Figure 3.3.16. Selected bond lengths and angles are given in 
Table 3.3.8. The average Ru-C(arene) distance for this complex is 2.189 Å and the 
separation from the metal atom to the arene ring centroid is 1.663 Å. The ruthenium 
and the pyridine nitrogen atoms are separated by 2.1348(16) Å. All of this data is 
comparable to the other complexes reported in this chapter that have been analysed 
by X-ray crystallography. 
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Figure 3.3.16 Molecular structure of complex 3.12. Displacement ellipsoids are at the 50% 
probability level. Hydrogen atoms are omitted for clarity 
Bond Distance (Å) Bond Distance (Å) 
Ru(1)-N(1) 2.1348(16) C(4)-C(8) 1.519(3) 
Ru(1)-Cl(1) 2.4254(5) C(8)-C(9) 1.542(3) 
Ru(1)-Cl(2) 2.4198(5) C(8)-C(10) 1.531(3) 
C(1)-C(2) 1.440(3) N(1)-C(11) 1.363(2) 
C(2)-C(3) 1.399(3) C(13)-N(2) 1.353(2) 
C(1)-C(7) 1.504(3) N(2)-C(16) 1.460(3) 
Ru(1)-Ring 
Centroid 
1.663 Ru(1)-C(arene) 2.189 
Bond Angle (°) Bond Angle (°) 
Cl(2)-Ru(1)-Cl(1) 88.858(18) C(6)-Ru(1)-C(1) 37.85(7) 
N(1)-C(11)-C(12) 124.14(18) C(6)-C(1)-C(2) 117.00(17) 
C(11)-N(1)-Ru(1) 120.91(13) C(10)-C(8)-C(9) 111.08(18) 
N(1)-Ru(1)-Cl(1) 85.40(4) N(2)-C(13)-C(12) 123.37(17) 
N(1)-Ru(1)-Cl(2) 86.87(4) C(17)-N(2)-C(16) 118.18(16) 
 
Table 3.3.8 Selected interatomic distances and angles for compound 3.12 with s.u.s. shown 
in parenthesis 
3.3.3 Synthesis of [RuCl(C10H14)(NC5H5)2][SbF6] (3.14) 
Compound 3.14 was obtained in 100% yield from complex 3.4, pyridine and 
NaSbF6 in refluxing methanol (Scheme 3.3.3). It was originally an orange oil which 
crystallised out as orange needles over the course of a month. Different versions of 
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compound 3.14 had been previously synthesised by Dixneuf et al. (with BF4
 
as 
counterion)
13
 and Stephenson and co-workers (with PF6 as counterion).
14
 
 
Scheme 3.3.3 Synthesis of complex 3.14 [RuCl(C10H14)(NC5H5)2][SbF6]
 
3.3.3.1 NMR Data for Compound 3.14 
A labelled diagram of complex 3.14 is shown in Figure 3.3.17. 
1
H and 
13
C{
1
H} NMR spectra are given in Figure 3.3.18 and Figure 3.3.19. The chemical 
shift assignment for this compound is summarised in Table 3.3.9. 
 
Figure 3.3.17 Labelled diagram of complex 3.14 
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Figure 3.3.18 
1
H NMR spectrum of 3.14 in CDCl3 at 300.13 MHz and 300.0 K 
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Figure 3.3.19 
13
C{
1
H} NMR spectrum of 3.14 in CDCl3 at 75.47 MHz and 300.1 K 
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1
H Chemical Shift, δ (ppm) Assignment 
9.03 (d, 
3
J(H-H) = 5.3 Hz, 4H) h 
7.85 (t, 
3
J(H-H) = 7.6 Hz, 2H) j 
7.48 (t, 
3
J(H-H) = 6.9 Hz, 4H) i 
5.91 (d, 
3
J(H-H) = 6.0 Hz, 2H) e 
5.63 (d, 
3
J(H-H) = 5.9 Hz, 2H) f 
2.58 (m, 1H) b 
1.74 (s, 3H) a 
1.16 (d, 
3
J(H-H) = 6.8 Hz, 6H) c 
13
C{
1
H} Chemical Shift, δ (ppm) Assignment 
153.1 (CH) h 
138.1 (CH) j 
125.3 (CH) i 
101.8 (Q) d 
101.0 (Q) g 
87.7 (CH) e 
81.0 (CH) f 
29.8 (CH) b 
21.2 (CH3) c 
16.7 (CH3) a 
 
Table 3.3.9 
1
H and 
13
C{
1
H} chemical shift assignment for complex 3.14 
3.3.3.2 X-Ray Crystallographic Analysis of Compound 3.14 
Yellow needles of complex 3.14 suitable for X-ray crystallography were 
obtained by vapour diffusion of pentane into a saturated solution of the complex in 
dichloromethane. Compound 3.14 crystallised in an orthorhombic cell, and structural 
solution was performed in the space group Pbca. A large residual electron density 
was found at the anion SbF6, but the disorder could not be completely modelled. The 
structure of the cation is shown in Figure 3.3.20. Selected bond lengths and angles 
are given in Table 3.3.10. The distances Ru-N(1) and Ru-N(2) are 2.183(3) and 
2.146(3) Å respectively, both in the range of Ru-N(pyridine) distances observed for 
the rest of the complexes in this project. The average Ru-C(arene) distance for this 
complex is 2.232 Å and the separation between the arene ring centroid and the 
ruthenium atom is 1.709 Å. 
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Figure 3.3.20 Structure of the cation of complex 3.14. Displacement ellipsoids are at the 
50% probability level. The counterion SbF6 and hydrogen atoms are omitted for clarity 
Bond Distance (Å) Bond Distance (Å) 
Ru(1)-N(1) 2.183(3) C(8)-C(9) 1.558(6) 
Ru(1)-N(2) 2.146(3) C(8)-C(10) 1.551(7) 
Ru(1)-Cl(1) 2.4342(9) N(1)-C(11) 1.371(5) 
C(1)-C(2) 1.444(5) N(2)-C(16) 1.365(5) 
C(1)-C(7) 1.516(5) C(16)-C(17) 1.409(5) 
C(4)-C(8) 1.537(5) C(11)-C(12) 1.406(5) 
Ru(1)-Ring 
Centroid 
1.709 Ru(1)-C(arene) 2.232 
Bond Angle (°) Bond Angle (°) 
N(2)-Ru(1)-N(1) 82.56(11) C(3)-Ru(1)-C(2) 37.22(14) 
N(2)-Ru(1)-Cl(1) 88.02(9) C(6)-C(1)-C(2) 118.7(3) 
N(1)-Ru(1)-Cl(1) 85.81(8) C(10)-C(8)-C(9) 111.3(4) 
 
Table 3.3.10 Selected interatomic distances and angles for compound 3.14 with s.u.s. shown 
in parenthesis 
The packing of complex 3.14 in the solid state shows intramolecular 
hydrogen bonds between C(11)-H and Cl(1) with a C...Cl distance of 3.158(4) Å, 
and intermolecular hydrogen bonds between C(14)-H and F(4) with a C...F distance 
of 3.274(5) Å, between C(16)-H and F(4) with a C...F distance of 3.234(4) Å and 
between C(18)-H and F(5) with a C...F distance of 3.180(10) Å. 
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3.4 Conclusions 
A library of ten pyridine η6-p-cymene ruthenium monomers and one tert-
butylamine η6-p-cymene ruthenium monomer has been prepared. These neutral 
complexes have been obtained in dichloromethane at room temperature, very mild 
conditions as opposed to reflux or ultrasound methods used and published previously 
for the synthesis of some of them. A charged η6-p-cymene ruthenium complex with 
two pyridines has also been obtained. Characterisation by X-ray crystallography of 
some of these compounds showed similar structures; all of them seem to present the 
typical “half-sandwich” or “piano stool” disposition, with comparable bond lengths 
and angles. 
The objective of these syntheses was the study of new potential homogeneous 
catalysts with labile monodentate ligands for hydrogen transfer reactions. An 
influence from the different substitutions in the pyridines on lability and activity was 
expected. The catalytic results will be presented in Chapter 5. 
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η5-Pentamethylcyclopentadienyl and (5-
Hydroxypentyl)-tetramethylcyclopentadienyl 
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4.1 Introduction 
This chapter includes the synthesis and characterisation of η5-
pentamethylcyclopentadienyl (Cp*) and η5-(5-hydroxypentyl)-
tetramethylcyclopentadienyl (Cp
#
) ruthenium complexes (4.3 to 4.12), and the 
corresponding η5-coordinating ligands employed for their syntheses (4.1 and 4.2). 
Compounds 4.3 and 4.4 have the general structure [RuCl2Cp*
/#
]n and were 
synthesised as starting materials for compounds 4.5 to 4.11, which contain diverse 
commercially available diphosphines as ligands and have the general structure 
[RuClCp*
/#
(PP)]. The PP ligands used were 1,1'-bis(diphenylphosphino)methane 
(dppm), 1,1'-bis(diphenylphosphino)ferrocene (dppf), bis(2-
diphenylphosphinophenyl)ether (DPEphos) and 4,5-bis(diphenylphosphino)-9,9-
dimethylxanthene (Xantphos) (Figure 4.1.1). Complex 4.12 was synthesised from 
compound 4.5 by reaction with NaSbF6 and acetonitrile in methanol. Two 
tetramethylfulvene ruthenium(II) complexes (4.13 and 4.14) were obtained from 
reactions of 4.3 with diphenylacac. All of the species discussed in this chapter are 
shown in Figure 4.1.2. 
 
Figure 4.1.1 Diphosphine ligands used for the synthesis of complexes 4.5 to 4.11. a) dppm, 
b) dppf, c) DPEphos, d) Xantphos 
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Figure 4.1.2 General structures of the complexes discussed in Chapter 4 
Compounds 4.4, 4.7 and 4.9 to 4.14 are all novel. This includes all of the η5-
(5-hydroxypentyl)-tetramethylcyclopentadienyl (Cp
#
) ruthenium complexes. The rest 
of the compounds have been previously synthesised with different methods and 
details will be given throughout the chapter. 
After demonstrating the instability of the functionalised η6-arene ruthenium 
complexes in Chapter 2, the search for new heterogeneous catalysts continued with 
the syntheses of complexes with η5-coordinating ligands, which are expected to 
present higher coordination stabilities. The Cp
#
 complexes, with a (CH2)5OH 
pendant chain, could offer good possibilities for flexible immobilisation by covalent 
reaction of the –OH group, while the equivalent Cp* complexes were synthesised, in 
principle, for homogeneous activity comparison. 
4.2 Pentamethylcyclopentadiene and (5-Hydroxypentyl)-
Tetramethylcyclopentadiene Ligands 
The general synthesis of ligands 4.1 and 4.2 consisted of a lithiation of 2-
bromo-2-butene and then reaction of the product with an ester (ethyl acetate for 4.1) 
or lactone (caprolactone for 4.2) whose number of carbons (excluding the carboxylic 
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one and the OCH2CH3 fragment in ethyl acetate, which acts as a leaving group) 
determined the length of the resulting pendant chain. The last step was performed in 
acidic media to yield the cyclisation, facilitated by the good leaving –OH2
+
 group. A 
general mechanism is shown in Scheme 4.2.1. 
 
Scheme 4.2.1 General mechanism for the formation of the η5 ligands 
Both 4.1 and 4.2 were obtained as yellow oils in 58 and 55% yields 
respectively. To prevent Diels-Alder reactions, these ligands were kept in the freezer 
at -20ºC approx. The assignment of 4.2 was made considering just one of the three 
isomers that can be observed in the NMR spectrum (Figure 4.2.1). When these 
ligands are η5-coordinated to a metal centre, they form C5(CH3)5 or 
C5(CH3)4(CH2)5OH, and these species are abbreviated as Cp* and Cp
#
 respectively.  
Ligand 4.1 had been previously synthesised by Bergman et al.
1
 and ligand 4.2 
had been reported by Blacker and co-workers.
2
 Both of the ligands have been used 
extensively as coordinating ligands to rhodium(III) or iridium(III), for instance, in 
the formation of the SCRAM transfer hydrogenation catalyst [IrI2Cp*]2, and its 
functionalised derivative [IrI2Cp
#
]2, which has been attached to 
poly(ethyleneglycol).
2
 The use of Cp* with ruthenium is less common, mainly due to 
more complicated synthetic processes, but some examples are presented within this 
chapter. The coordination of Cp
#
 to ruthenium had not been reported so far. 
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Figure 4.2.1 Three regioisomers of compound 4.2 
4.3 Cp* and Cp# Ruthenium(III) Oligomers 
4.3.1 Synthesis of [RuCl2Cp*
/#
]n (4.3 and 4.4) 
The reaction of ligands 4.1 or 4.2 with RuCl3 ∙ 3H2O produced air sensitive 
Cp* or Cp
#
 Ru(III) complexes (4.3 and 4.4), with the general structure [RuCl2Cp*
/#
]n 
(Scheme 4.3.1). They were obtained as dark red or orange solids in 74 and 48% 
yields respectively, and kept in the glove box. According to Suzuki and co-workers, 
the reaction could proceed in boiling methanol, ethanol or isopropanol, but whereas 
the product from the reaction in ethanol is soluble in dichloromethane and 
chloroform, those from the reactions in methanol or isopropanol are almost insoluble 
in such solvents, indicating higher molecular weights, i.e. longer oligomers.
3
 Thus, 
ethanol was the solvent used in the present work. Koelle and Kossakowski also 
published that structures of this type of compounds in the solid state are formed by 
dimers.
4
 Complex 4.3 had been previously synthesised by Suzuki
3
 and Bercaw.
5
 
Both compounds 4.3 and 4.4 are paramagnetic because the ruthenium centre 
is in the oxidation state +3, containing one unpaired electron. This is reflected in 
their 
1
H NMR spectra, which present very broad peaks and unusual chemical shifts 
for the methyl groups. For 4.3, the 
1
H NMR spectrum consists of only one broad 
singlet at 4.67 ppm. 
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Scheme 4.3.1 General scheme for the synthesis of the complexes [RuCl2Cp*
/#
]n 
4.3.1.1 NMR Data for Compound 4.4 
Figure 4.3.1 shows a labelled diagram of complex 4.4. The 
1
H and 
13
C{
1
H} 
NMR spectra for this compound are given in Figure 4.3.2 and Figure 4.3.3 
respectively. Table 4.3.1 summarises the chemical shift assignment for this 
complex. 
 
Figure 4.3.1 Labelled diagram of complex 4.4 
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Figure 4.3.2 
1
H NMR spectrum of 4.4 in CDCl3 at 500.57 MHz and 300.0 K 
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Figure 4.3.3 
13
C{
1
H} NMR spectrum of 4.4 in CDCl3 at 125.77 MHz and 299.2 K 
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1
H Chemical Shift, δ (ppm) Assignment 
5.11 (br. s, 6H) c or d 
4.15 (br. s, 6H) c or d 
4.09 (m, 4H) f & j 
3.35 (br. s, 2H) i 
2.73 (br. s, 2H) h 
2.29 (m, 2H) g 
13
C{
1
H} Chemical Shift, δ (ppm) Assignment 
142.3 (Q) a or b 
135.3 (Q) a or b 
128.2 (Q) e 
63.3 (CH2) j 
33.7 (CH2) f & g 
27.2 (CH2) h 
24.6 (CH2) i 
12.5 (CH3) c or d 
11.8 (CH3) c or d 
 
Table 4.3.1 
1
H and 
13
C{
1
H} chemical shift assignment for complex 4.4 
4.4 Cp* and Cp# Diphosphine Ruthenium(II) Monomers 
4.4.1 Synthesis of [RuClCp*/#(PP)] (4.5-4.11) 
The unstable and paramagnetic ruthenium(III) complexes 4.3 and 4.4 were 
easily reduced to air stable diamagnetic ruthenium(II) compounds (4.5 to 4.11) by 
reaction with commercially available diphosphines. The diphosphines used include 
1,1'-bis(diphenylphosphino)methane (dppm), 1,1'-bis(diphenylphosphino)ferrocene 
(dppf), bis(2-diphenylphosphinophenyl)ether (DPEphos) and 4,5-
bis(diphenylphosphino)-9,9-dimethylxanthene (Xantphos) (Figure 4.1.1), which 
were chosen as the most promising by one of the project’s industrial partners after 
some screening of conditions for redox neutral alkylations with Ru(p-cymene) 
complexes. The reaction between the phosphine and [RuCl2Cp*
/#
]n is a redox 
reaction where ruthenium is reduced and the diphosphine is believed to act as both 
ligand and, at the same time, reducing agent (Scheme 4.4.1). Thus, to facilitate this, 
1.5 equivalents of the diphosphine were used for 1 equivalent of Ru. This resulted in 
better yields than stoichiometric 1 : 1 mixtures. The complexes 4.5 to 4.11 were 
obtained as either yellow or orange solids in yields ranging from 19 to 86%. 
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Scheme 4.4.1 General scheme for the synthesis of the complexes [RuClCp*
/#
(PP)] 
All of the [RuClCp
#
(PP)] complexes (4.9 to 4.11), i.e. those with the 
C5(CH3)4(CH2)5OH ligand, are novel to the best of the knowledge of the author. 
Among the [RuClCp*(PP)] complexes, 4.7 is novel. Compound 4.5 had been 
previously synthesised by White,
6
 Kollipara
7
 and Heinekey
8
 from 
[RuCp*(PPh3)2Cl], by Girolami
9
 from [RuCp*Cl]4, by Nolan
10
 from 
[RuCp*(cod)Cl] and by Koelle
4
 and co-workers from [Ru2Cp*2(μ-Cl)3], and 
characterised by X-ray crystallography by White et al.
6
 Compound 4.6 had been 
prepared by Day,
11
 Asai
12
 and Moret
13
 from either [RuCp*(PPh3)2Cl], 
[RuCp*(PMe3)2Cl] or [RuCp*Cl2]n/Zn. Complex 4.8 was reported by Nozaki et al.
14
 
These types of compounds were employed mainly as starting materials to other 
complexes and in redox/electrochemical studies.
11, 13
 The simple and straightforward 
synthetic method presented in this chapter had not been used before, which involved 
reactions at room temperature in dichloromethane under inert atmosphere. 
4.4.1.1 NMR Data for Compound 4.9 
A labelled diagram of compound 4.9 is given in Figure 4.4.1. 
1
H and 
13
C{
1
H} NMR spectra are presented in Figure 4.4.2 and Figure 4.4.3 respectively. 
The most characteristic feature in the 
1
H NMR spectrum is the appearance of two 
doublets of triplets for the CH2 in dppm, due to the two protons having different 
environments and the coupling to the two phosphorus atoms, which is also observed 
in some peaks of the 
13
C{
1
H} NMR. The chemical shifts assignment is given in 
Table 4.4.1. 
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Figure 4.4.1 Labelled diagram of complex 4.9 
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Figure 4.4.2 
1
H NMR spectrum of 4.9 in toluene-d8 at 500.57 MHz and 300.0 K 
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Figure 4.4.3 
13
C{
1
H} NMR spectrum of 4.9 in toluene-d8 at 125.77 MHz and 299.2 K 
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1
H Chemical Shift, δ (ppm) Assignment 
7.64-6.82 (20H) Aromatics 
4.47 (dt, 
2
J(H-H) = 14.5 Hz, 
2
J(H-P) = 9.4 Hz, 1H) k 
4.22 (dt, 
2
J(H-H) = 14.2 Hz, 
2
J(H-P) = 11.3 Hz, 1H) k 
3.26 (t, 
3
J(H-H) = 6.2 Hz, 2H) j 
2.23 (m, 2H) f, g, h or i 
1.81 (t, 
4
J(H-P) = 1.9 Hz, 6H) c or d 
1.79 (t, 
4
J(H-P) = 2.0 Hz, 6H) c or d 
1.36 (quint, 
3
J(H-H) = 7.6 Hz, 2H) f, g, h or i 
1.25 (m, 4H) f, g, h or i 
13
C{
1
H} Chemical Shift, δ (ppm) Assignment 
137.5 (s, Q) Aromatics 
133.7 (t, 
2,3
J(C-P) = 5.4 Hz, CH) Aromatics 
133.0 (t, 
2,3
J(C-P) = 5.4 Hz, CH) Aromatics 
92.6 (m, Q) a, b or e 
89.1 (t, 
2
J(C-P) = 2.6 Hz, Q) a, b or e 
87.9 (t, 
2
J(C-P) = 2.6 Hz, Q) a, b or e 
62.6 (s, CH2) j 
49.2 (t, 
1
J(C-P) = 19.2 Hz, CH2) k 
33.1 (s, CH2) f, g, h or i 
30.8 (s, CH2) f, g, h or i 
26.6 (s, CH2) f, g, h or i 
26.4 (s, CH2) f, g, h or i 
10.9 (s, CH3) c or d 
10.8 (s, CH3) c or d 
 
Table 4.4.1 
1
H and 
13
C{
1
H} chemical shift assignment for complex 4.9 
4.4.2 Synthesis of [Ru(CH3CN)(C10H15)(C25H22P2)][SbF6] (4.12) 
Compound 4.12 was prepared from complex 4.5, acetonitrile and NaSbF6 in 
methanol at room temperature (Scheme 4.4.2). The bright yellow solid, which is air 
stable, was obtained in 77% yield. 
 
Scheme 4.4.2 Synthesis of complex 4.12 [Ru(CH3CN)(C10H15)(C25H22P2)][SbF6] 
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Similar complexes with different diphosphine ligands have been previously 
synthesised by Moret et al., using NH4PF6 instead of NaSbF6.
13
 Sato and Asai also 
published the synthesis of [RuCp*(CH3CN)(dppf)][BF4].
12
 
4.4.2.1 NMR Data for Compound 4.12 
A labelled diagram of compound 4.12 is given in Figure 4.4.4. The 
1
H and 
13
C{
1
H} NMR spectra are shown in Figure 4.4.5 and Figure 4.4.6 respectively. The 
complete assignment is given in Table 4.4.2. 
 
Figure 4.4.4 Labelled diagram of complex 4.12 
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Figure 4.4.5 
1
H NMR spectrum of 4.12 in CD2Cl2 at 300.13 MHz and 300.0 K 
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Figure 4.4.6 
13
C{
1
H} NMR spectrum of 4.12 in CD2Cl2 at 125.88 MHz and 300.0 K 
1
H Chemical Shift, δ (ppm) Assignment 
7.49 (m, 16H) Aromatics 
7.36 (m, 4H) Aromatics 
5.13 (dt, 
2
J(H-H) = 16 Hz, 
2
J(H-P) = 9.8 Hz, 1H) c 
4.37 (dt, 
2
J(H-H) = 16 Hz, 
2
J(H-P) = 10.5 Hz, 1H) c 
1.64 (t, 
5
J(H-P) = 1.7 Hz, 3H) e 
1.59 (t, 
4
J(H-P) = 2.2 Hz, 15H) b 
13
C{
1
H} Chemical Shift, δ (ppm) Assignment 
155.9 (s, Q) d 
132.8 (m, CH) Aromatics 
131.9 (t, 
2,3
J(C-P) = 5.2 Hz, CH) Aromatics 
131.2 (d, 
1
J(C-P) =  32.7 Hz, Q) Aromatics 
129.3 (dt, 
2,3
J(C-P) = 18.7, 5.2 Hz, CH) Aromatics 
92.0 (s, Q) a 
51.3 (s, CH2) c 
10.2 (s, CH3) b 
3.8 (s, CH3) e 
 
Table 4.4.2 
1
H and 
13
C{
1
H} chemical shift assignment for complex 4.12 
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4.4.2.2 X-Ray Crystallographic Analysis of Compound 4.12 
Yellow crystalline prisms of compound 4.12 suitable for X-ray 
crystallography were obtained by vapour diffusion of pentane into a saturated 
solution of the complex in chloroform. This compound crystallised in a triclinic cell, 
and structural solution was performed in the space group P  . The asymmetric unit 
comprises one molecule of compound 4.12, including the counterion SbF6. The 
molecular structure is shown in Figure 4.4.7 and selected bond lengths and angles 
are given in Table 4.4.3. 
 
Figure 4.4.7 Molecular structure of complex 4.12. Displacement ellipsoids are at the 50% 
probability level. Hydrogen atoms are omitted for clarity 
Bond Distance (Å) Bond Distance (Å) 
Ru(1)-N(1) 2.0775(16) P(2)-C(13) 1.8719(19) 
Ru(1)-P(1) 2.3201(6) N(1)-C(11) 1.153(2) 
Ru(1)-P(2) 2.3503(6) C(11)-C(12) 1.481(3) 
P(1)-C(13) 1.8792(18) Sb(1)-F(1) 1.9047(12) 
Ru(1)-Ring 
Centroid 
1.884 Ru(1)-C(Cp*) 2.25226 
Bond Angle (°) Bond Angle (°) 
P(1)-Ru(1)-P(2) 71.626(19) N(1)-Ru(1)-P(1) 90.22(5) 
N(1)-C(11)-C(12) 178.5(2) N(1)-Ru(1)-P(2) 87.10(4) 
C(11)-N(1)-Ru(1) 178.90(16) P(2)-C(13)-P(1) 93.53(8) 
 
Table 4.4.3 Selected interatomic distances and angles for compound 4.12 with s.u.s. shown 
in parenthesis 
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The distance between the ruthenium centre and the η5-ring centroid is 1.884 
Å, which is longer than the usual distance between a ruthenium atom and the centre 
of an η6-arene ligand coordinated to it (values ranging from 1.662 to 1.709 Å in 
Chapter 2 and Chapter 3). However, the average length between the ruthenium 
atom and the carbon atoms in the Cp* ring, 2.2523 Å, is comparable to the results for 
η6-arene complexes. If the structure of 4.12 (charged, with acetonitrile and dppm) is 
compared to that of 4.5 (neutral, with chloride and dppm), which was published by 
White et al.,
6
 there is a very small variation in the distances between the ruthenium 
centre and the phosphorus atoms, with those in 4.5 being approximately 2.29 Å. The 
angle formed by the two phosphorus atoms and the carbon in between them in dppm 
is 93.53(8)º in the structure of 4.12 and 92.7(3)º in 4.5, which are approximately 
equal values within a confidence interval. When packed, compound 4.12 does not 
show any π-π stacking interaction of the aromatic rings, but there is non-classical 
hydrogen bonding between C(9)-H and F(6) from the counterion, with a C...F 
distance of 3.198 Å (Figure 4.4.8). 
 
Figure 4.4.8 Compound 4.12 viewed along the a axis showing hydrogen bonding 
interactions (3.198 Å). Only the hydrogen atoms involved in these interactions are shown. 
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4.5  Tetramethylfulvene Ruthenium(II) Complexes 
4.5.1 Introduction 
Koelle and co-workers have reported the synthesis of Cp*Ru(acac) 
complexes (acac = CH3COCHCOCH3) by two different methods. In the first, the 
mixture of [RuCp*Cl2]2 with 2 equivalents of acacH and triethylamine in 
dichloromethane produced the monomer [RuCp*Cl(acac)]
4
 (a in Figure 4.5.1), and 
in the second, the reaction of [RuCp*Cl2]2 with 2 equivalents of acacH and K2CO3 in 
2-propanol resulted in the formation of the dimeric species [RuCp*(acac)]2
15
 (b in 
Figure 4.5.1). During this project, some attempts to synthesise similar Cp* 
ruthenium complexes to those aforementioned but with a diphenylacac ligand 
(PhCOCHCOPh) instead gave, unexpectedly, very different structures, which 
correspond to tetramethylfulvene complexes of ruthenium. 
 
            a)                                                       b) 
Figure 4.5.1 RuCp*(acac) complexes synthesised by Koelle et al.
4, 15
 
The tetramethylfulvene ligand is obtained by abstraction of one of the methyl 
hydrogens in the pentamethylcyclopentadienyl (Cp*) group, which normally occurs 
under the influence of strong bases or thermally. It is generally considered to bind in 
an η2,η4-fashion to metals (a in Figure 4.5.2), but some groups have described it as a 
methylenetetramethylcyclopentadienyl ligand instead, and considered an η1,η5-
coordination (b in Figure 4.5.2).
16, 17
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                        a)                                     b) 
Figure 4.5.2 a) Tetramethylfulvene and b) methylenetetramethylcyclopentadienyl ligands 
The two modes of coordination can be distinguished mainly by three features: 
 Bond length distribution inside the C5 ring. In η
1
,η5-ligands, the bonds 
are all equal, whereas in η2,η4-ligands it is normally possible to 
differentiate between the single and the double bonds.
18
 
 In the crystal structures of those complexes with η2,η4-ligands, the 
metal does not lie in the centre of the C5 ring. There is a displacement 
of the metal centre towards the exo double bond.
19
 
 The sp2 character of the carbons in the exo double bond of η2,η4-
tetramethylfulvene complexes vs. the sp
3
 character of the methylene 
carbon in η1,η5-methylenetetramethylcyclopentadienyl complexes. 
This can be determined from NMR spectroscopy analyses.
20, 21
 
There are several examples of fulvene complexes with ruthenium reported in 
the literature, such as the dimer [RuCl2(η
6
-C5Me4CH2)]2, which is obtained by 
oxidation of [RuCp*Cl2]2 with O2 followed by dehydration.
22-24
 Complex [RuCl(η2-
t
BuNSPh)(η6-C5Me4CH2)] can also be prepared from [RuCp*Cl2]2 when 
Li(
t
BuNSPh) is added at -78ºC.
25
 Other examples also involve molecular oxygen or 
strong bases.
26, 27
 
Fulvene complexes are more common with other metals, principally early 
transition metals
28-30
 and lanthanides,
31
 and they are most commonly obtained by 
thermolysis or photolysis. There are also some examples with rhenium, such as the 
complex [Re(CO)2(η
6
-C5Me4CH2)(C6F5)]
32
 or with iridium, like [Ir(dppe)Me(η6-
C5Me4CH2)]
33
 (dppe = 1,1'-bis(diphenylphosphino)ethane). 
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The reactions of complex 4.3 with diphenylacac and triethylamine in either 
dichloromethane at room temperature or toluene at reflux gave the novel complexes 
4.13 and 4.14 respectively. Both have been identified as η2,η4-tetramethylfulvene 
complexes by NMR spectroscopy and X-ray crystallography analyses. 
4.5.2 Synthesis of [RuCl(C10H14)(C15H11O2)] (4.13) 
Compound 4.13 was synthesised as a brown solid in 44% yield from complex 
4.3 with one equivalent of diphenylacac and two equivalents of triethylamine, by 
stirring in dry dichloromethane at room temperature overnight (Scheme 4.5.1). 
 
Scheme 4.5.1 Synthesis of complex 4.13 [RuCl(C10H14)(C15H11O2)] 
4.5.2.1 NMR Data for Compound 4.13 
A labelled diagram of complex 4.13 is given in Figure 4.5.3 and the 
1
H, 
13
C{
1
H} and 
1
J 
1
H-
13
C{
1
H} HMQC NMR spectra for this complex are shown in 
Figure 4.5.4, Figure 4.5.5 and Figure 4.5.6 respectively. The chemical shift 
assignment is summarised in Table 4.5.1. 
 
Figure 4.5.3 Labelled diagram of complex 4.13 
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Figure 4.5.4 
1
H NMR spectrum of 4.13 in CDCl3 at 300.13 MHz and 299.9 K 
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Figure 4.5.5 
13
C{
1
H} NMR spectrum of 4.13 in CDCl3 at 125.88 MHz and 300.0 K 
* 
* * 
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Figure 4.5.6 
1
J 
1
H-
13
C{
1
H} HMQC spectrum of 4.13 in CDCl3 at 300.0 K 
It can be seen from both the 
1
H and the 
13
C{
1
H} NMR spectra that compound 
4.13 shows a high degree of asymmetry; the four methyl groups appear as four 
singlets and the two protons in the exo double bond also show different chemical 
environments. However, those peaks marked with * in the 
1
H NMR spectrum are 
believed to belong to a higher symmetry isomer of the complex where the two =CH2 
protons are equivalent and there are only two peaks for the methyl groups. The 
1
J 
1
H-
13
C{
1
H} HMQC NMR spectrum shows that the two inequivalent protons in the exo 
double bond correspond to the same carbon at 80.5 ppm. This chemical shift implies 
a sp
2
-hybridised character for that carbon atom. This is confirmed by the fact that no 
coupling constant is seen between the two protons on that carbon. Coupling 
constants for geminal hydrogens attached to sp
2
 carbons are expected to lie between 
0 and 3 Hz, whereas geminal hydrogens attached to sp
3
 carbons have larger coupling 
constants around 12 Hz.
34
 An η2,η4-tetramethylfulvene coordination is deduced for 
complex 4.13 from these data. 
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1
H Chemical Shift, δ (ppm) Assignment 
7.96 (m, 5H) Aromatics 
7.42 (m, 5H) Aromatics 
6.62 (s, 1H) l 
5.42 (s, 1H) j 
5.01 (s, 1H) j 
1.98 (s, 3H) f, g, h or i 
1.78 (s, 3H) f, g, h or i 
1.70 (s, 3H) f, g, h or i 
1.54 (s, 3H) f, g, h or i 
13
C{
1
H} Chemical Shift, δ (ppm) Assignment 
181.8 (Q) k or m 
180.5 (Q) k or m 
139.5 (Q) Aromatics 
139.0 (Q) Aromatics 
130.9 (CH) Aromatics 
130.8 (CH) Aromatics 
128.2 (CH) Aromatics 
128.1 (CH) Aromatics 
127.2 (CH) Aromatics 
127.1 (CH) Aromatics 
103.0 (Q) a, b, c, d or e 
101.5 (Q) a, b, c, d or e 
100.3 (Q) a, b, c, d or e 
97.0 (Q) a, b, c, d or e 
95.0 (Q) a, b, c, d or e 
93.8 (CH) l 
80.5 (CH2) j 
8.8 (CH3) f, g, h or i 
8.3 (CH3) f, g, h or i 
8.2 (CH3) f, g, h or i 
7.6 (CH3) f, g, h or i 
 
Table 4.5.1 
1
H and 
13
C{
1
H} chemical shift assignment for complex 4.13 
4.5.2.2 X-Ray Crystallographic Analysis of Compound 4.13 
Orange prisms of compound 4.13 suitable for X-ray crystallography were 
obtained by vapour diffusion of pentane into a saturated solution of the complex in 
chloroform. This compound crystallised in an orthorhombic cell, and structural 
solution was performed in the space group P212121. The molecular structure is 
shown in Figure 4.5.7 and selected bond lengths and angles are given in Table 
4.5.2. 
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Figure 4.5.7 Molecular structure of complex 4.13. Displacement ellipsoids are at the 50% 
probability level. Hydrogen atoms are omitted for clarity 
Bond Distance (Å) Bond Distance (Å) 
Ru(1)-Cl(1) 2.428(2) C(3)-C(4) 1.435(12) 
Ru(1)-O(1) 2.085(6) C(4)-C(5) 1.485(12) 
Ru(1)-O(2) 2.072(6) C(1)-C(5) 1.467(12) 
Ru(1)-C(10) 2.241(9) C(1)-C(6) 1.523(14) 
Ru(1)-C(1) 2.157(10) C(2)-C(7) 1.503(12) 
Ru(1)-C(2) 2.212(8) C(3)-C(8) 1.480(12) 
Ru(1)-C(3) 2.227(9) C(4)-C(9) 1.493(13) 
Ru(1)-C(4) 2.196(9) C(5)-C(10) 1.373(12) 
Ru(1)-C(5) 2.048(9) O(2)-C(19) 1.264(11) 
C(1)-C(2) 1.386(12) O(1)-C(17) 1.288(10) 
C(2)-C(3) 1.462(12) C(17)-C(18) 1.397(11) 
Bond Angle (°) Bond Angle (°) 
O(2)-Ru(1)-O(1) 86.3(2) O(1)-Ru(1)-C(10) 172.4(3) 
O(1)-Ru(1)-Cl(1) 86.69(18) O(2)-Ru(1)-C(10) 87.4(3) 
O(2)-Ru(1)-Cl(1) 88.12(17) C(5)-Ru(1)-C(10) 37.0(3) 
C(10)-Ru(1)-Cl(1) 89.0(3) C(10)-C(5)-Ru(1) 79.2(6) 
 
Table 4.5.2 Selected interatomic distances and angles for compound 4.13 with s.u.s. shown 
in parenthesis 
The distances from the ruthenium atom to the carbons in the C5 ring vary 
significantly. The longer distances are those to C(2) (2.212(8) Å) and C(3) (2.227(9) 
Å), and the shorter distance is the one to C(5) (2.048(9) Å), indicating that the metal 
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is not exactly in the centre of the ring, but displaced towards the exo double bond, 
i.e. towards C(5). The distance between C(1) and C(2) (1.386(12) Å) is comparable 
to the distance between C(5) and C(10) (1.373(12) Å), and both correspond to 
double bonds. The distances between C(2) and C(3) (1.462(12) Å) and between C(4) 
and C(5) (1.485(12) Å) are the largest C-C distances within the ring. The bond 
length distribution which is typical of fulvenes cannot be completely observed. The 
Ru-C(10) bond length equals 2.241(9) Å. This solid state data reinforces the 
observations from the NMR studies, and an η2,η4-tetramethylfulvene coordination is 
concluded for complex 4.13. The molecules of compound 4.13 present 
intramolecular hydrogen bonding between C(12)-H and O(1), with a C...O distance 
of 2.715 Å (Figure 4.5.8). 
 
Figure 4.5.8 Compound 4.13 viewed along the a axis showing hydrogen bonding 
interactions (2.715 Å). Only the hydrogen atoms involved in these interactions are shown. 
4.5.3 Synthesis of [RuCl3(C10H14)][Ru(C10H15)(C7H8)] (4.14) 
Compound 4.14 was obtained as dark orange crystals from complex 4.3 with 
one equivalent of diphenylacac and one equivalent of triethylamine, which were 
heated to reflux in dry toluene over two hours (Scheme 4.5.2). Diphenylacac does 
not form part of the final complex. 
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Scheme 4.5.2 Synthesis of complex 4.14 [RuCl3(C10H14)][Ru(C10H15)(C7H8)] 
4.5.3.1 X-Ray Crystallographic Analysis of Compound 4.14 
Orange prisms of compound 4.14 suitable for X-ray crystallography were 
obtained at -20ºC after adding diethyl ether into a saturated solution of the reaction 
mixture in dichloromethane. This compound crystallised in a monoclinic cell, and 
structural solution was performed in the space group P21/c. The compound is formed 
by a cation of Cp*-ruthenium(II) which has incorporated a molecule of toluene in an 
η6-arene coordination mode and an anionic tetramethylfulvene ruthenium(II) 
counterion. The structure is shown in Figure 4.5.9 and selected bond lengths and 
angles are given in Table 4.5.3. 
 
Figure 4.5.9 Structure of complex 4.14. Displacement ellipsoids are at the 50% probability 
level. Hydrogen atoms are omitted for clarity 
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The distances from Ru(2) to the carbons in the C5 fulvene ring vary in the 
same way as those in complex 4.13, so the metal is again displaced towards the exo 
double bond. The only two clear double bonds in the fulvene ligand are those 
between C(22) and C(27) (1.372(8) Å) and C(18) and C(19) (1.398(8) Å), which is 
also similar to what was observed in complex 4.13. An η2,η4-tetramethylfulvene 
structure is considered for the anion in 4.14. The distance Ru(2)-C(27) is 2.253(6) Å. 
Compound 4.14 shows π-π stacking interactions (3.309 Å) between the 
tetramethylfulvene ligands of the anionic substructures in the solid state (Figure 
4.5.10).  
Bond Distance (Å) Bond Distance (Å) 
Ru(1)-Cp* centroid 1.806 Ru(2)-C(21) 2.179(5) 
Ru(1)-C(Cp*) 2.180 Ru(2)-C(22) 2.061(5) 
Ru(1)-Arene centroid 1.708 C(18)-C(19) 1.398(8) 
Ru(1)-C(arene) 2.214 C(19)-C(20) 1.450(7) 
C(1)-C(7) 1.506(8) C(20)-C(21) 1.420(7) 
Cl(1)-Ru(2) 2.4345(13) C(21)-C(22) 1.455(8) 
Ru(2)-Cl(2) 2.4123(15) C(18)-C(22) 1.486(8) 
Ru(2)-Cl(3) 2.4203(14) C(18)-C(23) 1.472(8) 
Ru(2)-C(27) 2.253(6) C(19)-C(24) 1.489(7) 
Ru(2)-C(18) 2.172(5) C(20)-C(25) 1.494(8) 
Ru(2)-C(19) 2.229(5) C(21)-C(26) 1.493(7) 
Ru(2)-C(20) 2.245(5) C(22)-C(27)  1.372(8) 
Bond Angle (°) Bond Angle (°) 
Cl(2)-Ru(2)-Cl(1) 87.53(5) C(27)-Ru(2)-Cl(2) 170.40(15) 
Cl(2)-Ru(2)-Cl(3) 86.96(5) C(27)-Ru(2)-Cl(3) 85.93(17) 
Cl(3)-Ru(2)-Cl(1) 91.16(5) C(22)-Ru(2)-C(27) 36.7(2) 
C(27)-Ru(2)-Cl(1) 86.18(16) C(27)-C(22)-Ru(2) 79.3(4) 
 
Table 4.5.3 Selected interatomic distances and angles for compound 4.14 with s.u.s. shown 
in parenthesis 
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Figure 4.5.10 Compound 4.14 viewed along the a axis showing π-π stacking interactions 
(3.309 Å) between tetramethylfulvene ligands. Hydrogen atoms are omitted for clarity 
4.6 Conclusions 
A series of η5-Cp* (Cp* = C5(CH3)5) and η
5
-Cp
#
 (Cp
#
 = C5(CH3)4(CH2)5OH) 
complexes of ruthenium have been obtained and successfully characterised. The 
starting materials for these syntheses have been pentamethylcyclopentadiene (4.1) 
and (5-hydroxypentyl)-tetramethylcyclopentadiene (4.2), two potential η5-
coordinating ligands which were prepared following established methods. The 
reactions of these ligands with RuCl3 ∙ 3H2O gave the initial complexes with general 
structure [RuCl2Cp*
/#
]n (4.3 and 4.4), and these were later used to synthesise various 
diphosphine RuCp*
/#
 neutral complexes with chloride (4.5 to 4.11) and a charged 
complex where chloride was substituted by acetonitrile (4.12). All of the complexes 
with Cp
#
 are novel, and also some of those with Cp*. The crystal structure of 
[RuCp*(CH3CN)(dppm)][SbF6] (4.12) is reported. 
The processes to synthesise these compounds were more complicated than 
those employed for η6-arene ruthenium complexes in previous chapters. This is in 
part due to the pronounced air sensitivity of the  [RuCl2Cp*
/#
]n species, which need 
to be stored in a glove box, but mainly due to difficult work-ups and purifications, 
even though the diphosphine complexes are all air stable. This fact probably explains 
the higher relative abundance of published η6-arene ruthenium complexes compared 
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to η5-Cp*/# complexes. The Cp* and Cp# compounds presented in this chapter have 
been tested as catalysts for hydrogen transfer reactions under homogeneous 
conditions (Chapter 5). 
Two tetramethylfulvene ruthenium(II) complexes (4.13 and 4.14) have been 
synthesised from [RuCl2Cp*]n (4.3) and diphenylacac, and characterised including 
crystal structures. 
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5.1 Introduction 
This chapter describes the catalytic results obtained with the ruthenium 
complexes presented in Chapters 2-4 for homogeneous hydrogen transfer reactions. 
Two particular transformations were selected as representatives and studied in detail: 
the redox neutral alkylation of tert-butylamine with phenethyl alcohol and the reduction 
of benzaldehyde. 
The redox neutral alkylation of tert-butylamine with phenethyl alcohol has been 
previously investigated by Williams and co-workers with different ruthenium catalytic 
systems, including [RuCl2(p-cymene)]2, [RuCl2(benzene)]2 or Ru(PPh3)3Cl2 and the 
bidentate phosphines DPEphos, Xantphos, BINAP, dppf, dippf, dppe or dppp (Figure 
5.1.1), or the monodentate phosphine PPh3. They suggested that the best combination 
was that of [RuCl2(p-cymene)]2 with either dppf or DPEphos. The stoichiometry of 
ruthenium to the diphosphine ligand was always 1 : 1.
1, 2
 The conditions reported for the 
N-alkylation involved reactions under an inert atmosphere with dry toluene and 
molecular sieves, and the use of K2CO3.
1
 During optimisation processes (with different 
bases and temperatures) with [RuCl2(p-cymene)]2 and dppf for the same reaction in this 
project, it was observed that the presence of molecular sieves and a base had a 
detrimental effect on the outcome of the catalysis. Thus, this reaction has been carried 
out without these additives and under non-inert atmosphere (Scheme 5.1.1). 
 
Figure 5.1.1 Diphosphine ligands: a) DPEphos, b) Xantphos, c) BINAP, d) dppf, e) dippf, f) 
dppe, g) dppp 
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Scheme 5.1.1 Conditions used for the redox neutral alkylation of tert-butylamine with 
phenethyl alcohol after optimisation. [Substrates] = 0.3 M in 10 ml of toluene 
After some optimisation work using [RuCl2(p-cymene)]2 and dppf for the 
reduction of benzaldehyde, the conditions used henceforth for the study of this reaction 
are presented in Scheme 5.1.2. 
 
Scheme 5.1.2 Conditions used for the benzaldehyde reduction after optimisation. [Substrate] = 
0.1 M in 10 ml of 2-propanol 
All of the complexes tested in this chapter for the two model reactions are η6-
arene or η5-C5(CH3)4R (R = CH3 or (CH2)5OH) ruthenium complexes, with the same 
half-sandwich structure, bearing either two X- and one L-type ligands or one X- and 
two L-type ligands (X = one electron donor ligand, L = two electron donor ligand) 
(Figure 5.1.2). The possible nature of the pre-catalyst species formed after addition of 
the relevant ligands has been investigated in some of the cases. 
 
Figure 5.1.2 General structures of the ruthenium complexes tested for hydrogen transfer 
reactions 
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All of the catalytic reactions have been monitored over 24 hours by either Gas 
Chromatography (GC) or 
1
H NMR spectroscopy (in this latter case the analyses were 
performed only on the final reaction mixtures after one day). The conversion 
percentages obtained by GC were calculated from the areas of both the starting substrate 
(phenethyl alcohol or benzaldehyde) and product peaks with the formula: [(area 
product)/(area product + area substrate)] × 100. 
5.2 Nature of the Pre-Catalyst 
After their studies on the redox neutral alkylation of tert-butylamine with 
phenethyl alcohol using [RuCl2(p-cymene)]2 and diphosphines, Williams and co-
workers proposed the formation of a [RuCl(p-cymene)(P−P)][Cl] species as pre-catalyst 
for the transformation.
2
 In consequence, they always reported the use of twice the 
amount of the correspondent diphosphine, this is, a stoichiometric relationship of [1:2] 
for [RuCl2(p-cymene)]2 and the diphosphine, which results in [1:1] Ru : diphosphine.
1, 2
 
The complex [RuCl(p-cymene)(dppf)][Cl] (5.1) was synthesised and isolated during 
this project by Mr. Joel Fonseca (Scheme 5.2.1).
3
 
 
Scheme 5.2.1 Synthesis of complex 5.1 [RuCl(C10H14)(C34H28FeP2)][Cl] 
Complex 5.1 could only be prepared using an alcohol (ethanol or 2-propanol) as 
the solvent. The mixture of 1 equivalent of [RuCl2(p-cymene)]2 (3.1) with 2 equivalents 
of dppf in refluxing 2-propanol, which are the conditions employed for the reduction of 
benzaldehyde, produced this yellow compound 5.1. A similar charged monomer with 
PF6 or SnCl3 as the counterion had been reported before,
4-8
 including its crystal 
structure,
4, 8
 where the most characteristic feature is the eclipsed conformation of the 
cyclopentadienyl rings. The 
1
H NMR spectrum of complex 5.1 presents two broad 
   Chapter 5 
146 
peaks at 5.89 and 5.19 ppm for the aromatic protons of the p-cymene ring, and four 
singlets at 5.07, 4.36, 4.27 and 4.08 ppm for the protons in the cyclopentadienyl rings. 
When the solvent employed was changed to dichloromethane, chloroform or 
toluene, complex 5.2 was obtained, with the formula [(RuCl2(p-cymene))2(dppf)] 
(Scheme 5.2.2). 
 
Scheme 5.2.2 Synthesis of complex 5.2 [Ru2Cl4(C10H14)2(C34H28FeP2)] 
The 
1
H NMR spectrum of compound 5.2 is characterised by the presence of a 
broad singlet at 5.07 ppm, which is the peak for the aromatic protons in the p-cymene 
rings. This is different to the usual two doublets observed for the rest of the p-cymene 
complexes studied during this project. The protons of the cyclopentadienyl rings in the 
dppf bridge are represented by two singlets at 4.17 and 3.89 ppm. This matches 
previous publications of the synthesis and characterisation of complex 5.2. The groups 
of Sieiro,
9
 Yamamoto
5
 and Kaim
7
 have reported this compound, prepared from a 1 : 1 
mixture of [RuCl2(p-cymene)]2 and dppf, but not its crystal structure.  
The structure of complex 5.2 was determined by X-ray crystallography. Orange 
single crystals were obtained by vapour diffusion of pentane into a saturated solution of 
the compound in dichloromethane. It crystallised in a triclinic cell, and the structural 
solution was performed in the space group P  . The asymmetric unit contains half of a 
molecule and two co-crystallised molecules of water. The molecular structure of this 
complex is shown in Figure 5.2.1 and selected bond lengths and angles are given in 
Table 5.2.1. 
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Figure 5.2.1 Molecular structure of complex 5.2. Displacement ellipsoids are at the 50% 
probability level. Hydrogen atoms and the water molecules are omitted for clarity 
Bond Distance (Å) Bond Distance (Å) 
Ru(1)-P(1) 2.3726(10) C(8)-C(9) 1.540(8) 
Ru(1)-Cl(1) 2.4259(10) C(8)-C(10) 1.501(7) 
Ru(1)-Cl(2) 2.4414(10) P(1)-C(11) 1.840(4) 
C(1)-C(2) 1.418(6) P(1)-C(17) 1.844(4) 
C(1)-C(8) 1.517(6) P(1)-C(23) 1.826(4) 
C(4)-C(7) 1.508(6) C(23)-C(24) 1.449(5) 
Ru(1)-Ring 
Centroid 
1.724 Ru(1)-C(arene) 2.2395 
Fe(1)-Ring 1.667 Fe(1)-C(Cp) 2.0702 
Bond Angle (°) Bond Angle (°) 
Cl(1)-Ru(1)-Cl(2) 88.83(4) C(6)-Ru(1)-C(1) 37.59(16) 
P(1)-Ru(1)-Cl(1) 88.10(3) C(10)-C(8)-C(9) 110.0(5) 
P(1)-Ru(1)-Cl(2) 87.93(3) C(2)-C(1)-C(6) 117.3(4) 
C(23)-P(1)-Ru(1) 115.11(13) C(11)-P(1)-C(17) 101.86(17) 
P(1)-C(23)-Fe(1) 131.86(19) C(24)-C(23)-C(27) 107.4(3) 
 
Table 5.2.1 Selected interatomic distances and angles for compound 5.2 with s.u.s. shown in 
parenthesis 
Both the distance between the ruthenium atom and the arene ring centroid (1.724 
Å) and the average distance between ruthenium and all the carbons in the ring (2.2395 
Å) are comparable to those observed in the other Ru(p-cymene) complexes reported in 
this document (approximately 1.69 and 2.20 Å respectively). Both ruthenium centres 
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present the typical piano-stool geometry, and the cyclopentadienyl rings are in a 
staggered conformation. No classic hydrogen bonds were found for complex 5.2 in the 
solid state. 
A series of control experiments were performed in order to find out what Ru-
dppf species is formed under the specific conditions employed for both the redox 
neutral alkylation and the reduction of benzaldehyde. The complexes were detected 
based on their different 
1
H NMR spectra. Figure 5.2.2 shows the 
1
H NMR spectra of 
complexes 5.1 and 5.2. A summary of the results obtained is presented in Figure 5.2.3. 
The reaction of 1 equivalent of 3.1 with only 1 equivalent of dppf produces exclusively 
compound 5.2, both at reflux of toluene and at reflux of 2-propanol. The reaction of 1 
equivalent of 3.1 with 2 equivalents of dppf also produces 5.2 in toluene, even in the 
presence of a 0.3 M alcohol. This was tested because phenethyl alcohol is used as the 
substrate for the N-alkylation, and it is at a 0.3 M concentration under catalytic 
conditions. Ethanol was employed instead of phenethyl alcohol, so it could be easily 
evaporated before recording the 
1
H NMR spectrum. The analysis only revealed the 
presence of 5.2. Complex 5.1 has only been observed under the conditions employed for 
the reduction of benzaldehyde, i.e. using 1 equivalent of 3.1 with 2 equivalents of dppf 
in refluxing 2-propanol. 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)  
Figure 5.2.2 
1
H NMR spectra of complexes 5.1 (red) and 5.2 (blue) 
5.89, 5.19 ppm: p-cymene ring 
5.07, 4.36, 4.27, 4.08 ppm: Cp rings 
5.07 ppm: p-cymene ring 
4.17, 3.89 ppm: Cp rings 
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Figure 5.2.3 Summary of control experiments with the conditions employed for the redox 
neutral alkylation of tert-butylamine with phenethyl alcohol and the reduction of benzaldehyde, 
and the Ru-dppf species obtained 
Compound 5.2 was tested for the redox neutral alkylation of tert-butylamine 
with phenethyl alcohol and the reduction of benzaldehyde, both with and without an 
extra equivalent of dppf, and the activities compared to those obtain with the in situ 
mixture of [RuCl2(p-cymene)]2 + 2 equivalents of dppf. 
For the redox neutral alkylation, the results are presented in Figure 5.2.4 and 
summarised in Table 5.2.2. In all of the cases the loading of ruthenium was 5 mol%. 
The complex [RuCl(p-cymene)(dppf)][BF4], which was synthesised by Mr. Joel 
Fonseca and is equivalent to 5.1 but with BF4 as the counterion, was also tested for 
comparison. It can be observed that compound 5.2 is active, giving 55% conversion 
after 24 hours (entry 2 in Table 5.2.2). When 1 equivalent of dppf was added to 5.2 (2.5 
mol% of dppf), the catalytic activity improved considerably, and matched that obtained 
with [RuCl(p-cymene)(dppf)][BF4], indicating the possible formation of the monomer 
5.1 (entries 3 and 4), which contradicts the previous control experiments. Curiously, the 
activity obtained with [RuCl2(p-cymene)]2 + 2 equivalents of dppf was still the best 
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(entry 1). This likely implies a better performance of the catalyst when it is formed in 
situ. 
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Figure 5.2.4 Catalytic activity of complexes 3.1, [RuCl(p-cymene)(dppf)][BF4] and 5.2 (5 
mol% Ru) with different number of equivalents of dppf against the redox neutral alkylation of 
tert-butylamine with phenethyl alcohol in toluene at 110°C, monitored over 24 hours by GC 
   Conv. % after: 
Entry Ru species dppf equiv. 3 h 9 h 24 h 
1 3.1 2 41.2 87.3 99.7 
2 5.2 
 5.1 
0 5.7 29.0 55.0 
3 5.2 1 32.2 74.4 86.8 
4 [RuCl(p-cymene)(dppf)][BF4] 
 
0 40.4 74.3 89.3 
 
Table 5.2.2 Summary of conversions obtained with complexes 3.1, [RuCl(p-
cymene)(dppf)][BF4] and 5.2 with different number of equivalents of dppf after 3, 9 and 24 
hours for the N-alkylation of tert-butylamine with phenethyl alcohol. The reactions were carried 
out using 5 mol% Ru in toluene at 110°C 
For the reduction of benzaldehyde, the results with 5 mol% of ruthenium are 
shown in Figure 5.2.5 and summarised in Table 5.2.3. Compound 5.2 is much more 
active by itself for this reaction, affording almost 95% conversion after only 2 hours 
(entry 2 in Table 5.2.3), but again the addition of 1 equivalent of dppf made the reaction 
slightly faster (entry 3), even though the final conversions after 24 hours were similar. 
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With 2 equivalents of dppf, the monomer 5.1 is formed under the benzaldehyde 
reduction conditions (see Figure 5.2.3), so it can be concluded that both 5.1 and 5.2 are 
very active for this reaction, but 5.1 is faster. The activity obtained with [RuCl2(p-
cymene)]2 + 2 equivalents of dppf was also the best for this reaction (entry 1). 
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Figure 5.2.5 Catalytic activity of complexes 3.1 and 5.2 (5 mol% Ru) with different number of 
equivalents of dppf against the reduction of benzaldehyde in 2-propanol at 85°C, monitored 
over 24 hours by GC 
   Conv. % after: 
Entry Ru species dppf equiv. 1 h 1.5 h 2 h 
1 3.1 2 100 100 100 
2 5.2 
 5.1 
0 70.3 85.2 94.6 
3 5.2 1 80.6 98.2 98.5 
 
Table 5.2.3 Summary of conversions obtained with complexes 3.1 and 5.2 with different 
number of equivalents of dppf after 1, 1.5 and 2 hours for the reduction of benzaldehyde. The 
reactions were carried out using 5 mol% Ru in 2-propanol at 85°C 
In conclusion, species 5.1 is believed to act as pre-catalyst for the reduction of 
benzaldehyde in 2-propanol, and 5.2 as pre-catalyst for the redox neutral alkylation of 
tert-butylamine with phenethyl alcohol in toluene. However, the best conversions were 
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observed with the use of [RuCl2(p-cymene)]2 (3.1) + 2 equivalents of dppf, so this 
mixture was employed as reference in subsequent investigations. 
5.3 Functionalised η6-Arene Ruthenium Complexes 
The acid- and ester-functionalised η6-arene ruthenium complexes presented in 
Chapter 2 were originally synthesised so that they could be potentially immobilised by 
covalent bonding onto a modified support and used as heterogeneous catalysts for 
hydrogen transfer reactions. As discussed in that chapter, their attachment to a solid 
support failed after some attempts, but several of those complexes have been tested as 
catalysts for the homogeneous N-alkylation of tert-butylamine with phenethyl alcohol.  
The results discussed in this section correspond to the complexes 2.3 to 2.7 
shown in Figure 5.3.1, together with [RuCl2(p-cymene)]2 (3.1) and RuCl3 ∙ 3H2O, used 
as references. When [RuCl2(p-cymene)]2 or RuCl3 ∙ 3H2O were tested without the 
presence of dppf, the conversions obtained in both cases did not exceed 3% for the 
formation of N-phenethyl-tert-butylamine. Consequently, dppf was used as ligand, and 
it was confirmed that it is not catalytically active by itself. 
 
Figure 5.3.1 Functionalised η6-arene ruthenium complexes tested for the homogeneous N-
alkylation of tert-butylamine with phenethyl alcohol 
A loading of 5 mol% of Ru and 5 mol% of dppf was employed in all cases. The 
reactions were monitored by GC over a period of 24 hours, and the catalytic activities 
are illustrated in Figure 5.3.2 and summarised in Table 5.3.1. 
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Figure 5.3.2 Catalytic activity of functionalised η6-arene ruthenium complexes 2.3 to 2.7, 
[RuCl2(p-cymene)]2 (3.1) and RuCl3 ∙ 3H2O (5 mol% Ru and 5 mol% dppf) against the redox 
neutral alkylation of tert-butylamine with phenethyl alcohol, monitored over 24 hours by GC 
  Conversion % after: 
Entry Ruthenium species 3 hours 9 hours 24 hours 
1 2.3 48.5 97.3 99.7 
2 2.4 35.6 80.0 99.7 
3 2.5 24.1 57.9 84.4 
4 2.6 16.3 86.2 99.6 
5 2.7 24.1 96.4 99.8 
6 [RuCl2(p-cymene)]2 (3.1) 41.2 87.3 99.7 
7 RuCl3 ∙ 3H2O 15.0 53.4 74.5 
 
Table 5.3.1 Summary of conversions obtained with complexes 2.3 to 2.7, [RuCl2(p-cymene)]2 
(3.1) and RuCl3 ∙ 3H2O after 3, 9 and 24 hours for the N-alkylation of tert-butylamine with 
phenethyl alcohol. The reactions were carried out using 5 mol% Ru and 5 mol% dppf in toluene 
at 110°C 
Complexes 2.3, 2.4, 2.6, 2.7 and [RuCl2(p-cymene)]2 all provided very high 
conversions above 99.5% after 24 hours, but at different rates. The fastest complexes 
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were 2.3 and 2.7, which gave conversions above 96% after 9 hours, improving the 
catalytic activity of [RuCl2(p-cymene)]2 (entries 1, 5 and 6 in Table 5.3.1). The reaction 
with complex 2.3 remarkably achieved almost 50% conversion after 3 hours (entry 1). It 
is noticeable that between the chloride complexes 2.3 and 2.6, the one with an acid (2.3) 
was the most active, whereas between the bromide complexes 2.4 and 2.7, complex 2.7 
(an ester) showed a faster reaction rate. In fact, complexes 2.4 and 2.6 behaved as 
slightly worse catalysts than [RuCl2(p-cymene)]2 (entries 2 and 4). Compound 2.5 
reached only 84.4% conversion after 24 hours, which might derive from possible 
decomposition due to its longer chain (entry 3). Interestingly, RuCl3 ∙ 3H2O also gave a 
moderate activity (74.5% after 24 hours) in the presence of dppf (entry 7). The 
complexes 2.3 and [RuCl2(p-cymene)]2 (3.1) were also tested with a lower loading of 1 
mol% Ru and 1 mol% dppf, but the activity in both cases did not surpass 3% after 24 
hours. 
5.4 η6-p-Cymene Ruthenium Dimers and Monomers 
The results discussed in this section correspond to the complexes 3.1 to 3.13, 
which were introduced in Chapter 3 (Figure 5.4.1). All of these complexes have an η6-
p-cymene unit coordinated to ruthenium in common, and compounds 3.3 to 3.13 have a 
labile N-ligand (pyridine or tert-butylamine) where the nitrogen atom acts as a two 
electron donor. Their activities against the N-alkylation of tert-butylamine with 
phenethyl alcohol have been investigated. Some studies on the reduction of 
benzaldehyde with complex 3.1 are also presented in this section. 
The higher activities against the N-alkylation of tert-butylamine with phenethyl 
alcohol in the absence of dppf were obtained with complexes 3.2 and 3.5, which 
reached conversions of 11.8% and 8.7% respectively after 24 hours. With the chloride 
species (3.1, 3.3, 3.4 and 3.6 to 3.13), on the other hand, no more than a final 
conversion of 4% was observed in any case. Therefore, the use of dppf was proven 
necessary to make an effective catalyst. The results obtained with complexes 3.1 to 3.13 
(5 mol% of Ru and 5 mol% of dppf) are summarised in Table 5.4.1. 
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Figure 5.4.1 η6-p-Cymene ruthenium complexes tested for the homogeneous N-alkylation of 
tert-butylamine with phenethyl alcohol using 5 mol% Ru and 5 mol% dppf 
  Conversion % after: 
Entry Ruthenium species 3 hours 9 hours 24 hours 
1 3.1 41.2 87.3 99.7 
2 3.2 75.3 93.3 99.7 
 3.2 (without dppf) 4.7 10.2 11.8 
3 3.3 19.3 85.3 99.5 
4 3.4 25.3 86.5 99.7 
5 3.5 87.5 99.7 99.7 
 3.5 (without dppf) 3.1 5.6 8.7 
6 3.6 31.5 50.1 73.4 
7 3.7 54.5 78.0 95.2 
8 3.8 45.1 71.7 97.2 
9 3.9 33.5 78.0 98.9 
10 3.10 39.1 80.5 99.3 
11 3.11 36.8 91.9 99.8 
12 3.12 17.3 64.1 93.5 
13 3.13 15.4 87.7 99.0 
 
Table 5.4.1 Summary of conversions obtained with complexes 3.1 to 3.13 after 3, 9 and 24 
hours for the N-alkylation of tert-butylamine with phenethyl alcohol. The reactions were carried 
out using 5 mol% Ru and 5 mol% dppf (unless otherwise indicated) in toluene at 110°C 
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Complexes 3.2 and 3.5 gave the best results also in the presence of dppf. Even 
though many chloride complexes reached similar conversions after 24 hours, the iodide 
compounds 3.2 and 3.5 were characterised by much higher reaction rates, affording 
product yields above 75% after 3 hours (entries 2 and 5 in Table 5.4.1). A comparison 
between these two complexes and their chloride equivalents 3.1 and 3.4, which only 
gave 41.2% and 25.3% conversions respectively after the same period of time (entries 1 
and 4), can be best seen in Figure 5.4.2. Varying the halide ligands in transition metal 
complexes may indeed change their activity and properties due to the combination of 
both steric and electronic factors.
10
 Examples of bromide complexes being more active 
than the analogous chloride ones had previously been observed within the McGowan 
group in anticancer trials.
11
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Figure 5.4.2 Catalytic activity of complexes 3.1 vs. 3.2 and 3.4 vs. 3.5 (5 mol% Ru and 5 mol% 
dppf) against the redox neutral alkylation of tert-butylamine with phenethyl alcohol, monitored 
over 24 hours by GC 
Between the two iodide complexes, the dimer 3.2 dropped activity before the 
monomer 3.5, so after 3 hours 3.5 seemed to be the only species maintaining its fast rate 
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(entries 2 and 5 in Table 5.4.1 and Figure 5.4.2). Clear differences can also be noticed 
for the chloride compounds; complexes 3.6 and 3.12 were particularly slow and gave 
low conversions even after 24 hours (entries 6 and 12), whereas 3.11 reached almost 
92% conversion after 9 hours, being the fastest complex among the chloride ones (entry 
11). These variations could be due to the presence of different pyridines in the reaction 
media, after de-coordination from ruthenium to allow the formation of the active species 
with dppf. 
For instance, one notable case is that of the 3-halopyridine complexes (3.8 to 
3.11). For these four compounds, the activity decreased in the order 3.11 > 3.10 > 3.9 > 
3.8, mainly in the range between 300 and 1440 minutes, as shown in Figure 5.4.3. In 
other words, the iodide substitution in the pyridine resulted in a better performance than, 
successively, the bromide, chloride and fluoride substitutions at the same position. The 
catalytic activity of these complexes was related to several properties of their halides 
such as electronegativity or covalent radii, and to the pKa of their pyridines. Figure 
5.4.4 shows these three features plotted against the areas under the curves from Figure 
5.4.3 for each complex, as a rough relative indicator of catalytic activity. These areas 
were approximated using the “trapezoid rule”. There is no straight correlation in any of 
the cases, which probably indicates a combination of factors (sterics and electronics) 
influencing the effect of the pyridines on the catalytic activity. 
For the reductions of benzaldehyde with complex 3.1, the reactions were carried 
out with either dppf or TsDPEN, and sometimes in the presence of the base 
triethylenediamine (Et3N). The results are presented in Figure 5.4.5 and summarised in 
Table 5.4.2. 100% conversions were obtained in the presence of Et3N with the two 
ligands after 24 hours, but the addition of dppf instead of TsDPEN gave much faster 
reactions, both with and without Et3N (entries 1-4 in Table 5.4.2) Despite this, TsDPEN 
presents a different advantage, which is that it could be used for asymmetric 
transformations, although in the case of benzaldehyde that is not a concern. When no 
ligand was used, complex 3.1 still gave moderate activities, as opposed to the case of 
the N-alkylation, and it is noteworthy that the single presence of Et3N improved the 
activity substantially (entries 5 and 6). Some control experiments without any 
ruthenium species were also performed, and benzaldehyde was recovered unchanged 
after 24 hours, indicating that the ligands are not active by themselves. 
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Figure 5.4.3 Catalytic activity of complexes 3.8 to 3.11 (5 mol% Ru and 5 mol% dppf) against 
the redox neutral alkylation of tert-butylamine with phenethyl alcohol, monitored over 24 hours 
by GC 
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Figure 5.4.4 Electronegativity of halides,
12
 pKa of pyridines
13
 and covalent radii of halides
12
 
against the areas under the catalytic activity curves for complexes 3.8, 3.9, 3.10 and 3.11 
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Figure 5.4.5 Catalytic activity of complex 3.1 (5 mol% of Ru) against the reduction of 
benzaldehyde in refluxing 2-propanol. The additives used in each case are indicated in the 
legend. The reactions were monitored over 24 hours by GC 
    Conv. % after: 
Entry Ru species Ligand (5 mol%) Base (8 mol%) 3 h 9 h 24 h 
1 3.1 (R,R)-TsDPEN Et3N 89.3 97.3 100 
2 3.1 (R,R)-TsDPEN - 12.9 38.3 62.7 
3 3.1 dppf Et3N 100 100 100 
4 3.1 dppf - 14.3 60.9 88.8 
5 3.1 - Et3N 38.5 50.6 56.3 
6 3.1 - - 4.2 11.8 22.2 
 
Table 5.4.2 Summary of conversions obtained with complex 3.1 (5 mol% of Ru) after 3, 9 and 
24 hours for the reduction of benzaldehyde in 2-propanol at 85°C in the presence of different 
additives 
5.5 Cp* and Cp# Ruthenium Complexes 
The homogeneous results discussed in this section correspond to the complexes 
4.5, 4.8 to 4.10 and 4.12, which were introduced in Chapter 4 (Figure 5.5.1). Of those, 
the Ru-Cp
#
 compounds (Cp
#
 = C5(CH3)4(CH2)5OH) were prepared with the possibility 
of a covalent attachment to a support in mind. 
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Figure 5.5.1 Cp* and Cp
 #
 ruthenium complexes tested for the homogeneous N-alkylation of 
tert-butylamine with phenethyl alcohol and the reduction of benzaldehyde 
Unfortunately, none of the Ru-Cp* or Ru-Cp
#
 complexes were active for either 
the reduction of benzaldehyde or the redox neutral alkylation of tert-butylamine with 
phenethyl alcohol under the catalytic conditions used so far. This is true not only for the 
neutral complexes (4.5 and 4.8 to 4.10), but also for the charged complex 4.12. 
In view of this, another hydrogen transfer reaction was tried: the racemisation of 
(R,R)-(+)-hydrobenzoin. This was kindly carried out by Mr. Peter Baldwin at the 
Institute of Process Research and Development (iPRD) at the University of Leeds. The 
two complexes tested were 4.5 and 4.12 and the conditions used were those shown in 
Scheme 5.5.1. No conversions were observed by Gas Chromatography for this 
transformation, even though the reaction conditions had been optimised for similar Ru-
indenyl complexes.
14
 Indenyl and Cp*, which are both η5-coordination ligands, are 
considered comparable in size (Figure 5.5.2), but it has been generally observed that 
substitution reactions proceeding by an associative mechanism are faster in metal-
indenyl than in metal-Cp/Cp* complexes. Leaving a vacant coordination site around the 
metal is more favourable for indenyl complexes because they can form η3-indenyl 
intermediates that generate a fully aromatic benzene ring.
15-17
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Scheme 5.5.1 Conditions used for the homogeneous racemisation of (R,R)-(+)-hydrobenzoin 
 
                                                a)                                            b) 
Figure 5.5.2 a) Pentamethylcyclopentadienyl and b) indenyl ligands 
In order to investigate other related reactions, the complexes 4.5, 4.6, 4.7 and 4.8 
shown in Figure 5.5.3 were tested for the homogeneous hydrogenation of N-
benzylphthalimide. This transformation needs molecular hydrogen, so it is not a 
hydrogen transfer reaction like the previous ones. The experiments were carried out at 
Reaxa Ltd. in a hydrogen pressure vessel, and the conditions used were those depicted 
in Scheme 5.5.2. 
1
H NMR spectra were taken for each experiment after 24 hours, and 
they corresponded entirely to the starting N-benzylphthalimide. No conversion was 
observed for any of the Ru-Cp* complexes tested. 
 
Figure 5.5.3 Cp* ruthenium complexes tested for the homogeneous hydrogenation of N-
benzylphthalimide 
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Scheme 5.5.2 Conditions used for the homogeneous hydrogenation of N-benzylphthalimide 
The homogeneous hydrogenation of N-benzylphthalimide and other similar 
transformations has been successfully performed by Ikariya et al. using 
[RuClCp*(P−NH2)] complexes.
18-20
 They claim that P−NH2 ligands like, for example, 
Ph2P(CH2)2NH2, and also P−NRH ligands to a lesser extent, are able to accelerate the 
reaction, as opposed to P−NMe2 ligands, which are completely ineffective. 
5.6 Conclusions 
Different functionalised η6-arene, η6-p-cymene and η5-Cp* or Cp# ruthenium 
complexes have been tested as potential catalysts for homogeneous hydrogen transfer 
reactions such as the redox neutral alkylation of tert-butylamine with phenethyl alcohol, 
the reduction of benzaldehyde or the racemisation of (R,R)-(+)-hydrobenzoin. 
It has been observed that a 1 : 2 mixture of [RuCl2(p-cymene)]2 and dppf in 
alcoholic solvents produces the monomer 5.1, and this is probably the pre-catalyst in the 
reductions of benzaldehyde, which have been carried out in 2-propanol. On the other 
hand, 1 : 1 or 1 : 2 mixtures of [RuCl2(p-cymene)]2 and dppf in toluene yield the dimer 
5.2, where dppf acts as a monodentate bridging ligand. 5.2 is believed to act as pre-
catalyst in the N-alkylation studied. 
The functionalised η6-arene ruthenium complexes were active for the N-
alkylation of tert-butylamine with phenethyl alcohol in the presence of dppf ligand, with 
2.3 and 2.7 being particularly good, better than [RuCl2(p-cymene)]2 (3.1). Complex 2.5, 
on the other hand, gave the worst conversion. 
Among the η6-p-cymene ruthenium pyridine complexes, those containing Ru-I 
bonds performed much better than those with Ru-Cl bonds for the N-alkylation of tert-
butylamine with phenethyl alcohol in the presence of dppf. The different pyridines seem 
to affect the catalytic activity by combinations of steric and electronic factors. 
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Complex [RuCl2(p-cymene)]2 was able to catalyse the reduction of 
benzaldehyde in the presence of Et3N with either dppf or TsDPEN, but it was much 
faster with dppf. However, TsDPEN would be the ligand chosen if asymmetric 
transformations were desired. 
The [RuClCp*
/#
(PP)] and [Ru(CH3CN)Cp*(PP)]
+
 complexes tested for hydrogen 
transfer reactions did not give any conversion to the expected products, and the same 
unfavourable results were obtained when the homogeneous hydrogenation of N-
benzylphthalimide with molecular hydrogen was attempted. 
5.7 Future Work 
Future work in this area of catalysis could include: 
 Exploration of the scope for the reactions studied with a range of different other 
substrates.  
 Mechanistic studies for the hydrogen transfer reactions, possibly by isolation or 
detection of intermediate species, mainly looking out for 16 electron species or 
metal hydride bonds, which could be detected by 
1
H NMR spectroscopy. 
 Synthesis of [RuClCp#(PPh3)2] complexes, to check if the presence of a 
chelating diphosphine is affecting the catalytic activity. 
 Synthesis of [RuClCp#(P−NH2)] complexes, which are long chain analogues of 
the [RuClCp*(P−NH2)] compounds that, according to Ikariya and co-workers, 
are active for hydrogenations,
18-20
 and would offer an –OH tethered arm for later 
immobilisation.  
 Study of new reactions that could be performed with Ru-Cp* and Ru-Cp# 
complexes, like the Kharasch-type reactions, which are atom-transfer radical 
additions (ATRA) of halogenated compounds to olefins, and have been 
successfully carried out with [Ru
III
Cp*Cl2PPh3] and [Ru
II
Cp*Cl(PPh3)2] 
complexes.
21
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6.1 Introduction 
Some diphosphines have demonstrated cytotoxicity against various cell lines, 
and their activity seems to be related to their autoxidation capabilities.
1
 For example, 
ethyl-substituted phosphines oxidise much more rapidly than phenyl-substituted 
phosphines, and, while the latter show anticancer potency, the former are inactive.
1
 It 
has been observed that, upon coordination to metals (principally gold), diphosphines 
produce complexes with improved anticancer activity compared to the free ligands. 
A general hypothesis considers that gold protects the ligands from oxidation before 
they interact with the corresponding biological target.
2
 A few groups have reported 
gold(I) complexes of the types [(AuX)2L] and [AuL2]X (L = diphosphine, commonly 
1,2-bis(diphenylphosphino)ethane (dppe), X = Cl or a deprotonated N-heterocyclic 
ring system), which have been tested both in vitro and in vivo with promising 
results.
3-5
  
Hetero tri- and bimetallic complexes where the diphosphine is a titanocene 
dichloride species coordinated to either gold, platinum or palladium have also been 
reported (Figure 6.1.1), and their cytotoxicity said to be higher than that of 
Cp2TiCl2.
6
  
 
Figure 6.1.1 Cytotoxic tri- and bimetallic TiAu2 and TiM (M = Pd or Pt) complexes 
The cytotoxicity of complexes of ruthenium with diphosphines has not been 
so widely studied. Samuelson and co-workers have published the use of η6-p-cymene 
ruthenium complexes with different diphosphines acting as either monodentate or 
chelating ligands, which showed good growth inhibitions against several cancer cell 
lines (IC50 values against the lung cancerous H460 cell line ranged from 1.6 to 22.1 
µM, compared to 1.7 µM for cisplatin, after 48 hours)
7
 This investigation proved 
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again that partial oxidation of the diphosphines reduces their anticancer activity, 
while coordination generally has the opposite effect. 
Among the (η6-arene)-ruthenium complexes screened as anticancer agents, 
two principal groups stand out as the most promising, which are the [(η6-
arene)Ru(NN)Cl]
+
 complexes (NN = chelating σ-donor nitrogen ligands, especially 
ethylenediamine (en)), initially developed by Sadler’s group,8 and the [(η6-
arene)Ru(pta)Cl2] (RAPTA) complexes (pta = 1,3,5-triaza-7-phosphatricyclo 
[3.3.1.1] decane), largely studied by Dyson and co-workers
9
 (Figure 6.1.2). For [(η6-
arene)Ru(en)Cl]
+
 complexes, it has been observed that more hydrophobic and larger 
arenes, especially fused systems, such as tetrahydroanthracene, improve cytotoxicity 
results to a large degree.
10, 11
 In the case of the RAPTA complexes, their activity has 
been demonstrated to be pH-dependent. The pKa of [(η
6
-p-cymene)Ru(pta)Cl2] is 
approximately 6.5, which means that the predominant species at physiological pH is 
neutral and can easily be transported through the lipid membranes, but the pH is 
generally lower in cancer cells, where the pta ligand will be protonated, and 
electrophoresis has shown that protonated species induce DNA damage more rapidly 
than their neutral analogues.
12
 In the McGowan group, several Ru-arene complexes 
containing different N,N- or N,O-coordinating picolinamide or ketoiminate ligands 
have been tested, which resulted in promising activities that vary with the binding 
mode adopted by the corresponding ligand.
13-15
  
 
                                     a)                                                        b) 
Figure 6.1.2 Structures of a) [(η6-tetrahydroanthracene)Ru(en)Cl]+ and b) [(η6-p-
cymene)Ru(pta)Cl2] (RAPTA-C) 
In contrast to the numerous efforts in the evaluation of η6-arene ruthenium 
complexes as anticancer agents, fewer examples have been studied with 
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cyclopentadienyl (Cp) or pentamethylcyclopentadienyl (Cp*) compounds. For 
instance, the group of Sava reported the synthesis of the compounds [(η5-
C5H5)Ru(pta)2Cl] and [(η
5
-C5Me5)Ru(pta)2Cl], as equivalents to the RAPTA 
complexes, and observed that, while the Cp* complex inhibits the proliferation of 
TS/A murine adenocarcinoma tumour cells, the Cp analogue does not.
16
 Compounds 
of the type [(η5-C5H5)Ru(PP)L][X], where PP = 2 × PPh3 or dppe, L = planar 
nitrogen σ-bonded ligand and X = CF3SO3 or PF6, have been synthesised by Moreno 
et al. and some of them show better cytotoxicities (IC50 = 0.38-2.26 µM against 
leukaemia HL-60 cancer cells after 72 hours) than cisplatin (IC50 = 2.15 µM).
17-19
 
Other examples with Cp* include the complexes of rhodium [(η5-C5Me5)Rh(pta)Cl2] 
and [(η5-C5Me5)Rh(pta)2Cl]
+
, which even surpass the activity of [(η6-p-
cymene)M(pta)Cl2] (M = Ru or Os) against certain cell lines.
20
 
It has been observed that ruthenium compounds are, in general, less toxic 
than platinum drugs, i.e. more selective towards cancer cells.
9
 Ruthenium normally 
accumulates in rapidly dividing cells, such as tumour cells, because it mimics the 
behaviour of iron and binds transferrin, which is the protein responsible for 
delivering iron to cells and is over-expressed in cancerous cells due to their higher 
iron requirements for fast proliferation.
9
 The other speculative explanation is that 
ruthenium(III) species (such as NAMI-A or KP1019), which are less active, can be 
reduced in vivo in the hypoxic environment of tumours to produce ruthenium(II) 
species (with increased lability of Ru(II)-Cl bonds).
21
 
There are some common features in the aqueous chemistry of organometallic 
ruthenium(II) and diamine platinum(II) chloride anticancer complexes. 
Organometallic ruthenium complexes also tend to bind DNA, and this interaction is 
stabilised through hydrogen-bonding and π-π stacking of the arene or 
cyclopentadienyl ligands with nucleobases (favoured with big fused arene 
systems).
11
 For this to happen, the Ru-Cl species needs to be “activated” by 
hydrolysis, so the Cl
− 
labile ligand(s) is replaced by H2O, because Ru-OH2 
complexes react faster than their Ru-Cl analogues with the corresponding biological 
targets. This hydrolysis is greatly suppressed in media with high chloride 
concentrations, like blood plasma, where [Cl
−
] is approximately 100 mM, but is 
favoured in the intracellular medium, with [Cl
−
] of 23 mM in the cytoplasm and 4 
mM inside the nucleus.
22, 23
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Compounds of iron, in particular, ferrocene-derivatives, also show 
exploitable properties as anticancer agents, and some examples include ferrocifen, 
which was firstly synthesised by Jaouen and co-workers as an alternative to 
tamoxifen
24
, and ferricenium ions.
25
 As with ruthenium, iron has the advantage of 
low general toxicity, and these two metals have in fact been combined in complexes 
tested by Dyson’s group with moderate cytotoxicity results.21, 26  
This chapter presents the results from cell line assays carried out with 
ruthenium complexes of general structures [RuCp*(PP)X], [RuCp
#
(PP)X] (Cp
#
 = 
C5Me4(CH2)5OH) or [RuCp*(PP)L][Z], where X = Cl, Z = SbF6, L = CH3CN and PP 
are diphosphine ligands, one of them being the ferrocene-derivative dppf (1,1'-
bis(diphenylphosphino)ferrocene). 
6.2 Cytotoxicity Screening Assays 
The MTT colorimetric assay was developed by T. Mosmann as a quantitative 
way of measuring mammalian cell survival and proliferation.
27
 It is based on the pale 
yellow salt 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), 
which accepts electrons from substrates such as NADH or NADPH, producing a 
reduced formazan product, which is dark blue (Scheme 6.2.1).
28
 It has been 
suggested that MTT reduction occurs mainly at the mitochondria, but it might take 
place at multiple active cellular sites.
29
 This assay only detects living cells, and is 
still one of the most commonly used for determination of cell survival in drug 
screening protocols in vitro. 
 
Scheme 6.2.1 Reduction of MTT to formazan 
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The drugs tested during this project were incubated with the cancer cells for 
five days at 37ºC, at concentrations ranging from 250 to 0.49 M. MTT was added 
as a solution in distilled water (5 mg/ml) to each well plate after drug exposure, and 
incubated for a further three hours, when the reduction to formazan occurred. The 
cell medium was then removed and the formazan crystals dissolved in 
dimethylsulfoxide (DMSO), and these solutions used to measure the absorbance at a 
wavelength of 540 nm to determine cell survival. The results are expressed as IC50 
values, which are the half maximal inhibitory concentrations, i.e. the concentration 
of each complex needed to kill half of the cells. These values were obtained from 
plots of percentage cell survival against drug concentration (μM), like the example in 
Figure 6.2.1. Each IC50 number was obtained as the average from three assays, 
which were performed by Miss Rianne Lord (HT-29) and Miss Aida Basri (A2780). 
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Figure 6.2.1 % Cell survival versus drug concentration (logarithmic scale) for complex 4.5 
against the cell line HT-29 after exposures of five days 
No reaction between the complexes tested and DMSO has been observed by 
1
H NMR spectroscopy in deuterated DMSO after a period of five days, but some of 
the compounds did not dissolve completely in the DMSO/media mixture used for the 
cell line assays. This is detailed later on in the results section. 
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6.3 Results and Discussion 
6.3.1 Introduction 
Some of the Cp* and Cp
#
 diphosphine-ruthenium(II) complexes (4.5, 4.6 and 
4.8 to 4.12) presented in Chapter 4 (Figure 6.3.1), together with the corresponding 
free diphosphines (Figure 6.3.2) and cisplatin as a reference have been tested as 
potential anticancer agents against the cell lines HT-29 (colon cancerous cells) and 
A2780 (ovarian cancerous cells), with exposures of five days at 37ºC. This allows 
for a comparison of the activities of free and coordinated diphosphines. The effect of 
the −(CH2)5OH chain in the Cp
#
 ruthenium complexes is also analysed. Complexes 
4.5 and 4.12 have been used for NMR spectroscopy studies in mixtures of 90% 
deuterated dimethylsulfoxide and 10% deuterium oxide to determine the extent of 
ligand-exchange reactions from either chloride or acetonitrile ligands to yield a 
hydrolysed product, and how this is related to their anticancer activity. 
 
Figure 6.3.1 Cp* and Cp
#
 ruthenium complexes tested as anticancer agents against the cell 
lines HT-29 and A2780 
6.3.2 Cytotoxicity IC50 Values 
The IC50 results for cisplatin, dppm, dppf, Xantphos and the ruthenium 
complexes after five-day exposures are presented in Table 6.3.1, Figure 6.3.3 and 
Figure 6.3.4. Although the cytotoxicity trends are repeated in both cell lines, the 
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compounds tested gave, in general, better results against the A2780 ovarian 
cancerous cells. 
 
Figure 6.3.2 Structures of a) dppm, b) dppf and c) Xantphos 
 IC50 Values After 5-Day Exposures (μM) 
Compound HT-29 (Colon) ± A2780 (Ovarian) ± 
Cisplatin 2.52 0.09 1.4 0.3 
dppm 1.47 0.02 1 1 
4.5 0.73 0.05 1.1 0.2 
4.9 0.791 0.007 0.9 0.1 
4.12 0.61 0.01 0.70 0.02 
dppf 11.6 0.7 0.4 0.4 
4.6 >250 - 40 10 
4.10 20 1 11.9 0.3 
Xantphos >250 - >250 - 
4.8 10.1 0.5 3.6 0.4 
4.11 11.9 0.7 4.0 0.3 
 
Table 6.3.1 IC50 values for Cp* and Cp
#
 diphosphine-ruthenium complexes, cisplatin, dppm, 
dppf and Xantphos against the HT-29 and A2780 cell lines after exposures of five days 
Dppf and the complexes 4.6 and 4.10, formed with this ligand, had very low 
solubilities in the mixture DMSO/media used for the cell line assays, and 
precipitation was observed in the plates used for the in vitro studies, which implies 
less accuracy in those particular IC50 concentrations. Despite not having been 
quantified, complex 4.6 seemed less soluble than 4.10, probably because of the –OH 
polar group in 4.10. All of the values have been calculated from an average of three 
assays. 
The most active complexes were those with the ligand dppm (4.5, 4.9 and 
4.12), all with better cytotoxicities than cisplatin for both HT-29 and A2780 cell 
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lines. It can be seen that dppm is very active by itself and it is still unclear whether 
the activity of the aforementioned complexes comes mostly from the ligand. 
However, 
1
H and 
31
P NMR spectroscopy experiments in deuterated DMSO showed 
no de-coordination of dppm from complexes 4.5 and 4.12 after five days. 
Compounds 4.8 and 4.11 with the ligand Xantphos presented moderate to good 
activities, despite the ligand not being active in this case, but they did not improve on 
cisplatin. This shows that the coordination of Xantphos to ruthenium increases the 
anticancer activity to a large degree. Complexes 4.6 and 4.10 did not seem to surpass 
the activity of dppf alone, but the lack of solubility makes these results hardly 
comparable. 
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Figure 6.3.3 IC50 values for Cp* and Cp
#
 diphosphine-ruthenium complexes, cisplatin, 
dppm, dppf and Xantphos against the HT-29 and A2780 cell lines after exposures of five 
days. The blank spaces indicate no activity 
Except in the case of the dppf complexes 4.6 and 4.10 where solubility might 
be an issue, the –(CH2)5OH chain in the Cp
#
 compounds produced no great effect on 
the anticancer activity, as can be seen within the couples 4.5-4.9 and 4.8-4.11. The 
presence of CH3CN in complex 4.12, on the other hand, improved considerably its 
cytotoxicity in comparison to that of 4.5. This may be either the result of faster 
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hydrolysis of the CH3CN group (see below) or better solubility of 4.12, which is a 
charged (monocationic) species. 
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Figure 6.3.4 Enlargement of Figure 6.3.3 for the compounds with better activities than 
cisplatin 
6.3.3 Hydrolysis Studies 
10 μM samples of complex 4.5 and complex 4.12 in 0.6 ml of deuterated 
solvent (90% deuterated DMSO + 10% deuterium oxide) were prepared in NMR 
tubes and analysed by 
1
H NMR spectroscopy every 24 hours during five days at 
room temperature. The results are shown in Figure 6.3.5 and Figure 6.3.8 
respectively, with enlargements of different sections of the spectra in Figure 6.3.6, 
Figure 6.3.7, Figure 6.3.9 and Figure 6.3.10. The peaks at 2.50 and 3.68 ppm are 
residual DMSO and H2O. When higher percentages of deuterium oxide were tried in 
the mixture, complex 4.5 could not be dissolved or, with a 20% of D2O, it 
crystallised in the NMR tube after one day, indicating a lower solubility than that of 
the cationic complex 4.12. 
Complex 4.5 gave, initially, a triplet at 1.56 ppm for the Cp* methyl protons 
and two doublets of triplets at 3.95 and 5.15 ppm for the CH2 protons of dppm 
     Chapter 6 
175 
(Figure 6.3.5). After five days, a new set of peaks at 5.14 and 1.61 ppm appeared 
(Figure 6.3.6 and Figure 6.3.7). The fresh sample of complex 4.12 gave peaks at 
1.50 ppm for the Cp* methyl protons, at 1.76 ppm for the CH3 protons in the 
coordinated acetonitrile and at 4.52 and 5.33 ppm for the CH2 protons of dppm 
(Figure 6.3.8). After five days, a new set of peaks at 5.14, 2.03 (free acetonitrile) 
and 1.61 ppm appeared (Figure 6.3.9 and Figure 6.3.10). The new peaks coincide in 
both experiments, and they belong to the hydrolysed species [RuCp*(dppm)(OH2)]
+
 
(6.1, further characterisation in Chapter 7). From integrations of the NMR peaks, 
this new species forms, after five days, in 48% yield from complex 4.5 and in 67% 
yield from complex 4.12, which hydrolyses to a higher extent under the same 
conditions, and this coincides with the higher anticancer activity of compound 4.12. 
Figure 6.3.11 shows a plot of the IC50 values of 4.5 and 4.12 for both cell lines 
against the percentages of hydrolysed complex 6.1 obtained during these 
experiments. 
8 7 6 5 4 3 2 1
Chemical Shift (ppm)  
Figure 6.3.5 
1
H NMR spectra of complex 4.5 (10 μM) in 90% deuterated DMSO + 10% 
D2O after 0, 1, 2, 3, 4 and 5 days at room temperature 
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Figure 6.3.6 Enlargement of Figure 6.3.5 in the CH2 area 
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Figure 6.3.7 Enlargement of Figure 6.3.5 in the Cp* area 
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Chemical Shift (ppm)  
Figure 6.3.8 
1
H NMR spectra of complex 4.12 (10 μM) in 90% deuterated DMSO + 10% 
D2O after 0, 1, 2, 3, 4 and 5 days at room temperature 
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Figure 6.3.9 Enlargement of Figure 6.3.8 in the CH2 area 
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Figure 6.3.10 Enlargement of Figure 6.3.8 in the Cp* and CH3 (acetonitrile) area 
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Figure 6.3.11 IC50 values of compounds 4.5 and 4.12 for the cell lines HT-29 and A2780 
against the percentages of hydrolysed species 6.1 obtained from each complex in the NMR 
experiments 
 
 
4.5 4.12 
0 days 
2 days 
3 days 
4 days 
5 days 
1 day 
     Chapter 6 
179 
6.4 Conclusions 
A series of RuCp* and RuCp
#
 (Cp
#
 = C5Me4(CH2)5OH) complexes bearing 
diphosphines as chelating ligands have been tested in vitro against the cancerous cell 
lines HT-29 and A2780, and the corresponding cytotoxicity values obtained using 
the MTT colorimetric assay after exposures of five days. 
The complexes with the ligand dppm showed the best anticancer activities, 
probably due to the intrinsic cytotoxicity of free dppm. All of these complexes 
improved on the performance of cisplatin. On the other hand, it was demonstrated 
that the coordination of the diphosphine Xantphos reduces the IC50 values very 
significantly, because this compound is not cytotoxic by itself. The complexes with 
the ligand dppf showed very low solubilities in the mixture DMSO/media used for 
the assays and so the results cannot really be compared with those of the other PP 
ligands. 
The complexes with Cp
#
 did not introduce any appreciable improvement with 
respect to those with Cp*. However, changing the chloride ligands for acetonitrile 
resulted in a slight increase in cytotoxicity, and hydrolysis studies by 
1
H NMR 
spectroscopy showed that the bond Ru-NCCH3 is hydrolysed to a higher extent than 
Ru-Cl over the same period of time. Complexes 4.5 and 4.12 were converted to 
different extents to the aqua species [RuCp*(dppm)(OH2)]
+ 
(6.1) in 90% deuterated 
DMSO/10% D2O solutions. 
6.5 Future Work 
Future work in this area of anticancer agents could include: 
 Further studies of hydrolysis reactions for the rest of the compounds and 
comparison of hydrolysis rates/percentages with the cytotoxicities shown by 
the different complexes. 
 Lipophilicity studies in water/octanol to elucidate relative solubilities and 
how they might have affected the cell line results. 
 Synthesis and testing of other CH3CN charged analogues which may, as 4.12, 
give better activities due to increased aquation rates. The use of 
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counteranions different to SbF6 could also provide a range of various 
solubilities. 
 Investigation of the anticancer activity exhibited by other complexes 
synthesised during this project, for example, the functionalised η6-arene 
complexes presented in Chapter 2. 
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7.1 Experimental Techniques 
7.1.1 General Procedures 
 All of the manipulations for the syntheses of the 2,5-dihydrophenyl carboxy 
ligands (2.1 and 2.2), the pentamethylcyclopentadiene and (5-hydroxypentyl)-
tetramethylcyclopentadiene ligands (4.1 and 4.2), the η5-
pentamethylcyclopentadienyl and η5-(5-hydroxypentyl)-tetramethylcyclopentadienyl 
ruthenium complexes (4.3 to 4.12) and the tetramethylfulvene complexes (4.13 and 
4.14) were conducted using standard Schlenk line techniques under an inert 
atmosphere of dry dinitrogen in a dual vacuum/dinitrogen line. Dry dinitrogen was 
obtained by passing dinitrogen gas through a double column with phosphorus 
pentoxide and activated 4 Å molecular sieves. 
 Dry diethyl ether, toluene, methanol, ethanol, dichloromethane and hexane 
were collected from the stills in the Department of Chemistry, using a Pure Solvent 
MD Solvent Purification System, and were subsequently stored in ampoules under 
dinitrogen. Glassware, cannulae and filter papers were stored in an oven at 100-
150°C prior to use. A Braun Labmaster 100 glove box was used to store all of the air 
sensitive compounds. 
 The liquid ammonia needed for the synthesis of the 2,5-dihydrophenyl 
carboxy ligands (2.1 and 2.2) was transferred to the reaction flask from a gas 
ammonia cylinder and condensed using an acetone/dry ice bath that maintained a 
constant temperature of -78ºC. 
 All of the η6-arene ruthenium complexes were synthesised under non-inert 
atmosphere, with non pre-dried solvents. All of the catalytic reactions were also 
performed in non-dry conditions, unless otherwise stated. 
 Chemicals were supplied by Sigma-Aldrich Chemicals Co., Alfa Aesar, 
Fisher Scientific, SAFC Supply Solutions, Fluka Analytical, Acros Organics, VWR 
International Ltd. and the Department of Chemistry breached bottle store, and they 
were used without further purification. 
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 Deuterated NMR solvents were purchased from Sigma-Aldrich Chemicals 
Co. The deuterated chloroform used in the glove box was degassed using freeze-
pump-thaw cycles and stored over molecular sieves. 
7.1.2 Instrumentation 
 All of the NMR spectra were recorded either by the author using a Bruker 
DPX 300 MHz spectrometer, a Bruker Avance 400 MHz spectrometer or a Bruker 
DRX 500 MHz spectrometer, or by Mr. Simon Barrett using a Bruker DRX 500 
MHz spectrometer. Microanalyses were obtained by Mr. Ian Blakely at the 
University of Leeds Microanalytical Service. Mass spectra were obtained by Ms. 
Tanya Marinko-Covell at the University of Leeds Mass Spectrometry Service. Solid 
state infrared spectra were obtained by the author on a PerkinElmer Spectrum One 
FT-IR spectrometer. Gas chromatography analyses were obtained by the author 
using a Hewlett Packard Agilent HP6890 Series GC system with a HP7683 Series 
injector and a capillary column HP-5 (5% phenyl methyl siloxane) HP 19091J-413, 
with a length of 30 m, a diameter of 0.32 mm and a film thickness of 0.25 μm. The 
solvent used was acetonitrile. 
7.1.3 X-Ray Crystallography 
 X-Ray diffraction data were collected either by the author or Mr. Colin 
Kilner. Suitable single crystals were selected under the microscope and immersed in 
inert oil. The crystals were mounted on a glass capillary and attached to a 
goniometer head on a Bruker X8 Apex diffractometer using graphite 
monochromated Mo-Kα radiation (λ = 0.71073 Å) and 1.0° Φ-rotation frames. The 
crystals were cooled to 150 K by an Oxford cryostream low temperature device.
1
 
The full data sets were recorded and the images processed using the Apex2 software, 
Bruker Nonius 2004. The structures were resolved by the author, Mr. Colin Kilner 
and Dr. Christopher Pask. 
 Structure solution by direct methods was achieved through the use of the 
SHELXS-97 program,
2
 and the structural model refined by full matrix least squares 
on F2 using SHELXL-97.
2
 Molecular graphics were plotted using POV-Ray via the 
XSeed program.
3
 Editing of Crystallographic Information Files (CIFs) and 
construction of tables of bond lengths and angles were achieved using WC.
4
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Hydrogen atoms were placed using idealised geometric positions (with free rotation 
for methyl groups), allowed to move in a “riding model” along with the atoms to 
which they were attached, and refined isotropically. 
7.2 2,5-Dihydrophenyl Carboxy Ligands 
 The ligands in this section (2.1 and 2.2) were synthesised following a route 
based on previous work by Sheldrick et al.
5 1
H NMR spectra were recorded for each 
of them to confirm product formation, but further characterisation was not 
completed. 
7.2.1 Preparation of C8H10O2 (2.1) 
 Phenylacetic acid (4.08 g, 30 mmol) in diethyl ether (50 ml) was added to a 
mixture of sodium (6.9 g, 300 mmol) in liquid ammonia (200 ml) at -78°C under N2. 
Ethanol (100 ml) was added dropwise at -78°C and the mixture stirred until the dark 
blue colour disappeared. The ammonia was left to evaporate overnight, water (100 
ml) added and then HCl was added dropwise until pH 2. The product was extracted 
in diethyl ether, dried (MgSO4) and the solvent removed in vacuo to afford a white 
solid that was recrystallised from petrol (40-60ºC). 
Yield: 3.4 g, 24.6 mmol (82%).  
Characterisation:  
1
H NMR (CDCl3, 400.13 MHz, 293.8 K)  
δ 5.70 [m, 2H, (CH(CH2)2(CH)2C)CH2CO2H], 5.64 [br. s, 1H, 
(CH(CH2)2(CH)2C)CH2CO2H], 3.03 [s, 2H, (CH(CH2)2(CH)2C)CH2CO2H], 2.73 [m, 
4H, (CH(CH2)2(CH)2C)CH2CO2H].  
7.2.2 Preparation of C10H14O2 (2.2) 
4-Phenylbutyric acid (4.93 g, 30 mmol) in diethyl ether (50 ml) was added to 
a mixture of sodium (6.9 g, 300 mmol) in liquid ammonia (200 ml) at -78°C under 
N2. Ethanol (100 ml) was added dropwise at -78°C and the mixture stirred until the 
dark blue colour disappeared. The ammonia was left to evaporate overnight, water 
(150 ml) added and then HCl was added dropwise until pH 2. The product was 
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extracted in diethyl ether, dried (MgSO4) and the solvent removed in vacuo to afford 
a dark solid. 
Yield: 4.39 g, 26.4 mmol (88%).  
Characterisation: 
1
H NMR (CDCl3, 400.13 MHz, 300.0 K)  
δ 5.62 [m, 2H, (CH(CH2)2(CH)2C)CH2CH2CH2CO2H], 5.36 [br. s, 1H, 
(CH(CH2)2(CH)2C)CH2CH2CH2CO2H], 2.55 [m, 4H, 
(CH(CH2)2(CH)2C)CH2CH2CH2CO2H], 2.27 [m, 2H, 
(CH(CH2)2(CH)2C)CH2CH2CH2CO2H], 2.21 [m, 2H, 
(CH(CH2)2(CH)2C)CH2CH2CH2CO2H], 1.69 [m, 2H, 
(CH(CH2)2(CH)2C)CH2CH2CH2CO2H]. 
7.3 Functionalised η6-Arene Ruthenium Complexes 
 Most of these complexes (2.3 to 2.8) were synthesised by a method 
developed by Sheldrick et al.
5
 and used previously within the McGowan group.
6
 
Complex 2.9 was synthesised by a slight modification of the procedures used by 
Keppler et al.
7
 and some partners of this project in similar transformations.
8
 
Complexes 2.3, 2.5 and 2.6 were known
5
 and their formation was confirmed by 
1
H 
NMR and elemental analysis. The rest of the complexes are novel.  
7.3.1 Preparation of [RuCl2C6H5CH2COOH]2 (2.3) 
Ligand 2.1 (4.5 g, 32.6 mmol) was added to a round bottom flask with 
RuCl3·3H2O (2.13 g, 8.14 mmol) in acetone/water (5:1 v/v, 54 ml). The mixture was 
heated under reflux for 5.5 hours, concentrated in vacuo, and the precipitate filtered, 
washed with diethyl ether and dried under vacuum to afford an orange solid.  
Yield: 2.19 g, 3.56 mmol (87%).  
Characterisation: 
Calculated for C16H16Cl4O4Ru2 (616.27 g mol
-1
): C 31.2; H 2.6; Cl 23.0% 
Found: C 31.3; H 2.6; Cl 22.8% 
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1
H NMR (CD3CN, 400.13 MHz, 293.9 K) 
δ 5.76 [m, 4H, meta-CH of C6H5CH2CO2H], 5.69 [m, 2H, para-CH of 
C6H5CH2CO2H], 5.56 [d, 
3
J(H-H) = 5.8 Hz, 4H, ortho-CH of C6H5CH2CO2H], 3.61 [s, 
4H, C6H5CH2CO2H]. 
7.3.2 Preparation of [RuBr2C6H5CH2COOH]2 (2.4) 
Ligand 2.1 (0.5 g, 3.6 mmol) was added to a round bottom flask with RuBr3 
(0.31 g, 0.9 mmol) in acetone/water (5:1 v/v, 6 ml). The mixture was heated under 
reflux for 3 days, concentrated in vacuo, and the precipitate filtered, washed with 
diethyl ether and dried under vacuum to afford a red solid.  
Yield: 0.30 g, 0.37 mmol (82%).  
Characterisation: 
Calculated for C16H16Br4O4Ru2 (793.86 g mol
-1
): C 24.2; H 2.0; Br 40.3% 
Found: C 24.2; H 2.1; Br 40.0% 
1
H NMR (CD3CN, 400.13 MHz, 294.6 K) 
δ 5.77 [m, 6H, meta & para-CH of C6H5CH2CO2H], 5.64 [d, 
3
J(H-H) = 2.9 Hz, 4H, 
ortho-CH of C6H5CH2CO2H], 3.64 [s, 4H, C6H5CH2CO2H]; 
13
C{
1
H} NMR (CD3CN, 100.62 MHz, 295.6 K) 
 157.6 [C6H5CH2CO2H], 116.4 [Quaternary C of C6H5CH2CO2H], 84.6 [ortho-CH 
of C6H5CH2CO2H], 84.5 [meta-CH of C6H5CH2CO2H], 83.0 [para-CH of 
C6H5CH2CO2H], 38.3 [C6H5CH2CO2H]. 
7.3.3 Preparation of [RuCl2C6H5(CH2)3COOH]2 (2.5) 
Ligand 2.2 (6.2 g, 37 mmol) was added to a round bottom flask with 
RuCl3∙3H2O (2.42 g, 9.25 mmol) in acetone/water (5:1 v/v, 60 ml). The mixture was 
heated under reflux for 3 days, concentrated in vacuo, and the precipitate filtered, 
washed with diethyl ether and dried under vacuum to afford an orange solid.  
Yield: 1.80 g, 2.67 mmol (58%).  
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Characterisation: 
Calculated for C20H24Cl4O4Ru2 (672.33 g mol
-1
): C 35.7; H 3.6; Cl 21.1% 
Found: C 36.0; H 3.6; Cl 21.0% 
1
H NMR (CD3CN, 400.13 MHz, 300.0 K) 
δ 5.69 [t, 3J(H-H) =  5.7 Hz, 4H, meta-CH of C6H5CH2CH2CH2CO2H], 5.62 [t, 
3
J(H-H) 
=  5.6 Hz, 2H, para-CH of C6H5CH2CH2CH2CO2H], 5.45 [d, 
3
J(H-H) = 5.6 Hz, 4H, 
ortho-CH of C6H5CH2CH2CH2CO2H], 2.57 [m, 4H, C6H5CH2CH2CH2CO2H], 2.39 
[t, 
3
J(H-H) = 7.5 Hz, 4H, C6H5CH2CH2CH2CO2H], 1.91 [m, 4H, 
C6H5CH2CH2CH2CO2H]. 
7.3.4 Preparation of [RuCl2C6H5CH2COOCH2CH3]2 (2.6) 
Ligand 2.1 (0.83 g, 6 mmol) was added to a round bottom flask with 
RuCl3·3H2O (0.52 g, 2 mmol) in ethanol (30 ml). The mixture was heated under 
reflux for 2 hours, concentrated in vacuo, and the precipitate filtered, washed with 
ethanol and dried under vacuum to afford an orange solid.  
Yield: 0.37 g, 0.56 mmol (56%).  
Characterisation: 
Calculated for C20H24Cl4O4Ru2 (672.33 g mol
-1
): C 35.7; H 3.6; Cl 21.1% 
Found: C 35.8; H 3.5; Cl 21.4% 
1
H NMR (CDCl3, 400.13 MHz, 300.0 K) 
δ 5.68 [m, 6H, meta & para-CH of C6H5CH2CO2CH2CH3], 5.50 [d, 
3
J(H-H) = 5.6 Hz, 
4H, ortho-CH of C6H5CH2CO2CH2CH3], 4.16 [q, 
3
J(H-H) = 7.0 Hz, 4H, 
C6H5CH2CO2CH2CH3], 3.66 [s, 4H, C6H5CH2CO2CH2CH3], 1.26 [t, 
3
J(H-H) = 7.2 Hz, 
6H, C6H5CH2CO2CH2CH3]. 
7.3.5 Preparation of [RuBr2C6H5CH2COOCH2CH3]2 (2.7) 
Ligand 2.1 (0.5 g, 3.6 mmol) was added to a round bottom flask with RuBr3 
(0.31 g, 0.9 mmol) in ethanol (30 ml). The mixture was heated under reflux for 24 
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hours, concentrated in vacuo, and the precipitate filtered, washed with ethanol and 
dried under vacuum to afford an orange solid.  
Yield: 0.12 g, 0.14 mmol (31%).  
Characterisation: 
Calculated for C20H24Br4O4Ru2 (849.93 g mol
-1
):  C 28.2; H 2.9; Br 37.6% 
Found: C 28.1; H 2.8; Br 37.4% 
1
H NMR (CDCl3, 400.13 MHz, 294.4 K) 
δ 5.77 [m, 2H, para-CH of C6H5CH2CO2CH2CH3], 5.67 [t, 
3
J(H-H) = 5.6 Hz, 4H, 
meta-CH of C6H5CH2CO2CH2CH3], 5.54 [d, 
3
J(H-H) = 5.6 Hz, 4H, ortho-CH of 
C6H5CH2CO2CH2CH3], 4.16 [q, 
3
J(H-H) = 7.0 Hz, 4H, C6H5CH2CO2CH2CH3], 3.68 
[s, 4H, C6H5CH2CO2CH2CH3], 1.26 [t, 
3
J(H-H) = 7.2 Hz, 6H, C6H5CH2CO2CH2CH3]; 
13
C{
1
H} NMR (CDCl3, 125.76 MHz, 300.0 K) 
 169.4 [C6H5CH2CO2CH2CH3], 92.6 [Quaternary C of C6H5CH2CO2CH2CH3], 83.8 
[ortho-CH of C6H5CH2CO2CH2CH3], 83.1 [meta-CH of C6H5CH2CO2CH2CH3], 
82.4 [para-CH of C6H5CH2CO2CH2CH3], 61.7 [C6H5CH2CO2CH2CH3], 39.7 
[C6H5CH2CO2CH2CH3], 14.1 [C6H5CH2CO2CH2CH3]. 
7.3.6 Preparation of [RuCl2C6H5(CH2)3COOCH2CH3]2 (2.8) 
Ligand 2.2 (1 g, 6 mmol) was added to a round bottom flask with 
RuCl3∙3H2O (0.52 g, 2 mmol) in ethanol (30 ml). The mixture was heated under 
reflux for 4 days, concentrated in vacuo, and the precipitate filtered, washed with 
ethanol and dried under vacuum to afford an orange solid. 
Yield: 0.04 g, 0.05 mmol (5%).  
Characterisation: 
Calculated for C24H32Cl4O4Ru2 (728.37 g mol
-1
): C 39.5; H 4.4; Cl 19.5% 
Found: C 39.5; H 4.4; Cl 19.2% 
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1
H NMR (CDCl3, 400.13 MHz, 300.0 K) 
δ 5.66 [t, 3J(H-H) = 5.4 Hz, 4H, meta-CH of C6H5CH2CH2CH2CO2CH2CH3], 5.61 [t, 
3
J(H-H) = 5.3 Hz, 2H, para-CH of C6H5CH2CH2CH2CO2CH2CH3], 5.39 [d, 
3
J(H-H) = 
5.6 Hz, 4H, ortho-CH of C6H5CH2CH2CH2CO2CH2CH3], 4.12 [q, 
3
J(H-H) = 7.1 Hz, 
4H, C6H5CH2CH2CH2CO2CH2CH3], 2.60 [m, 4H, C6H5CH2CH2CH2CO2CH2CH3], 
2.37 [t, 
3
J(H-H) = 7.3 Hz, 4H, C6H5CH2CH2CH2CO2CH2CH3], 1.92 [quintet, 
3
J(H-H) = 
7.5 Hz, 4H, C6H5CH2CH2CH2CO2CH2CH3], 1.26 [t, 
3
J(H-H) = 7.0 Hz, 6H, 
C6H5CH2CH2CH2CO2CH2CH3]; 
13
C{
1
H} NMR (CDCl3, 100.61 MHz, 300.0 K) 
 172.7 [C6H5CH2CH2CH2CO2CH2CH3], 100.5 [Quaternary C of 
C6H5CH2CH2CH2CO2CH2CH3], 84.1 [meta-CH of C6H5CH2CH2CH2CO2CH2CH3], 
80.5 [ortho-CH of C6H5CH2CH2CH2CO2CH2CH3], 80.0 [para-CH of 
C6H5CH2CH2CH2CO2CH2CH3], 60.6 [C6H5CH2CH2CH2CO2CH2CH3], 33.5 
[C6H5CH2CH2CH2CO2CH2CH3], 32.9 [C6H5CH2CH2CH2CO2CH2CH3], 24.8 
[C6H5CH2CH2CH2CO2CH2CH3], 14.3 [C6H5CH2CH2CH2CO2CH2CH3]. 
7.3.7 Preparation of [RuI2C6H5CH2COOCH2CH3]2 (2.9) 
NaI (0.23 g, 1.525 mmol) was added to a solution of complex 2.6 (33.6 mg. 
0.05 mmol) in chloroform (10 ml). The mixture was stirred for three days and then 
filtered and washed with chloroform. The washings were collected and the solvent 
was evaporated to give a red solid that was recrystallised from 
dichloromethane/hexane. 
Yield: 0.0071 g, 0.0068 mmol (14%). 
Characterisation: 
Calculated for C20H24I4O4Ru2 (1037.93 g mol
-1
): C 23.1; H 2.3% 
Found: C 23.8; H 2.3% 
1
H NMR (CDCl3, 500.23 MHz, 298.4 K) 
δ 5.84 [t, 3J(H-H) = 5.4 Hz, 2H, para-CH of C6H5CH2CO2CH2CH3], 5.67 [t, 
3
J(H-H) = 
5.6 Hz, 4H, meta-CH of C6H5CH2CO2CH2CH3], 5.61 [d, 
3
J(H-H) = 5.6 Hz, 4H, ortho-
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CH of C6H5CH2CO2CH2CH3], 4.16 [q, 
3
J(H-H) = 7.2 Hz, 4H, C6H5CH2CO2CH2CH3], 
3.69 [s, 4H, C6H5CH2CO2CH2CH3], 1.27 [t, 
3
J(H-H) = 7.2 Hz, 6H, 
C6H5CH2CO2CH2CH3];  
13
C{
1
H} NMR (CDCl3, 125.77 MHz, 300.2 K) 
 170.0 [C6H5CH2CO2CH2CH3], 96.8 [Quaternary C of C6H5CH2CO2CH2CH3], 86.1 
[ortho-CH of C6H5CH2CO2CH2CH3], 84.0 [para-CH of C6H5CH2CO2CH2CH3], 83.0 
[meta-CH of C6H5CH2CO2CH2CH3], 61.7 [C6H5CH2CO2CH2CH3], 40.6 
[C6H5CH2CO2CH2CH3], 14.1 [C6H5CH2CO2CH2CH3]. 
ES MS (+): m/z 912.69 [M – I]+. 
7.3.8 Preparation of [RuCl2(C6H5CH2COOCH2CH3)(NC5H5)] (2.10) 
Complex 2.6 (67 mg, 0.1 mmol) was dissolved in dichloromethane (10 ml) 
and pyridine (16 µl, 0.2 mmol) was added. The mixture was stirred overnight to give 
an orange solution and the solvent was evaporated to give an orange/yellow product. 
Yield: 0.0592 g, 0.14 mmol (71 %). 
Characterisation: 
Calculated for C15H17Cl2NO2Ru (415.83 g mol
-1
): C 43.3; H 4.1; N 3.4; Cl 17.1% 
Found: C 43.2; H 4.1; N 3.3; Cl 16.9%   
1
H NMR (CDCl3, 500.23 MHz, 298.6 K) 
δ 9.05 [d, 3J(H-H) = 5.2 Hz, 2H, 2,6-CH of NC5H5], 7.77 [t, 
3
J(H-H) = 7.4 Hz, 1H, 4-CH 
of NC5H5], 7.33 [t, 
3
J(H-H) = 6.8 Hz, 2H, 3,5-CH of NC5H5], 5.64 [t, 
3
J(H-H) = 5.4 Hz, 
2H, meta-CH of C6H5CH2CO2CH2CH3], 5.58 [t, 
3
J(H-H) = 5.2 Hz, 1H, para-CH of 
C6H5CH2CO2CH2CH3], 5.54 [d, 
3
J(H-H) = 5.6 Hz, 2H, ortho-CH of 
C6H5CH2CO2CH2CH3], 4.20 [q, 
3
J(H-H) = 7.2 Hz, 2H, C6H5CH2CO2CH2CH3], 3.67 
[s, 2H, C6H5CH2CO2CH2CH3], 1.29 [t, 
3
J(H-H) = 7.2 Hz, 3H, C6H5CH2CO2CH2CH3]; 
13
C{
1
H} NMR (CDCl3, 75.47 MHz, 300.0 K) 
 169.6 [C6H5CH2CO2CH2CH3], 155.3 [2,6-CH of NC5H5], 138.0 [4-CH of NC5H5], 
124.9 [3,5-CH of NC5H5], 94.8 [Quaternary C of C6H5CH2CO2CH2CH3], 85.9 
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[meta-CH of C6H5CH2CO2CH2CH3], 83.8 [ortho-CH of C6H5CH2CO2CH2CH3], 
82.1 [para-CH of C6H5CH2CO2CH2CH3], 61.7 [C6H5CH2CO2CH2CH3], 38.8 
[C6H5CH2CO2CH2CH3], 14.2 [C6H5CH2CO2CH2CH3]. 
ES MS (+): m/z 379.99 [M – Cl]+; 300.95 [M – Cl – py]+. 
7.4 η6-p-Cymene Ruthenium Dimers 
 Compound 3.1 was synthesised according to a method already utilised in the 
McGowan group,
9
 and compound 3.2 was synthesised from the previous one by 
modification of some existing treatments.
7, 8
 
7.4.1 Preparation of [RuCl2(C10H14)]2 (3.1) 
α-Terpinene (19 ml, 116.7 mmol) was added to a solution of RuCl3 ∙ 3H2O 
(2.51 g, 9.6 mmol) in absolute ethanol (150 ml) and heated under reflux for two 
days. After that, the volume was reduced in vacuo and the solution stored in the 
freezer for three days. The red precipitate formed was filtered off, washed with ice 
cold diethyl ether and dried to yield a red crystalline powder. 
Yield: 2.61 g, 4.27 mmol (89%). 
Characterisation: 
Calculated for C20H28Cl4Ru2 (612.36 g mol
-1
): C 39.2; H 4.6; Cl 23.2% 
Found: C 39.4; H 4.6; Cl 23.1% 
1
H NMR (CDCl3, 500.23 MHz, 300.0 K) 
δ 5.47 [d, 3J(H-H) = 6.0 Hz, 4H, CH3C(CH)2(CH)2CCH(CH3)2], 5.34 [d, 
3
J(H-H) = 6.0 
Hz, 4H, CH3C(CH)2(CH)2CCH(CH3)2], 2.92 [sep, 
3
J(H-H) = 6.9 Hz, 2H, 
CH3C(CH)2(CH)2CCH(CH3)2], 2.16 [s, 6H, CH3C(CH)2(CH)2CCH(CH3)2], 1.28 [d, 
3
J(H-H) = 6.8 Hz, 12H, CH3C(CH)2(CH)2CCH(CH3)2]; 
13
C{
1
H} NMR (CDCl3, 75.47 MHz, 299.9 K) 
 101.2 [CH3C(CH)2(CH)2CCH(CH3)2], 96.7 [CH3C(CH)2(CH)2CCH(CH3)2], 81.3 
[CH3C(CH)2(CH)2CCH(CH3)2], 80.6 [CH3C(CH)2(CH)2CCH(CH3)2], 30.6 
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[CH3C(CH)2(CH)2CCH(CH3)2], 22.1 [CH3C(CH)2(CH)2CCH(CH3)2], 18.9 
[CH3C(CH)2(CH)2CCH(CH3)2]. 
ES MS (+): m/z 575.9 [M – H – Cl]+. 
7.4.2 Preparation of [RuI2(C10H14)]2 (3.2) 
A solution of NaI (3.7 g, 24.4 mmol) in water (25 ml) was added to a solution 
of complex 3.1 (0.49 g, 0.8 mmol) in chloroform (20 ml), and the mixture was 
stirred overnight. The two phases were separated and the organic layer was washed 
with water and brine, dried over Na2SO4 and filtered, and the solvent removed to 
give a dark red solid, which was recrystallised from dichloromethane/hexane. 
Yield: 0.68 g, 0.69 mmol (86%). 
Characterisation: 
Calculated for C20H28I4Ru2 (977.98 g mol
-1
): C 24.5; H 2.9; I 51.9% 
Found: C 24.3; H 2.8; I 51.9% 
1
H NMR (CDCl3, 400.13 MHz, 294.4 K) 
δ 5.54 [d, 3J(H-H) = 6.0 Hz, 4H, CH3C(CH)2(CH)2CCH(CH3)2], 5.44 [d, 
3
J(H-H) = 5.6 
Hz, 4H, CH3C(CH)2(CH)2CCH(CH3)2], 3.02 [sep, 
3
J(H-H) = 6.8 Hz, 2H, 
CH3C(CH)2(CH)2CCH(CH3)2], 2.37 [s, 6H, CH3C(CH)2(CH)2CCH(CH3)2], 1.26 [d, 
3
J(H-H) = 6.8 Hz, 12H, CH3C(CH)2(CH)2CCH(CH3)2]; 
13
C{
1
H} NMR (CDCl3, 100.62 MHz, 295.2 K) 
 104.3 [CH3C(CH)2(CH)2CCH(CH3)2], 97.6 [CH3C(CH)2(CH)2CCH(CH3)2], 82.5 
[CH3C(CH)2(CH)2CCH(CH3)2], 82.1 [CH3C(CH)2(CH)2CCH(CH3)2], 31.5 
[CH3C(CH)2(CH)2CCH(CH3)2], 22.8 [CH3C(CH)2(CH)2CCH(CH3)2], 20.3 
[CH3C(CH)2(CH)2CCH(CH3)2]. 
ES MS (+): m/z 852.7 [MH – I]+. 
7.5 η6-p-Cymene Ruthenium Monomers 
Compounds 3.3 to 3.13 were synthesised in dichloromethane at room 
temperature from complexes 3.1 or 3.2 and the correspondent pyridine or amine. 
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Compounds 3.3, 3.4, 3.6 and 3.12 had been previously synthesised in high 
temperatures or ultrasound conditions.
10-12
  
 Compound 3.14 was synthesised by variation of some experiments already 
performed within the McGowan group which, in turn, were adapted from published 
work.
13
 
7.5.1 Preparation of [RuCl2(C10H14)(NH2C(CH3)3)] (3.3) 
Complex 3.1 (0.15 g, 0.25 mmol) was dissolved in dichloromethane (10 ml), 
and tert-butylamine (0.1 ml, 1 mmol) was added. The mixture was stirred overnight 
to give an orange solution and the solvent was evaporated to give an orange solid. 
Yield: 0.14 g, 0.37 mmol (74%).  
Characterisation: 
Calculated for C14H25Cl2NRu (379.27 g mol
-1
): C 44.3; H 6.6; N 3.7; Cl 18.7% 
Found: C 44.4; H 6.7; N 3.6; Cl 18.9% 
1
H NMR (CDCl3, 500.23 MHz, 300.0 K) 
δ 5.51 [d, 3J(H-H) = 6.0 Hz, 2H, CH3C(CH)2(CH)2CCH(CH3)2], 5.46 [d, 
3
J(H-H) = 5.6 
Hz, 2H, CH3C(CH)2(CH)2CCH(CH3)2], 3.07 [sep, 
3
J(H-H) = 6.8 Hz, 1H, 
CH3C(CH)2(CH)2CCH(CH3)2], 2.28 [s, 3H, CH3C(CH)2(CH)2CCH(CH3)2], 1.35 [s, 
9H, NH2C(CH3)3], 1.30 [d, 
3
J(H-H) = 6.8 Hz, 6H, CH3C(CH)2(CH)2CCH(CH3)2]; 
13
C{
1
H} NMR (CDCl3, 75.47 MHz, 300.1 K) 
 103.4 [CH3C(CH)2(CH)2CCH(CH3)2], 95.0 [CH3C(CH)2(CH)2CCH(CH3)2], 81.6 
[CH3C(CH)2(CH)2CCH(CH3)2], 79.1 [CH3C(CH)2(CH)2CCH(CH3)2], 53.2 
[NH2C(CH3)3], 31.1 [NH2C(CH3)3], 30.7 [CH3C(CH)2(CH)2CCH(CH3)2], 22.1 
[CH3C(CH)2(CH)2CCH(CH3)2], 18.6 [CH3C(CH)2(CH)2CCH(CH3)2]. 
ES MS (+): m/z 344.1 [M – Cl]+. 
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7.5.2 Preparation of [RuCl2(C10H14)(NC5H5)] (3.4) 
Complex 3.1 (0.6 g, 1 mmol) was dissolved in dichloromethane (30 ml), and 
pyridine (0.32 ml, 4 mmol) was added. The mixture was stirred overnight to give an 
orange solution and the solvent was evaporated to give an orange solid. 
Yield: 0.689 g, 1.79 mmol (89%). 
Characterisation: 
Calculated for C15H19Cl2NRu (385.22 g mol
-1
): C 46.7; H 5.0; N 3.6; Cl 18.4% 
Found: C 46.6; H 5.0; N 3.5; Cl 18.8% 
1
H NMR (CDCl3, 500.23 MHz, 300.0 K) 
δ 9.06 [d, 3J(H-H) = 5.1 Hz, 2H, 2,6-CH of NC5H5], 7.75 [t, 
3
J(H-H) = 7.7 Hz, 1H, 4-CH 
of NC5H5], 7.32 [t, 
3
J(H-H) =  6.8 Hz, 2H, 3,5-CH of NC5H5], 5.45 [d, 
3
J(H-H) = 6.0 Hz, 
2H, CH3C(CH)2(CH)2CCH(CH3)2], 5.23 [d, 
3
J(H-H) = 5.1 Hz, 2H, 
CH3C(CH)2(CH)2CCH(CH3)2], 3.01 [m, 1H, CH3C(CH)2(CH)2CCH(CH3)2], 2.11 [s, 
3H, CH3C(CH)2(CH)2CCH(CH3)2], 1.32 [d, 
3
J(H-H) = 6.8 Hz, 6H, 
CH3C(CH)2(CH)2CCH(CH3)2]; 
13
C{
1
H} NMR (CDCl3, 75.47 MHz, 300.1 K) 
 154.9 [2,6-CH of NC5H5], 137.6 [4-CH of NC5H5], 124.6 [3,5-CH of NC5H5], 
103.6 [CH3C(CH)2(CH)2CCH(CH3)2], 97.1 [CH3C(CH)2(CH)2CCH(CH3)2], 82.8 
[CH3C(CH)2(CH)2CCH(CH3)2], 82.3 [CH3C(CH)2(CH)2CCH(CH3)2], 30.7 
[CH3C(CH)2(CH)2CCH(CH3)2], 22.3 [CH3C(CH)2(CH)2CCH(CH3)2], 18.2 
[CH3C(CH)2(CH)2CCH(CH3)2]. 
ES MS (+): m/z 350.0 [M – Cl]+. 
7.5.3 Preparation of [RuI2(C10H14)(NC5H5)] (3.5) 
Complex 3.2 (0.15 g, 0.15 mmol) was dissolved in dichloromethane (10 ml), 
and pyridine (49 μl, 0.6 mmol) was added. The mixture was stirred overnight to give 
a dark red solution and the solvent was evaporated to give a brown solid. 
Yield: 0.15 g, 0.26 mmol (88%). 
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Characterisation: 
Calculated for C15H19I2NRu (568.02 g mol
-1
): C 31.7; H 3.4; N 2.5; I 44.7% 
Found: C 32.1; H 3.5; N 2.5; I 44.6% 
1
H NMR (CDCl3, 300.13 MHz, 299.9 K) 
δ 9.48 [m, 2H, 2,6-CH of NC5H5], 7.72 [t, 
3
J(H-H) = 6.8 Hz, 1H, 4-CH of NC5H5], 
7.20 [t, 
3
J(H-H) = 5.6 Hz, 2H, 3,5-CH of NC5H5], 5.69 [d, 
3
J(H-H) = 4.8 Hz, 2H,  
CH3C(CH)2(CH)2CCH(CH3)2], 5.32 [d, 
3
J(H-H) = 4.8 Hz, 2H, 
CH3C(CH)2(CH)2CCH(CH3)2], 3.05 [m, 1H, CH3C(CH)2(CH)2CCH(CH3)2], 1.89 
[br. s, 3H, CH3C(CH)2(CH)2CCH(CH3)2], 1.26 [d, 
3
J(H-H) = 6.8 Hz, 6H, 
CH3C(CH)2(CH)2CCH(CH3)2]; 
13
C{
1
H} NMR (CDCl3, 75.47 MHz, 299.9 K) 
 160.0 [2,6-CH of NC5H5], 137.4 [4-CH of NC5H5], 124.4 [3,5-CH of NC5H5], 
103.3 [CH3C(CH)2(CH)2CCH(CH3)2], 97.9 [CH3C(CH)2(CH)2CCH(CH3)2], 83.9 
[CH3C(CH)2(CH)2CCH(CH3)2], 83.2 [CH3C(CH)2(CH)2CCH(CH3)2], 31.8 
[CH3C(CH)2(CH)2CCH(CH3)2], 22.9 [CH3C(CH)2(CH)2CCH(CH3)2], 18.8 
[CH3C(CH)2(CH)2CCH(CH3)2]. 
ES MS (+): m/z 442.0 [MH – I]+. 
7.5.4 Preparation of [RuCl2(C10H14)(2- NH2NC5H4)] (3.6) 
Complex 3.1 (0.15 g, 0.25 mmol) was dissolved in dichloromethane (10 ml), 
and 2-aminopyridine (47 mg, 0.5 mmol) was added. The mixture was stirred 
overnight to give a red/orange solution and the solvent was evaporated to give a 
brown/orange solid. 
Yield: 0.169 g, 0.42 mmol (85%). 
Characterisation: 
Calculated for C15H20Cl2N2Ru (400.23 g mol
-1
): C 45.0; H 5.0; N 7.0% 
Found: C 44.7; H 5.0; N 6.7% 
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1
H NMR (CDCl3, 500.23 MHz, 300.0 K) 
δ 8.60 [d, 3J(H-H) = 6.0 Hz, 1H, 6-CH of 2-NH2NC5H4], 7.36 [br. t, 
3
J(H-H) = 7.3 Hz, 
1H, 4-CH of 2-NH2NC5H4], 6.59 [m, 1H, 5-CH of 2-NH2NC5H4], 6.53 [d, 
3
J(H-H) = 
7.7 Hz, 1H, 3-CH of 2-NH2NC5H4], 5.54 [d, 
3
J(H-H) = 5.1 Hz, 2H, 
CH3C(CH)2(CH)2CCH(CH3)2], 5.33 [d, 2H, 
3
J(H-H) = 5.1 Hz, 
CH3C(CH)2(CH)2CCH(CH3)2], 2.97 [m, 1H, CH3C(CH)2(CH)2CCH(CH3)2], 2.03 [s, 
3H, CH3C(CH)2(CH)2CCH(CH3)2], 1.30 [d, 
3
J(H-H) = 6.8 Hz, 6H, 
CH3C(CH)2(CH)2CCH(CH3)2]; 
13
C{
1
H} NMR (CDCl3, 125.77 MHz, 299.2 K) 
 162.6 [Quaternary C of 2-NH2NC5H4], 138.8 [6-CH of 2-NH2NC5H4], 129.0 [4-
CH of 2-NH2NC5H4], 126.3 [5-CH of 2-NH2NC5H4], 114.5 [3-CH of 2-NH2NC5H4], 
103.2 [CH3C(CH)2(CH)2CCH(CH3)2], 96.8 [CH3C(CH)2(CH)2CCH(CH3)2], 81.3 
[CH3C(CH)2(CH)2CCH(CH3)2], 80.6 [CH3C(CH)2(CH)2CCH(CH3)2], 33.7 
[CH3C(CH)2(CH)2CCH(CH3)2], 22.3 [CH3C(CH)2(CH)2CCH(CH3)2], 18.3 
[CH3C(CH)2(CH)2CCH(CH3)2 ]. 
ES MS (+): m/z 365.0 [M – Cl]+. 
7.5.5 Preparation of [RuCl2(C10H14)(3-OHNC5H4)] (3.7) 
Complex 3.1 (0.15 g, 0.25 mmol) was dissolved in dichloromethane (10 ml), 
and 3-hydroxypyridine (47.6 mg, 0.5 mmol) was added. The mixture was stirred 
overnight and changed from a dark orange solution to an orange suspension that was 
filtered and washed with cold hexane to give a yellow solid. 
Yield: 0.149 g, 0.37 mmol (74%). 
Characterisation: 
Calculated for C15H19Cl2NORu (401.22 g mol
-1
): C 44.9; H 4.8; N 3.5; Cl 17.7% 
Found: C 44.7; H 4.8; N 3.4; Cl 17.8% 
1
H NMR (CDCl3, 500.23 MHz, 300.0 K) 
δ 8.63 [m, 1H, 2-CH of 3-OHNC5H4], 8.34 [d, 
3
J(H-H) = 5.1 Hz, 1H, 6-CH of 3-
OHNC5H4], 7.02 [dd, 
3
J(H-H) = 8.3, 1.5 Hz, 1H, 4-CH of 3-OHNC5H4], 6.89 [dd, 
3
J(H-
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H) = 8.1, 5.6 Hz, 1H, 5-CH of 3-OHNC5H4], 5.47 [d, 
3
J(H-H) = 5.1 Hz, 2H, 
CH3C(CH)2(CH)2CCH(CH3)2], 5.23 [d, 
3
J(H-H) = 6.0 Hz, 2H, 
CH3C(CH)2(CH)2CCH(CH3)2], 2.98 [m, 1H, CH3C(CH)2(CH)2CCH(CH3)2], 2.04 [s, 
3H, CH3C(CH)2(CH)2CCH(CH3)2], 1.31 [d, 
3
J(H-H) = 6.8 Hz, 6H, 
CH3C(CH)2(CH)2CCH(CH3)2]; 
13
C{
1
H} NMR (CDCl3, 125.77 MHz, 299.2 K) 
 153.3 [Quaternary C of 3-OHNC5H4], 146.1 [6-CH of 3-OHNC5H4], 144.2 [2-CH 
of 3-OHNC5H4], 126.3 [4-CH of 3-OHNC5H4], 124.6 [5-CH of 3-OHNC5H4], 103.5 
[CH3C(CH)2(CH)2CCH(CH3)2], 97.4 [CH3C(CH)2(CH)2CCH(CH3)2], 83.1 
[CH3C(CH)2(CH)2CCH(CH3)2], 82.1 [CH3C(CH)2(CH)2CCH(CH3)2], 30.7 
[CH3C(CH)2(CH)2CCH(CH3)2], 22.3 [CH3C(CH)2(CH)2CCH(CH3)2], 18.2 
[CH3C(CH)2(CH)2CCH(CH3)2]. 
ES MS (+): m/z 366.0 [M – Cl]+. 
7.5.6 Preparation of [RuCl2(C10H14)(3-FNC5H4)] (3.8) 
Complex 3.1 (0.15 g, 0.25 mmol) was dissolved in dichloromethane (10 ml), 
and 3-fluoropyridine (86 μl, 1 mmol) was added. The mixture was stirred overnight 
to give an orange solution and the solvent was evaporated to give an orange solid. 
Yield: 0.195 g, 0.48 mmol (97%).  
Characterisation: 
Calculated for C15H18Cl2FNRu (403.21 g mol
-1
): C 44.6; H 4.5; N 3.5; Cl 17.6% 
Found: C 44.9; H 4.5; N 3.6; Cl 18.0% 
1
H NMR (CDCl3, 500.23 MHz, 300.0 K) 
δ 8.99 [br. s, 1H, 2-CH of 3-FNC5H4], 8.90 [d, 
3
J(H-H) = 4.8 Hz, 1H, 6-CH of 3-
FNC5H4], 7.50 [m, 1H, 4-CH of 3-FNC5H4], 7.33 [m, 1H, 5-CH of 3-FNC5H4], 5.46 
[d, 
3
J(H-H) = 5.2 Hz, 2H, CH3C(CH)2(CH)2CCH(CH3)2], 5.25 [d, 
3
J(H-H) = 5.2 Hz, 2H, 
CH3C(CH)2(CH)2CCH(CH3)2], 2.98 [m, 1H, CH3C(CH)2(CH)2CCH(CH3)2], 2.10 [s, 
3H, CH3C(CH)2(CH)2CCH(CH3)2], 1.31 [d, 
3
J(H-H) = 6.8 Hz, 6H, 
CH3C(CH)2(CH)2CCH(CH3)2]; 
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13
C{
1
H} NMR (CDCl3, 75.47 MHz, 300.1 K) 
 158.7 [d, 1J(C-F) = 254.3 Hz, Quaternary C of 3-FNC5H4], 151.3 [d, 
4
J(C-F) = 3.8 Hz, 
6-CH of 3-FNC5H4], 143.9 [d, 
2
J(C-F) = 31.7 Hz, 2-CH of 3-FNC5H4], 124.9 [m, 4- 
and 5-CH of 3-FNC5H4], 103.7 [s, CH3C(CH)2(CH)2CCH(CH3)2], 97.3 [s, 
CH3C(CH)2(CH)2CCH(CH3)2], 82.8 [s, CH3C(CH)2(CH)2CCH(CH3)2], 82.3 [s, 
CH3C(CH)2(CH)2CCH(CH3)2], 30.7 [s, CH3C(CH)2(CH)2CCH(CH3)2], 22.3 [s, 
CH3C(CH)2(CH)2CCH(CH3)2], 18.2 [s, CH3C(CH)2(CH)2CCH(CH3)2]. 
ES MS (+): m/z 368.0 [M – Cl]+. 
7.5.7 Preparation of [RuCl2(C10H14)(3-ClNC5H4)] (3.9) 
Complex 3.1 (0.15 g, 0.25 mmol) was dissolved in dichloromethane (10 ml), 
and 3-chloropyridine (95 μl, 1 mmol) was added. The mixture was stirred overnight 
to give an orange solution and the solvent was evaporated to give an orange solid. 
Yield: 0.201 g, 0.48 mmol (96%).  
Characterisation: 
Calculated for C15H18Cl3NRu (419.71 g mol
-1
): C 42.9; H 4.3; N 3.3; Cl 25.4% 
Found: C 42.8; H 4.3; N 3.2; Cl 25.3% 
1
H NMR (CDCl3, 500.23 MHz, 300.0 K) 
δ 9.05 [m, 1H, 2-CH of 3-ClNC5H4], 8.98 [d, 
3
J(H-H) = 5.1 Hz, 1H, 6-CH of 3-
ClNC5H4], 7.74 [d, 
3
J(H-H) = 7.7 Hz, 1H, 4-CH of 3-ClNC5H4], 7.29 [m, 1H, 5-CH of 
3-ClNC5H4], 5.47 [d, 
3
J(H-H) = 6.0 Hz, 2H, CH3C(CH)2(CH)2CCH(CH3)2], 5.25 [d, 
3
J(H-H) = 5.1 Hz, 2H, CH3C(CH)2(CH)2CCH(CH3)2], 2.98 [sep, 
3
J(H-H) = 6.8 Hz, 1H, 
CH3C(CH)2(CH)2CCH(CH3)2], 2.11 [s, 3H, CH3C(CH)2(CH)2CCH(CH3)2], 1.32 [d, 
3
J(H-H) = 6.8 Hz, 6H, CH3C(CH)2(CH)2CCH(CH3)2]; 
13
C{
1
H} NMR (CDCl3, 75.47 MHz, 300.0 K) 
 153.7 [2-CH of 3-ClNC5H4], 153.0 [6-CH of 3-ClNC5H4], 137.7 [4-CH of 3-
ClNC5H4], 132.5 [Quaternary C of 3-ClNC5H4], 124.7 [5-CH of 3-ClNC5H4], 103.7 
[CH3C(CH)2(CH)2CCH(CH3)2], 97.3 [CH3C(CH)2(CH)2CCH(CH3)2], 82.9 
[CH3C(CH)2(CH)2CCH(CH3)2], 82.2 [CH3C(CH)2(CH)2CCH(CH3)2], 30.7 
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[CH3C(CH)2(CH)2CCH(CH3)2], 22.3 [CH3C(CH)2(CH)2CCH(CH3)2], 18.3 
[CH3C(CH)2(CH)2CCH(CH3)2]. 
ES MS (+): m/z 384.0 [M – Cl]+. 
7.5.8 Preparation of [RuCl2(C10H14)(3-BrNC5H4)] (3.10) 
Complex 3.1 (0.15 g, 0.25 mmol) was dissolved in dichloromethane (10 ml), 
and 3-bromopyridine (96.3 μl, 1 mmol) was added. The mixture was stirred 
overnight to give an orange solution and the solvent was evaporated to give an 
orange solid. 
Yield: 0.209 g, 0.45 mmol (90%). 
Characterisation: 
Calculated for C15H18BrCl2NRu (464.12 g mol
-1
): C 38.8; H 3.9; N 3.0% 
Found: C 38.8; H 3.9; N 2.9% 
1
H NMR (CDCl3, 500.23 MHz, 300.0 K) 
δ 9.15 [m, 1H, 2-CH of 3-BrNC5H4], 9.02 [d, 
3
J(H-H) = 5.6 Hz, 1H, 6-CH of 3-
BrNC5H4], 7.89 [d, 
3
J(H-H) = 7.9 Hz, 1H, 4-CH of 3-BrNC5H4], 7.23 [dd, 
3
J(H-H) = 7.7, 
5.8 Hz, 1H, 5-CH of 3-BrNC5H4], 5.47 [d, 
3
J(H-H) = 6.0 Hz, 2H, 
CH3C(CH)2(CH)2CCH(CH3)2], 5.25 [d, 
3
J(H-H) = 6.0 Hz, 2H, 
CH3C(CH)2(CH)2CCH(CH3)2], 2.98 [sep, 
3
J(H-H) = 6.9 Hz, 1H, 
CH3C(CH)2(CH)2CCH(CH3)2], 2.12 [s, 3H, CH3C(CH)2(CH)2CCH(CH3)2], 1.32 [d, 
3
J(H-H) = 6.8 Hz, 6H, CH3C(CH)2(CH)2CCH(CH3)2]; 
13
C{
1
H} NMR (CDCl3, 75.47 MHz, 300.0 K) 
 155.7 [2-CH of 3-BrNC5H4], 153.4 [6-CH of 3-BrNC5H4], 140.5 [4-CH of 3-
BrNC5H4], 125.1 [5-CH of 3-BrNC5H4], 120.4 [Quaternary C of 3-BrNC5H4], 103.7 
[CH3C(CH)2(CH)2CCH(CH3)2], 97.4 [CH3C(CH)2(CH)2CCH(CH3)2], 82.9 
[CH3C(CH)2(CH)2CCH(CH3)2], 82.2 [CH3C(CH)2(CH)2CCH(CH3)2], 30.7 
[CH3C(CH)2(CH)2CCH(CH3)2], 22.3 [CH3C(CH)2(CH)2CCH(CH3)2], 18.3 
[CH3C(CH)2(CH)2CCH(CH3)2]. 
ES MS (+): m/z 429.9 [M – Cl]+. 
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7.5.9 Preparation of [RuCl2(C10H14)(3-INC5H4)] (3.11) 
Complex 3.1 (0.15 g, 0.25 mmol) was dissolved in dichloromethane (10 ml), 
and 3-iodopyridine (0.2 g, 1 mmol) was added. The mixture was stirred overnight to 
give an orange solution that formed a suspension after less than 5 minutes. This 
suspension was filtered and washed with cold hexane to give a yellow solid. 
Yield: 0.19 g, 0.37 mmol (74%).  
Characterisation: 
Calculated for C15H18Cl2INRu (511.11 g mol
-1
): C 35.2; H 3.6; N 2.7% 
Found: C 35.5; H 3.5; N 2.7% 
1
H NMR (CDCl3, 500.23 MHz, 300.0 K) 
δ 9.29 [m, 1H, 2-CH of 3-INC5H4], 9.06 [d, 
3
J(H-H) = 5.2 Hz, 1H, 6-CH of 3-INC5H4], 
8.07 [d, 
3
J(H-H) = 7.9 Hz, 1H, 4-CH of 3-INC5H4], 7.10 [dd, 
3
J(H-H) = 7.9, 5.6 Hz, 1H, 
5-CH of 3-INC5H4], 5.46 [d, 
3
J(H-H) = 6.0 Hz, 2H, CH3C(CH)2(CH)2CCH(CH3)2], 
5.24 [d, 
3
J(H-H) = 5.6 Hz, 2H, CH3C(CH)2(CH)2CCH(CH3)2], 2.98 [m, 1H, 
CH3C(CH)2(CH)2CCH(CH3)2], 2.12 [s, 3H, CH3C(CH)2(CH)2CCH(CH3)2], 1.33 [d, 
3
J(H-H) = 6.8 Hz, 6H, CH3C(CH)2(CH)2CCH(CH3)2]; 
13
C{
1
H} NMR (CDCl3, 75.47 MHz, 300.1 K) 
 160.3 [2-CH of 3-INC5H4], 153.7 [6-CH of 3-INC5H4], 146.0 [4-CH of 3-INC5H4], 
125.4 [5-CH of 3-INC5H4], 103.6 [CH3C(CH)2(CH)2CCH(CH3)2], 97.3 
[CH3C(CH)2(CH)2CCH(CH3)2], 91.8 [Quaternary C of 3-INC5H4], 82.9 
[CH3C(CH)2(CH)2CCH(CH3)2], 82.2 [CH3C(CH)2(CH)2CCH(CH3)2], 30.7 
[CH3C(CH)2(CH)2CCH(CH3)2], 22.3 [CH3C(CH)2(CH)2CCH(CH3)2], 18.3 
[CH3C(CH)2(CH)2CCH(CH3)2]. 
ES MS (+): m/z 475.9 [M – Cl]+. 
7.5.10 Preparation of [RuCl2(C10H14)(4-N(CH3)2NC5H4)] (3.12) 
Complex 3.1 (0.15 g, 0.25 mmol) was dissolved in dichloromethane (10 ml), 
and 4-(dimethylamino)pyridine (61.1 mg, 0.5 mmol) was added. The mixture was 
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stirred for two days to give an orange solution and the solvent was evaporated to 
give an orange solid. 
Yield: 0.15 g, 0.35 mmol (70%). 
Characterisation: 
Calculated for C17H24Cl2N2Ru (428.26 g mol
-1
): C 47.6; H 5.7; N 6.5; Cl 16.6% 
Found: C 47.2; H 5.6; N 6.4; Cl 17.1% 
1
H NMR (CDCl3, 300.13 MHz, 300.0 K) 
δ 8.42 [dm, 3J(H-H) = 7.2 Hz, 2H, 2,6-CH of 4-N(CH3)2NC5H4], 6.41 [dm, 
3
J(H-H) = 7.2 
Hz, 2H, 3,5-CH of 4-N(CH3)2NC5H4], 5.40 [d, 
3
J(H-H) = 5.7 Hz, 2H, 
CH3C(CH)2(CH)2CCH(CH3)2], 5.17 [d, 
3
J(H-H) = 5.7 Hz, 2H, 
CH3C(CH)2(CH)2CCH(CH3)2], 2.99 [s, 6H, 4-N(CH3)2NC5H4], 2.97 [m, 1H, 
CH3C(CH)2(CH)2CCH(CH3)2], 2.09 [s, 3H, CH3C(CH)2(CH)2CCH(CH3)2], 1.29 [d, 
3
J(H-H) = 7.2 Hz, 6H, CH3C(CH)2(CH)2CCH(CH3)2]; 
13
C{
1
H} NMR (CDCl3, 75.47 MHz, 300.0 K) 
 153.3 [2,6-CH of 4-N(CH3)2NC5H4], 107.4 [3,5-CH of 4-N(CH3)2NC5H4], 102.9 
[CH3C(CH)2(CH)2CCH(CH3)2], 96.8 [CH3C(CH)2(CH)2CCH(CH3)2], 89.8 
[Quaternary C of 4-N(CH3)2NC5H4], 82.8 [CH3C(CH)2(CH)2CCH(CH3)2], 81.8 
[CH3C(CH)2(CH)2CCH(CH3)2], 39.3 [4-N(CH3)2NC5H4], 30.6 
[CH3C(CH)2(CH)2CCH(CH3)2], 22.4 [CH3C(CH)2(CH)2CCH(CH3)2], 18.3 
[CH3C(CH)2(CH)2CCH(CH3)2]. 
ES MS (+): m/z 393.1 [M – Cl]+. 
7.5.11 Preparation of [RuCl2(C10H14)(4-BrNC5H4)] (3.13) 
Complex 3.1 (0.15 g, 0.25 mmol) was dissolved in dichloromethane (10 ml), 
and 4-bromopyridine hydrochloride (97.23 mg, 0.5 mmol) was added. The mixture 
was stirred overnight to give an orange solution with some undissolved powder that 
was filtered, and the filtrate evaporated to give an orange solid. 
Yield: 0.23 g, 0.5 mmol (100%). 
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Characterisation: 
Calculated for C15H18BrCl2NRu (464.11 g mol
-1
): C 38.8; H 3.9; N 3.0% 
Found: C 39.1; H 3.9; N 2.9% 
1
H NMR (CDCl3, 500.23 MHz, 300.0 K) 
δ 8.87 [d, 3J(H-H) = 5.2 Hz, 2H, 2,6-CH of 4-BrNC5H4], 7.49 [d, 
3
J(H-H) = 5.6 Hz, 2H, 
3,5-CH of 4-BrNC5H4], 5.46 [d, 
3
J(H-H) = 4.8 Hz, 2H, CH3C(CH)2(CH)2CCH(CH3)2], 
5.25 [d, 
3
J(H-H) = 4.8 Hz, 2H, CH3C(CH)2(CH)2CCH(CH3)2], 2.99 [m, 1H, 
CH3C(CH)2(CH)2CCH(CH3)2], 2.12 [s, 3H, CH3C(CH)2(CH)2CCH(CH3)2], 1.32 [d, 
3
J(H-H) = 6.8 Hz, 6H, CH3C(CH)2(CH)2CCH(CH3)2]; 
13
C{
1
H} NMR (CDCl3, 75.47 MHz, 300.0 K) 
 155.3 [2,6-CH of 4-BrNC5H4], 135.5 [Quaternary C of 4-BrNC5H4], 128.1 [3,5-CH 
of 4-BrNC5H4], 103.7 [CH3C(CH)2(CH)2CCH(CH3)2], 97.2 
[CH3C(CH)2(CH)2CCH(CH3)2], 82.8 [CH3C(CH)2(CH)2CCH(CH3)2], 82.2 
[CH3C(CH)2(CH)2CCH(CH3)2], 30.7 [CH3C(CH)2(CH)2CCH(CH3)2], 22.3 
[CH3C(CH)2(CH)2CCH(CH3)2], 18.3 [CH3C(CH)2(CH)2CCH(CH3)2]. 
ES MS (+): m/z 429.9 [M – Cl]+. 
7.5.12 Preparation of [RuCl(C10H14)(NC5H5)2][SbF6] (3.14) 
Complex 3.4 (57.8 mg, 0.15 mmol) and pyridine (24.3 µl, 0.3 mmol) were 
dissolved in methanol (5 ml) and NaSbF6 (0.23 g, 0.9 mmol), dissolved in methanol 
(5 ml), was added. The mixture was stirred and heated to reflux. After four hours, the 
solvent was evaporated. Chloroform was added to the solid obtained to separate the 
product from the salts by filtering, and then the filtrate was evaporated and the 
resulting residue dissolved in the minimum quantity of dichloromethane. Hexane 
was added, which gave an orange oil. After approximately one month, crystals 
suitable for X-ray diffraction studies formed. 
Yield: 0.1 g, 0.15 mmol (100%). 
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Characterisation: 
Calculated for [C20H24ClN2Ru][F6Sb] (664.51 g mol
-1
): C 36.1; H 3.6; N 4.2; Cl 
5.3% 
Found: C 36.3; H 3.7; N 4.1; Cl 5.2% 
1
H NMR (CDCl3, 300.13 MHz, 300.0 K) 
δ 9.03 [d, 3J(H-H) = 5.3 Hz, 4H, 2,6-CH of NC5H5], 7.85 [t, 
3
J(H-H) = 7.6 Hz, 2H, 4-CH 
of NC5H5], 7.48 [t, 
3
J(H-H) = 6.9 Hz, 4H, 3,5-CH of NC5H5], 5.91 [d, 
3
J(H-H) = 6.0 Hz, 
2H, CH3C(CH)2(CH)2CCH(CH3)2], 5.63 [d, 
3
J(H-H) = 5.9 Hz, 2H, 
CH3C(CH)2(CH)2CCH(CH3)2], 2.58 [m, 1H, CH3C(CH)2(CH)2CCH(CH3)2], 1.74 [s, 
3H, CH3C(CH)2(CH)2CCH(CH3)2], 1.16 [d, 
3
J(H-H) = 6.8 Hz, 6H, 
CH3C(CH)2(CH)2CCH(CH3)2]; 
13
C{
1
H} NMR (CDCl3,  75.47 MHz,  300.1 K) 
δ 153.1 [2,6-CH of NC5H5], 138.1 [4-CH of NC5H5], 125.3 [3,5-CH of NC5H5], 
101.8 [CH3C(CH)2(CH)2CCH(CH3)2], 101.0 [CH3C(CH)2(CH)2CCH(CH3)2], 87.7 
[CH3C(CH)2(CH)2CCH(CH3)2], 81.0 [CH3C(CH)2(CH)2CCH(CH3)2], 29.8 
[CH3C(CH)2(CH)2CCH(CH3)2], 21.2 [CH3C(CH)2(CH)2CCH(CH3)2], 16.7 
[CH3C(CH)2(CH)2CCH(CH3)2]. 
ES MS (+): m/z 429.07 [M – SbF6]
+
. 
7.6 Pentamethylcyclopentadiene and (5-Hydroxypentyl)-
Tetramethylcyclopentadiene Ligands 
Compound 4.1 was synthesised according to the method by Bergman et al.
14
 
Compound 4.2 had been synthesised previously by Blacker and co-workers with a 
similar procedure to that of ligand 4.1, but changing ethyl acetate to caprolactone to 
obtain the long –OH tether.15 Their synthetic method was the one employed here. 
7.6.1 Preparation of C10H16 (4.1) 
2-Bromo-2-butene (60.2 ml, 0.59 mol) was added dropwise from an addition 
funnel to lithium wire (7.92 g, 1.14 mol) in dry diethyl ether under a nitrogen 
atmosphere. The reaction started to reflux and was stirred for three hours. Ethyl 
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acetate (26.3 ml, 0.27 mol) diluted in diethyl ether was added through the addition 
funnel and stirred for one hour. The mixture was poured into 600 ml of saturated 
aqueous NH4Cl. The layers were separated, and the aqueous layer extracted with 
diethyl ether (×3). The ether layers were combined, washed with water, dried over 
MgSO4, filtered and concentrated to approx. 200 ml. This concentrate was added to 
p-toluensulphonic acid (4.91 g, 0.026 mol) in dry diethyl ether (300 ml) under 
nitrogen, maintaining a gentle reflux. The mixture was stirred for one hour and then 
saturated aqueous NaHCO3 was added. The ether layer was separated and the 
aqueous layer extracted with diethyl ether (×3). The combined ether layers were 
washed with water, dried over Na2SO4, filtered and evaporated. The yellow oil 
obtained was purified by distillation (34°C) under reduced pressure and stored in the 
freezer. 
Yield: 21.44 g, 0.157 mol (58%). 
Characterisation: 
1
H NMR (CDCl3, 300.13 MHz, 300.0 K) 
δ 2.52 [q, 3J(H-H) = 7.6 Hz, 1H, (CCH3)4CHCH3], 1.84 [s, 6H, (CCH3)4CHCH3], 1.80 
[s, 6H, (CCH3)4CHCH3], 1.04 [d, 
3
J(H-H) = 7.7 Hz, 3H, (CCH3)4CHCH3]. 
ES MS (+): m/z 136.13 [M]
+
. 
7.6.2 Preparation of C14H24O (4.2) 
2-Bromo-2-butene (12.2 ml, 0.12 mol) was added dropwise from an addition 
funnel to lithium wire (1.6 g, 0.23 mol) in dry diethyl ether under a nitrogen 
atmosphere. The reaction started to reflux and was stirred for two hours. ε-
Caprolactone (5.98 ml, 0.054 mol) was added from the dropping funnel and the 
reaction was stirred for one hour. The mixture was poured into a saturated aqueous 
solution of NH4Cl. The ether layer was separated and the aqueous layer was 
extracted with tert-butyl-methyl ether (×3). The ether layers were combined, washed 
with brine, dried over MgSO4 and concentrated to approx. 100 ml. A 10% solution 
of HCl (150 ml) was added to the concentrate and stirred for three hours. Two 
orange/dark yellow layers formed and the aqueous one was extracted with tert-butyl-
methyl ether (×3) after separating the organic layer. The combined ether layers were 
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washed with water (×2), dried over Na2SO4, filtered and the solvent evaporated to 
give a dark orange oil, which was purified by column chromatography with silica 
and a solvent mixture of hexane : ethyl acetate (10 : 1). The resulting yellow oil was 
kept in the freezer. 
Yield: 6.2 g, 0.0299 mol (55%). 
Characterisation: 
1
H NMR (CDCl3, 500.23 MHz, 303.4 K) 
δ 3.64 [t, 3J(H-H) = 6.4 Hz, 2H, (CCH3)3(CHCH3)C(CH2)5OH], 2.21 [m, 2H, 
(CCH3)3(CHCH3)C(CH2)5OH], 1.82 [br. s, 3H, (CCH3)3(CHCH3)C(CH2)5OH], 1.78 
[br. s, 6H, (CCH3)3(CHCH3)C(CH2)5OH], 1.59 [m, 2H, 
(CCH3)3(CHCH3)C(CH2)5OH], 1.44 [br. s, 1H, (CCH3)3(CHCH3)C(CH2)5OH], 1.39 
[m, 2H, (CCH3)3(CHCH3)C(CH2)5OH], 1.28 [m, 2H, (CCH3)3(CHCH3)C(CH2)5OH], 
1.01 [dd, 
3
J(H-H) = 7.8, 4.6 Hz, 3H, (CCH3)3(CHCH3)C(CH2)5OH]. 
7.7 Cp* and Cp# Ruthenium(III) Oligomers 
Compound 4.3 was synthesised with a combination of the methods published 
by Suzuki
16
 and Bercaw.
17
 This procedure was also adapted for the preparation of the 
novel compound 4.4. 
7.7.1 Preparation of [RuCl2(C10H15)]n (4.3) 
Cyclopentadiene (4.1) (2 g, 15.1 mmol) was added to a solution of RuCl3 ∙ 
3H2O (1.73 g, 6.62 mmol) in dry ethanol (50 ml). The mixture was stirred and heated 
to reflux under nitrogen for three hours. After that, it was concentrated and left in the 
freezer overnight, and the red/brown solid obtained was filtered and washed with dry 
hexane (×3). Once this was dried under vacuum, it was kept in the glove box. 
Yield: 1.5 g, 4.90 mmol (74%). 
Characterisation: 
Calculated for [C10H15Cl2Ru]n (307.19 g mol
-1
): C 39.1; H 4.9; Cl 23.1% 
Found: C 38.9; H 4.9; Cl 23.3% 
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1
H NMR (CDCl3, 300.13 MHz, 300.1 K)  
δ 4.67 [br. s, 15H, C5(CH3)5]; 
13
C{
1
H} NMR (CDCl3,  75.48 MHz,  300.0 K)  
δ 138.1 [C5(CH3)5], 12.0 [C5(CH3)5]. 
7.7.2 Preparation of [RuCl2(C14H23)]n (4.4) 
(5-Hydroxypentyl)-tetramethylcyclopentadiene (4.2) (3.14 g, 15.1 mmol) was 
added to a solution of RuCl3 ∙ 3H2O (1.73 g, 6.62 mmol) in dry ethanol (50 ml) and 
the mixture was stirred and heated to reflux under nitrogen for three hours. After 
that, it was concentrated and left in the freezer overnight, which resulted in 
precipitation of an orange solid. This was filtered, washed with dry hexane (×3), 
dried under vacuum and kept in the glove box. 
Yield: 1.214 g, 3.20 mmol (48%). 
Characterisation: 
Calculated for [C14H23Cl2Ru]n (379.25 g mol
-1
): C 44.3; H 6.1; Cl 18.7% 
Found: C 44.7; H 6.3; Cl 18.3% 
1
H NMR (CDCl3, 500.57 MHz, 300.0 K) 
δ 5.11 [br. s, 6H, C5(CH3)4(CH2)5OH], 4.15 [br. s, 6H, C5(CH3)4(CH2)5OH], 4.09 [m, 
4H, C5(CH3)4(CH2)5OH], 3.35 [br. s, 2H, C5(CH3)4(CH2)5OH], 2.73 [br. s, 2H, 
C5(CH3)4(CH2)5OH], 2.29 [m, 2H, C5(CH3)4(CH2)5OH]; 
13
C{
1
H} NMR (CDCl3,  125.77 MHz,  299.2 K) 
δ 142.3 [C5(CH3)4(CH2)5OH], 135.3 [C5(CH3)4(CH2)5OH], 128.2 
[C5(CH3)4(CH2)5OH], 63.3 [C5(CH3)4(CH2)5OH], 33.7 [C5(CH3)4(CH2)5OH], 27.2 
[C5(CH3)4(CH2)5OH], 24.6 [C5(CH3)4(CH2)5OH], 12.5 [C5(CH3)4(CH2)5OH], 11.8 
[C5(CH3)4(CH2)5OH]. 
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7.8 Cp* and Cp# Diphosphine Ruthenium(II) Monomers 
The compounds 4.5 to 4.11 were synthesised using the same general method 
adapted from those of Suzuki
16
 and Bercaw.
17
 Complexes 4.3 or 4.4 were used as 
starting materials, and the diphosphines were all commercially available. The solvent 
used was dichloromethane, and the reactions proceeded at room temperature. 
Compound 4.12 was synthesised from complex 4.5 by adapting the method 
published by Moret et al.
18
 
7.8.1 Preparation of [RuCl(C10H15)(C25H22P2)] (4.5) 
1,1'-Bis(diphenylphosphino)methane (0.46 g, 1.2 mmol) was added to a 
solution of compound 4.3 (0.25 g, 0.8 mmol) in dry dichloromethane (100 ml) and 
the mixture was stirred under nitrogen overnight. The solvent was evaporated to give 
a dark yellow/brown residue, which was extracted with diethyl ether (×3). The 
solvent was evaporated from the extract and the orange residue was recrystallised 
from dichloromethane/hexane to give orange needles. 
Yield: 0.3724 g, 0.568 mmol (71%). 
Characterisation: 
Calculated for C35H37ClP2Ru (655.80 g mol
-1
): C 64.0; H 5.7; Cl 5.4% 
Found: C 63.9; H 5.7; Cl 5.6% 
1
H NMR (C6D5CD3, 300.13 MHz, 299.9 K) 
δ 7.61-6.71 [20H, (C6H5)4P2CH2], 4.45 [dt, 
2
J(H-H) = 14.2 Hz, 
2
J(H-P) = 9.4 Hz, 1H, 
(C6H5)4P2CH2], 4.21 [dt, 
2
J(H-H) = 14.2 Hz, 
2
J(H-P) = 11.2 Hz, 1H, (C6H5)4P2CH2], 1.74 
[t, 
4
J(H-P) = 2.0 Hz, 15H, C5(CH3)5]; 
31
P{
1
H} NMR (C6D5CD3, 121.49 MHz, 300.0 K) δ 12.81 [s]; 
13
C{
1
H} NMR (C6D5CD3, 75.48 MHz,  300.0 K) 
δ 137.5 [s, (C6H5)4P2CH2], 133.6 [m, (C6H5)4P2CH2], 132.9 [m, (C6H5)4P2CH2], 88.5 
[t, 
2
J(C-P) = 2.5 Hz, C5(CH3)5], 49.1 [m, (C6H5)4P2CH2], 10.7 [s, C5(CH3)5]. 
ES MS (+): m/z 621.1 [M – Cl]+. 
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7.8.2 Preparation of [RuCl(C10H15)(C34H28FeP2)] (4.6) 
1,1'-Bis(diphenylphosphino)ferrocene (0.42 g, 0.75 mmol) was added to a 
solution of compound 4.3 (0.15 g, 0.5 mmol) in dry dichloromethane (100 ml) and 
the mixture was stirred under nitrogen overnight. The solvent was evaporated to give 
a dark yellow residue, which was washed with diethyl ether (×4) and recrystallised 
from dichloromethane (filtered solution)/hexane to give a yellow microcrystalline 
solid. 
Yield: 0.0856 g, 0.1036 mmol (21%). 
Characterisation: 
Calculated for C44H43ClFeP2Ru (825.77 g mol
-1
) + CH2Cl2 (85.02 g mol
-1
) : C 
59.3; H 5.0; Cl 11.7% 
Found: C 60.1; H 5.1; Cl 11.4% 
1
H NMR (C6D5CD3, 300.13 MHz, 300.1 K) 
δ 8.12-6.70 [20H, (C6H5)4P2Fe(C5H4)2], 5.46 [s, 2H, (C6H5)4P2Fe(C5H4)2], 4.01 [s, 
2H, (C6H5)4P2Fe(C5H4)2], 3.87 [s, 2H, (C6H5)4P2Fe(C5H4)2], 3.63 [s, 2H, 
(C6H5)4P2Fe(C5H4)2], 1.11 [t, 
4
J(H-P) = 1.5 Hz, 15H, C5(CH3)5]; 
31
P{
1
H} NMR (C6D5CD3, 121.49 MHz, 300.0 K) δ 42.37 [s]; 
13
C{
1
H} NMR (C6D5CD3, 125.77 MHz,  299.2 K) 
δ 137.4 [m, (C6H5)4P2Fe(C5H4)2], 136.8 [t, 
2,3
J(C-P) = 4.8 Hz, (C6H5)4P2Fe(C5H4)2], 
134.9 [t, 
2,3
J(C-P) = 4.8 Hz, (C6H5)4P2Fe(C5H4)2], 91.3 [m, (C6H5)4P2Fe(C5H4)2], 89.1 
[s, C5(CH3)5], 77.8 [m, (C6H5)4P2Fe(C5H4)2], 72.8 [s, (C6H5)4P2Fe(C5H4)2], 72.2 [s, 
(C6H5)4P2Fe(C5H4)2], 67.3 [s, (C6H5)4P2Fe(C5H4)2], 9.2 [s, C5(CH3)5]. 
ES MS (+): m/z 791.1 [M – Cl]+. 
7.8.3 Preparation of [RuCl(C10H15)(C36H28OP2)] (4.7) 
Bis(2-diphenylphosphinophenyl)ether (0.4 g, 0.75 mmol) was added to a 
solution of compound 4.3 (0.15 g, 0.5 mmol) in dry dichloromethane (100 ml) and 
the mixture was stirred under nitrogen overnight. The solvent was evaporated to give 
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an orange/brown residue, which was extracted with diethyl ether (×4). The orange 
ether extract was evaporated and the residue was recrystallised from 
dichloromethane/hexane to give an orange solid. 
Yield: 0.1033 g, 0.13 mmol (26%). 
Characterisation: 
Calculated for C46H43ClOP2Ru (809.85 g mol
-1
): C 68.2; H 5.4; Cl 4.4% 
Found: C 67.9; H 5.3; Cl 4.7% 
1
H NMR (C6D5CD3, 300.13 MHz, 300.0 K) 
δ 9.04-5.91 [28H, (C6H5)4P2O(C6H4)2], 1.23 [m, 15H, C5(CH3)5]; 
31
P{
1
H} NMR (C6D5CD3, 202.46 MHz, 299.2 K) δ 22.41 [s]; 
DEPT135 
13
C{
1
H} NMR (C6D5CD3, 125.77 MHz,  299.2 K) 
δ 137.4-118.4 [(C6H5)4P2O(C6H4)2], 8.2 [s, C5(CH3)5]. 
ES MS (+): m/z 775.2 [M – Cl]+. 
7.8.4 Preparation of [RuCl(C10H15)(C39H32OP2)] (4.8) 
4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene (0.43 g, 0.75 mmol) was 
added to a solution of compound 4.3 (0.15 g, 0.5 mmol) in dry dichloromethane (100 
ml) and the mixture was stirred under nitrogen overnight. The solvent was 
evaporated to give a brown residue, which was extracted with diethyl ether (×4). The 
yellow ether extract was evaporated and the residue was recrystallised from 
dichloromethane/hexane to give a yellow solid. 
Yield: 0.2062 g, 0.24 mmol (49%). 
Characterisation: 
Calculated for C49H47ClOP2Ru (849.97 g mol
-1
): C 69.2; H 5.6; Cl 4.2% 
Found: C 70.9; H 5.7; Cl 4.3% 
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1
H NMR (C6D5CD3, 300.13 MHz, 300.0 K) 
δ 8.16-6.49 [26H, (C6H5)4P2OC(CH3)2(C6H3)2], 1.58 [s, 6H, 
(C6H5)4P2OC(CH3)2(C6H3)2], 1.00 [t, 
4
J(H-P) = 1.6 Hz, 15H, C5(CH3)5]; 
31
P{
1
H} NMR (C6D5CD3, 121.49 MHz, 300.0 K) δ 34.02 [s]; 
13
C{
1
H} NMR (C6D5CD3, 125.77 MHz,  299.2 K) 
δ 155.9-123.1 [(C6H5)4P2OC(CH3)2(C6H3)2], 88.2 [s, C5(CH3)5], 36.8 [s, 
(C6H5)4P2OC(CH3)2(C6H3)2], 30.7 [s, (C6H5)4P2OC(CH3)2(C6H3)2], 22.5 [s, 
(C6H5)4P2OC(CH3)2(C6H3)2], 9.1 [s, C5(CH3)5]. 
ES MS (+): m/z 815.2 [M – Cl]+. 
7.8.5 Preparation of [RuCl(C14H23)(C25H22P2)] (4.9) 
1,1'-Bis(diphenylphosphino)methane (0.29 g, 0.75 mmol) was added to a 
solution of compound 4.4 (0.19 g, 0.5 mmol) in dry dichloromethane (100 ml) and 
the mixture was stirred under nitrogen overnight. The solvent was evaporated to give 
a brown residue, which was extracted with diethyl ether (×2). The orange ether 
extract was concentrated and left in the freezer. A precipitate formed, which was 
then filtered. The obtained filtrate was evaporated to give an orange solid, and this 
was recrystallised from dichloromethane/hexane. 
Yield: 0.1184 g, 0.163 mmol (33%). 
Characterisation: 
Calculated for C39H45ClOP2Ru (727.87 g mol
-1
): C 64.3; H 6.2; Cl 4.9% 
Found: C 64.1; H 6.3; Cl 5.1% 
1
H NMR (C6D5CD3, 500.57 MHz, 300.0 K) 
δ 7.64-6.82 [20H, (C6H5)4P2CH2], 4.47 [dt, 
2
J(H-H) = 14.5 Hz, 
2
J(H-P) = 9.4 Hz, 1H, 
(C6H5)4P2CH2], 4.22 [dt, 
2
J(H-H) = 14.2 Hz, 
2
J(H-P) = 11.3 Hz, 1H, (C6H5)4P2CH2], 3.26 
[t, 
3
J(H-H) = 6.2 Hz, 2H, C5(CH3)4(CH2)4CH2OH], 2.23 [m, 2H, 
C5(CH3)4(CH2)4CH2OH], 1.81 [t, 
4
J(H-P) = 1.9 Hz, 6H, C5(CH3)4(CH2)4CH2OH], 1.79 
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[t, 
4
J(H-P) = 2.0 Hz, 6H, C5(CH3)4(CH2)4CH2OH], 1.36 [quint, 
3
J(H-H) = 7.6 Hz, 2H, 
C5(CH3)4(CH2)4CH2OH], 1.25 [m, 4H, C5(CH3)4(CH2)4CH2OH];  
31
P{
1
H} NMR (C6D5CD3, 121.49 MHz, 300.0 K)  δ 12.38 [s]; 
13
C{
1
H} NMR (C6D5CD3, 125.77 MHz,  299.2 K) 
δ 137.5 [s, (C6H5)4P2CH2], 133.7 [t, 
2,3
J(C-P) = 5.4 Hz, (C6H5)4P2CH2], 133.0 [t, 
2,3
J(C-
P) = 5.4 Hz, (C6H5)4P2CH2], 92.6 [m, C5(CH3)4(CH2)4CH2OH], 89.1 [t, 
2
J(C-P) = 2.6 
Hz, C5(CH3)4(CH2)4CH2OH], 87.9 [t, 
2
J(C-P) = 2.6 Hz, C5(CH3)4(CH2)4CH2OH], 62.6 
[s, C5(CH3)4(CH2)4CH2OH], 49.2 [t, 
1
J(C-P) = 19.2 Hz, (C6H5)4P2CH2], 33.1 [s, 
C5(CH3)4(CH2)4CH2OH], 30.8 [s, C5(CH3)4(CH2)4CH2OH], 26.6 [s, 
C5(CH3)4(CH2)4CH2OH], 26.4 [s, C5(CH3)4(CH2)4CH2OH], 10.9 [s, 
C5(CH3)4(CH2)4CH2OH], 10.8 [s, C5(CH3)4(CH2)4CH2OH]. 
ES MS (+): m/z 693.2 [M – Cl]+. 
7.8.6 Preparation of [RuCl(C14H23)(C34H28FeP2)] (4.10) 
1,1'-Bis(diphenylphosphino)ferrocene (0.42 g, 0.75 mmol) was added to a 
solution of compound 4.4 (0.19 g, 0.5 mmol) in dry dichloromethane (100 ml) and 
the mixture was stirred under nitrogen overnight. The solvent was evaporated to give 
an orange/brown residue, which was washed with diethyl ether (×4) and 
recrystallised from dichloromethane/hexane to give a dark yellow solid. 
Yield: 0.3852 g, 0.43 mmol (86%). 
Characterisation: 
Calculated for C48H51ClFeOP2Ru (897.76 g mol
-1
): C 64.2; H 5.7; Cl 4.0% 
Found: C 64.1; H 5.6; Cl 4.4% 
1
H NMR (C6D5CD3, 500.13 MHz, 299.2 K) 
δ 8.17-6.82 [20H, (C6H5)4P2Fe(C5H4)2], 5.48 [s, 2H, (C6H5)4P2Fe(C5H4)2], 4.01 [s, 
2H, (C6H5)4P2Fe(C5H4)2], 3.88 [s, 2H, (C6H5)4P2Fe(C5H4)2], 3.64 [s, 2H, 
(C6H5)4P2Fe(C5H4)2], 3.22 [m, 2H, C5(CH3)4(CH2)4CH2OH], 1.52 [m, 2H, 
C5(CH3)4(CH2)4CH2OH], 1.35 [br. s, 2H, C5(CH3)4(CH2)4CH2OH], 1.31 [m, 2H, 
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C5(CH3)4(CH2)4CH2OH], 1.24 [br. s, 6H, C5(CH3)4(CH2)4CH2OH], 1.20 [br. s, 6H, 
of C5(CH3)4(CH2)4CH2OH], 1.11 [t, 
3
J(H-H) = 7.0 Hz, 2H, C5(CH3)4(CH2)4CH2OH]; 
31
P{
1
H} NMR (C6D5CD3, 121.49 MHz, 300.0 K) δ 40.86 [s]; 
13
C{
1
H} NMR (C6D5CD3, 125.77 MHz,  299.2 K) 
δ 137.5 [s, (C6H5)4P2Fe(C5H4)2], 136.9 [m, (C6H5)4P2Fe(C5H4)2], 134.9 [m, 
(C6H5)4P2Fe(C5H4)2], 77.8 [s, (C6H5)4P2Fe(C5H4)2], 72.8 [s, (C6H5)4P2Fe(C5H4)2], 
72.2 [s, (C6H5)4P2Fe(C5H4)2], 67.3 [s, (C6H5)4P2Fe(C5H4)2], 62.6 [s, 
C5(CH3)4(CH2)4CH2OH], 32.8 [s, C5(CH3)4(CH2)4CH2OH], 29.3 [s, 
C5(CH3)4(CH2)4CH2OH], 26.6 [s, C5(CH3)4(CH2)4CH2OH], 24.3 [s, 
C5(CH3)4(CH2)4CH2OH], 9.4 [s, C5(CH3)4(CH2)4CH2OH], 9.3 [s, 
C5(CH3)4(CH2)4CH2OH].  
ES MS (+): m/z 863.2 [M – Cl]+. 
7.8.7 Preparation of [RuCl(C14H23)(C39H32OP2)] (4.11) 
4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene (0.43 g, 0.75 mmol) was 
added to a solution of compound 4.4 (0.19 g, 0.5 mmol) in dry dichloromethane (100 
ml) and the mixture was stirred under nitrogen overnight. The solvent was 
evaporated to give a brown residue, which was extracted with diethyl ether (×4). The 
yellow ether extract was concentrated and left in the freezer overnight. The 
precipitate formed was filtered, and the orange filtrate evaporated. The residue was 
recrystallised from dichloromethane/hexane to give a yellow solid. 
Yield: 0.0897 g, 0.097 mmol (19%). 
Characterisation: 
Calculated for C53H55ClO2P2Ru (921.94 g mol
-1
): C 69.0; H 6.0; Cl 3.9% 
Found: C 68.3; H 6.1; Cl 4.3% 
1
H NMR (C6D5CD3, 300.13 MHz, 300.0 K) 
δ 8.20-6.49 [26H, (C6H5)4P2OC(CH3)2(C6H3)2], 3.15 [t, 
3
J(H-H) = 6.2 Hz, 2H, 
C5(CH3)4(CH2)4CH2OH], 1.64 [s, 3H, (C6H5)4P2OC(CH3)2(C6H3)2], 1.59 [s, 3H, 
(C6H5)4P2OC(CH3)2(C6H3)2], 1.57 [br. s, 6H, C5(CH3)4(CH2)4CH2OH], 1.29 [m, 2H, 
   Chapter 7 
215 
C5(CH3)4(CH2)4CH2OH], 0.98 [br. s, 6H, C5(CH3)4(CH2)4CH2OH], 0.85 [m, 4H, 
C5(CH3)4(CH2)4CH2OH], 0.45 [m, 2H, C5(CH3)4(CH2)4CH2OH]; 
31
P{
1
H} NMR (C6D5CD3, 202.63 MHz, 300.0 K) δ 33.26 [s]; 
13
C{
1
H} NMR (C6D5CD3, 125.77 MHz,  299.2 K) 
δ 137.5 [(C6H5)4P2OC(CH3)2(C6H3)2], 92.4 [s, C5(CH3)4(CH2)4CH2OH], 62.5 [s, 
C5(CH3)4(CH2)4CH2OH], 36.8 [s, (C6H5)4P2OC(CH3)2(C6H3)2], 32.0 [s, 
C5(CH3)4(CH2)4CH2OH], 30.7 [s, C5(CH3)4(CH2)4CH2OH], 30.3 [s, 
(C6H5)4P2OC(CH3)2(C6H3)2], 26.7 [s, C5(CH3)4(CH2)4CH2OH], 23.6 [s, 
C5(CH3)4(CH2)4CH2OH], 23.1 [s, (C6H5)4P2OC(CH3)2(C6H3)2], 9.6 [s, 
C5(CH3)4(CH2)4CH2OH], 9.2 [s, C5(CH3)4(CH2)4CH2OH].  
ES MS (+): m/z 922.2 [M]
+
; 887.3 [M-Cl]
+
. 
7.8.8 Preparation of [Ru(CH3CN)(C10H15)(C25H22P2)][SbF6] (4.12) 
Dry methanol (80 ml) and dry acetonitrile (4 ml) were added to a mixture of 
complex 4.5 (0.15 g, 0.23 mmol) and NaSbF6 (0.6 g, 2.3 mmol) under nitrogen. The 
initial orange suspension changed to a light yellow solution, and this was stirred 
overnight. The solvent was evaporated and the residue treated with dichloromethane 
and filtered. The filtrate was concentrated and, after adding diethyl ether and placing 
the mixture in the freezer for some hours, the light yellow precipitate formed was 
filtered off, washed with diethyl ether and dried. 
Yield: 0.1597 g, 0.178 mmol (77%). 
Characterisation: 
Calculated for C37H40F6NP2RuSb (897.07 g mol
-1
): C 49.5; H 4.5; N 1.6% 
Found: C 49.6; H 4.6; N 1.5% 
1
H NMR (CD2Cl2, 300.13 MHz, 300.0 K) 
δ 7.49 [m, 16H, (C6H5)4P2CH2], 7.36 [m, 4H, (C6H5)4P2CH2], 5.13 [dt, 
2
J(H-H) = 16 
Hz, 
2
J(H-P) = 9.8 Hz, 1H, (C6H5)4P2CH2], 4.37 [dt, 
2
J(H-H) = 16 Hz, 
2
J(H-P) = 10.5 Hz, 
1H, (C6H5)4P2CH2], 1.64 [t, 
5
J(H-P) = 1.7 Hz, 3H, CH3CN], 1.59 [t, 
4
J(H-P) = 2.2 Hz 
15H, C5(CH3)5]; 
   Chapter 7 
216 
31
P{
1
H} NMR (CD2Cl2, 121.49 MHz, 300.0 K) δ 9.56 [s]; 
13
C{
1
H} NMR (CD2Cl2, 125.88 MHz,  300.0 K) 
δ 155.9 [s, CH3CN], 132.8 [m, (C6H5)4P2CH2], 131.9 [t, 
2,3
J(C-P) = 5.2 Hz, 
(C6H5)4P2CH2], 131.2 [d, 
1
J(C-P) = 32.7 Hz, (C6H5)4P2CH2], 129.3 [dt, 
2,3
J(C-P) = 18.7, 
5.2 Hz, (C6H5)4P2CH2], 92.0 [s, C5(CH3)5], 51.3 [s, (C6H5)4P2CH2], 10.2 [s, 
C5(CH3)5], 3.8 [s, CH3CN]. 
ES MS (+): m/z 662.2 [M-SbF6]
+
. 
7.9 Tetramethylfulvene Ruthenium(II) Complexes 
The compounds 4.13 and 4.14 were obtained from complex 4.3 and 
commercial diphenylacac (dibenzoylmethane) using different amounts of 
triethylamine in dichloromethane or toluene respectively. 
7.9.1 Preparation of [RuCl(C10H14)(C15H11O2)] (4.13) 
Complex 4.3 (0.2 g, 0.65 mmol) was dissolved in dry dichloromethane (50 
ml) and diphenylacac (0.15 g, 0.65 mmol) and triethylamine (0.18 ml, 1.3 mmol) 
were added. The mixture was stirred at room temperature overnight, the solvent 
evaporated and the brown residue treated with dichloromethane and diethyl ether. 
Triethylamine hydrochloride precipitated. The filtrate was evaporated and the 
residue washed with pentane and recrystallised in a mixture of dichloromethane and 
hexane at -20ºC. 
Yield: 0.142 g, 0.29 mmol (44%). 
Characterisation: 
Calculated for C25H25ClO2Ru (493.77 g mol
-1
): C 60.8; H 5.1; Cl 7.2% 
Found: C 60.3; H 5.2; Cl 6.7% 
1
H NMR (CDCl3, 300.13 MHz, 299.9 K) 
δ 7.96 [m, 5H, CH(COC6H5)2], 7.42 [m, 5H, CH(COC6H5)2], 6.62 [s, 1H, 
CH(COC6H5)2], 5.42 [s, 1H, C5(CH3)4CH2], 5.01 [s, 1H, C5(CH3)4CH2], 1.98 [s, 3H, 
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C5(CH3)4CH2], 1.78 [s, 3H, C5(CH3)4CH2], 1.70 [s, 3H, C5(CH3)4CH2], 1.54 [s, 3H, 
C5(CH3)4CH2]; 
13
C{
1
H} NMR (CDCl3, 125.88 MHz,  300.0 K) 
δ 181.8 [CH(COC6H5)2], 180.5 [CH(COC6H5)2], 139.5 [Quaternary C of 
CH(COC6H5)2], 139.0 [Quaternary C of CH(COC6H5)2], 130.9 [CH(COC6H5)2], 
130.8 [CH(COC6H5)2], 128.2 [CH(COC6H5)2], 128.1 [CH(COC6H5)2], 127.2 
[CH(COC6H5)2], 127.1 [CH(COC6H5)2], 103.0 [C5(CH3)4CH2], 101.5 
[C5(CH3)4CH2], 100.3 [C5(CH3)4CH2], 97.0 [C5(CH3)4CH2], 95.0 [C5(CH3)4CH2], 
93.8 [CH(COC6H5)2], 80.5 [C5(CH3)4CH2], 8.8 [C5(CH3)4CH2], 8.3 [C5(CH3)4CH2], 
8.2 [C5(CH3)4CH2], 7.6 [C5(CH3)4CH2]. 
ES MS (+): m/z 459.09 [M-Cl]
+
. 
7.9.2 Preparation of [RuCl3(C10H14)][Ru(C10H15)(C7H8)] (4.14) 
Complex 4.3 (0.15 g, 0.5 mmol) was dissolved in dry toluene (50 ml) and 
diphenylacac (0.11 g, 0.5 mmol) and triethylamine (70 μl, 0.5 mmol) were added. 
The mixture was stirred at reflux for two hours, filtered, the solvent evaporated and 
the orange residue treated with dichloromethane and diethyl ether, from where dark 
orange crystals formed at -20ºC. 
Characterisation: 
Calculated for C27H37Cl3Ru2 (669.93 g mol
-1
): C 48.4; H 5.6; Cl 15.9% 
Found: C 48.2; H 5.6; Cl 16.0% 
ES MS (+): m/z 329.1 [C17H23Ru]
+
. 
7.10 Dppf η6-p-Cymene Ruthenium Complexes 
Complex 5.1 was prepared and isolated by Mr. Joel Fonseca, former member 
of the McGowan group.
19 
7.10.1 Preparation of [RuCl(C10H14)(C34H28FeP2)][Cl] (5.1) 
A mixture of complex 3.1 (0.15 g, 0.25 mmol) and 1,1'-
bis(diphenylphosphino)ferrocene (0.28 g, 0.5 mmol) in  ethanol (8 ml) and benzene 
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(1 ml) was heated to 55°C for 50 minutes and then stirred overnight.  After 
evaporating the solvent, dichloromethane was used to dissolve the residue and 
diethyl ether added to precipitate a dark yellow solid. This was recrystallised from 
methanol/diethyl ether. 
Yield: 0.2295 g, 0.267 mmol (53%). 
Characterisation: 
Calculated for C44H42Cl2FeP2Ru (860.09 g mol
-1
): C 61.4; H 4.9; Cl 8.2% 
Found: C 58.8; H 5.0; Cl 8.2% 
1
H NMR (CDCl3, 500.23 MHz, 300.0 K) 
δ 7.73 [br. s, 6H, (C6H5)4P2Fe(C5H4)2], 7.61 [br. s, 8H, (C6H5)4P2Fe(C5H4)2], 7.46 
[br. s, 6H, (C6H5)4P2Fe(C5H4)2], 5.89 [br. s, 2H, CH3C(CH)2(CH)2CCH(CH3)2], 5.19 
[br. s, 2H, CH3C(CH)2(CH)2CCH(CH3)2], 5.07 [s, 2H, (C6H5)4P2Fe(C5H4)2], 4.36 [s, 
2H, (C6H5)4P2Fe(C5H4)2], 4.27 [s, 2H, (C6H5)4P2Fe(C5H4)2], 4.08 [s, 2H, 
(C6H5)4P2Fe(C5H4)2], 2.68 [m, 1H, CH3C(CH)2(CH)2CCH(CH3)2], 1.10 [s, 3H, 
CH3C(CH)2(CH)2CCH(CH3)2], 0.90 [d, 
3
JHH = 6.4 Hz, 6H, 
CH3C(CH)2(CH)2CCH(CH3)2]; 
31
P{
1
H} NMR (CDCl3, 121.49 MHz, 300.0 K) δ 36.44 [s]; 
13
C{
1
H} NMR (CDCl3, 125.88 MHz,  300.0 K) 
δ 183.3-128.6 [(C6H5)4P2Fe(C5H4)2], 99.4 [CH3C(CH)2(CH)2CCH(CH3)2], 96.9 
[CH3C(CH)2(CH)2CCH(CH3)2], 90.9 [Quaternary C of (C6H5)4P2Fe(C5H4)2], 83.9 
[CH3C(CH)2(CH)2CCH(CH3)2], 83.4 [CH3C(CH)2(CH)2CCH(CH3)2], 78.6 
[(C6H5)4P2Fe(C5H4)2], 74.7 [(C6H5)4P2Fe(C5H4)2], 73.7 [(C6H5)4P2Fe(C5H4)2], 69.1 
[(C6H5)4P2Fe(C5H4)2], 31.0 [CH3C(CH)2(CH)2CCH(CH3)2], 20.9 
[CH3C(CH)2(CH)2CCH(CH3)2], 15.8 [CH3C(CH)2(CH)2CCH(CH3)2].  
ES MS (+): m/z 825.1 [M-Cl]
+
. 
7.10.2 Preparation of [Ru2Cl4(C10H14)2(C34H28FeP2)] (5.2) 
Complex 3.1 (0.2 g, 0.33 mmol) and 1,1'-bis(diphenylphosphino)ferrocene 
(0.18 g, 0.33 mmol) were dissolved in dichloromethane (20 ml) and stirred overnight 
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at room temperature. After that, the solution was concentrated, diethyl ether added 
and a precipitate formed. The mixture was kept in the freezer for 1 hour and then the 
orange precipitate was filtered, washed with diethyl ether and dried under vacuum. 
Yield: 0.2866 g, 0.246 mmol (74%). 
Characterisation: 
Calculated for C54H56Cl4FeP2Ru2 (1166.18 g mol
-1
) + 
 
 
CH2Cl2 (42.46 g mol
-1
): C 
54.1; H 4.8; Cl 14.7% 
Found: C 54.0; H 4.8; Cl 14.5% 
1
H NMR (CDCl3, 300.13 MHz, 300.1 K) 
δ 7.74 [t, 3J(H-H) = 7.9 Hz, 8H, (C6H5)4P2Fe(C5H4)2], 7.38 [br. s, 12H, 
(C6H5)4P2Fe(C5H4)2], 5.07 [br. s, 8H, CH3(C6H4)CH(CH3)2], 4.17 [br. s, 4H, 
(C6H5)4P2Fe(C5H4)2], 3.89 [br. s, 4H, (C6H5)4P2Fe(C5H4)2], 2.51 [m, 2H, 
CH3(C6H4)CH(CH3)2], 1.71 [s, 6H, CH3(C6H4)CH(CH3)2], 0.97 [d, 
3
J(H-H) = 6.6 Hz, 
12H, CH3(C6H4)CH(CH3)2]; 
31
P{
1
H} NMR (CDCl3, 121.49 MHz, 299.8 K) δ 18.19 [s]. 
13
C{
1
H} NMR (CDCl3, 125.88 MHz,  300.0 K) 
δ 136.3 [(C6H5)4P2Fe(C5H4)2], 136.0 [(C6H5)4P2Fe(C5H4)2], 134.0 
[(C6H5)4P2Fe(C5H4)2], 130.0 [(C6H5)4P2Fe(C5H4)2], 127.5 [(C6H5)4P2Fe(C5H4)2], 
109.6 [CH3C(CH)2(CH)2CCH(CH3)2], 95.3 [CH3C(CH)2(CH)2CCH(CH3)2], 90.0 
[CH3C(CH)2(CH)2CCH(CH3)2], 85.9 [CH3C(CH)2(CH)2CCH(CH3)2], 75.7 
[(C6H5)4P2Fe(C5H4)2], 74.3 [(C6H5)4P2Fe(C5H4)2], 29.9 [CH3C(C4H4)CCH(CH3)2], 
21.8 [CH3C(C4H4)CCH(CH3)2], 17.0 [CH3C(C4H4)CCH(CH3)2].  
ES MS (+): m/z 1131.0 [M-Cl]
+
; 1191 [M+Na]
+
. 
7.11 Experimental Procedures for Homogeneous Catalysis 
The procedures presented below are only general, and some variations may 
have been reported in Chapter 5. 
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7.11.1 Redox Neutral Alkylation of tert-Butylamine with Phenethyl Alcohol 
Phenethyl alcohol (0.36 ml, 3 mmol) and toluene (10 ml) were added to a 
mixture of the corresponding ruthenium species (if used, 5 mol% Ru) and dppf (if 
used, 5 mol%) in a 25 ml round bottom flask with a suba-seal at the side-neck. The 
mixture was stirred at reflux for 10 minutes. After this time, tert-butylamine (0.32 
ml, 3 mmol) was added and the first sample of 20 μl was taken with a micro syringe 
through the suba-seal, dissolved in 2 ml of acetonitrile and kept in the freezer. 
Samples were taken at 0, 20, 40, 60, 90, 120, 180, 300, 540 and 1440 min, thus 
maintaining the reflux for 24 hours.  
All of the samples were analysed by gas chromatography. Injection volume = 
1μl. The oven temperature ramped from 60ºC (hold for 3 minutes) to 280ºC (hold for 
3 minutes) at 20ºC/min. Inlet pressure = 4.3 psi. The retention time for phenethyl 
alcohol is approximately 7.0 minutes, and the retention time for N-phenethyl-tert-
butylamine is 8.8 minutes. 
The solvent was evaporated from the final reaction mixture after 24 hours 
and the residue analysed by 
1
H NMR: 
1
H NMR of phenethyl alcohol (CDCl3, 500.23 MHz, 300.0 K) 
δ 7.36-7.17 [m, 5H, C6H5(CH2)2OH], 3.85 [t, 
3
J(H-H) = 6.6 Hz, 2H, C6H5(CH2)2OH], 
2.87 [t, 
3
J(H-H) = 6.8 Hz, 2H, C6H5(CH2)2OH]. 
1
H NMR of N-phenethyl-tert-butylamine (CDCl3, 500.23 MHz, 300.0 K) 
δ 7.36-7.17 [m, 5H, C6H5(CH2)2NHC(CH3)3], 2.80 [m, 4H, C6H5(CH2)2NHC(CH3)3], 
1.07 [s, 9H, C6H5(CH2)2NHC(CH3)3]. 
7.11.2 Benzaldehyde Reduction 
Isopropanol (10 ml) was added to a mixture of the corresponding ruthenium 
species (if used, 5 mol% Ru) and the ligand (dppf or (R,R)-TsDPEN, if used, 5 
mol%) in a 25 ml round bottom flask with a suba-seal at the side-neck. 
Triethylamine (5 μl, 0.08 mmol, 8 mol%) was added next and the mixture was 
stirred at reflux for half an hour. After this time, benzaldehyde (0.1 ml, 1 mmol) was 
added and the first sample of 20 μl was taken with a micro syringe through the suba-
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seal, dissolved in 2 ml of acetonitrile and kept in the freezer. Samples were taken at 
0, 20, 40, 60, 90, 120, 180, 300, 540 and 1440 min, thus maintaining the reflux for 
24 hours.  
All of the samples were analysed by gas chromatography. Injection volume = 
1 μl. The oven temperature ramped from 60ºC (hold for 3 minutes) to 200ºC (hold 
for 3 minutes) at 20ºC/min. Inlet pressure = 4.3 psi. The retention time for 
benzaldehyde is 5.2 minutes and the retention time for benzylalcohol is 
approximately 6.2 minutes. 
The solvent was evaporated from the final reaction mixture after 24 hours 
and the residue analysed by 
1
H NMR: 
1
H NMR of benzaldehyde (CDCl3, 300.13 MHz, 294.4 K) 
δ 9.88 [s, 1H, C6H5COH], 7.77 [d, 
3
J(H-H) = 7.0 Hz, 2H, C6H5COH], 7.53 [t, 
3
J(H-H) = 
7.4 Hz, 1H, C6H5COH], 7.44 [d, 
3
J(H-H) = 7.6 Hz, 2H, C6H5COH]. 
1
H NMR of benzyl alcohol (CDCl3, 300.13 MHz, 294.4 K) 
δ 7.25-7.23 [m, 5H, C6H5CH2OH], 4.54 [s, 2H, C6H5CH2OH], 2.91 [br. s, 1H, 
C6H5CH2OH]. 
7.12 Cp* Ruthenium Aqua Complex 
7.12.1 Preparation of [Ru(H2O)(C10H15)(C25H22P2)][X] (6.1) 
Compound 6.1 formed slowly inside NMR tubes from either complex 4.5 (X 
= Cl) or complex 4.12 (X = SbF6) in solutions of 90% deuterated dimethylsulfoxide 
and 10% deuterium oxide, giving very light yellow solutions after 100% conversion. 
Characterisation: 
1
H NMR ((CD3)2SO, 500.57 MHz, 300.0 K) 
δ 7.60 [q, 3J(H-H) = 5.8 Hz, 4H, (C6H5)4P2CH2], 7.51 [m, 8H, (C6H5)4P2CH2], 7.40 [t, 
3
J(H-H) = 7.5 Hz, 4H, (C6H5)4P2CH2], 7.30 [m, 4H, (C6H5)4P2CH2], 5.14 [m, 2H, 
(C6H5)4P2CH2], 1.61 [s, 15H, C5(CH3)5]; 
31
P{
1
H} NMR ((CD3)2SO, 121.49 MHz, 300.0 K) δ 5.07 [s]; 
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13
C{
1
H} NMR ((CD3)2SO, 125.88 MHz,  300.0 K) 
δ 134.6 [m, (C6H5)4P2CH2], 132.3 [m, (C6H5)4P2CH2], 131.7 [t, 
2,3
J(C-P) = 4.9 Hz, 
(C6H5)4P2CH2], 130.8 [t, 
2,3
J(C-P) = 5.2 Hz, (C6H5)4P2CH2], 130.7 [s, (C6H5)4P2CH2], 
130.5 [s, (C6H5)4P2CH2], 128.9 [t, 
2,3
J(C-P) = 4.7 Hz, (C6H5)4P2CH2], 128.5 [t, 
2,3
J(C-P) 
= 4.7 Hz, (C6H5)4P2CH2], 94.5 [s, C5(CH3)5], 44.5 [s, (C6H5)4P2CH2], 10.3 [s, 
C5(CH3)5]. 
ES MS (+): m/z 621.1 [M-H2O]
+
. 
7.13 Experimental Procedure for Cell Line Assessments 
The in vitro studies were performed at the Institute of Cancer Therapeutics, 
Bradford, on the cell lines A2780 (human ovarian carcinoma) and HT29 (human 
colon carcinoma) by Miss Aida Basri and Miss Rianne Lord respectively. Cells were 
incubated in 96-well plates at a cell concentration of 2.0 x 10
4 
cells/mL.  Complete 
cell media containing RPMI-1640, supplemented with 10% foetal calf serum, 
sodium pyruvate (1 mM) and L-glutamine (2 mM), was used to prepare the desired 
cell concentration and reference wells. Plates containing cells were incubated for 24 
hours at 37 °C in an atmosphere of 5% CO2, prior to drug exposure. All compounds 
were dissolved in dimethylsulfoxide to give an initial concentration of 25 mM and 
diluted further with cell media to obtain concentrations ranging from 250-0.49 M. 
A final dimethylsulfoxide concentration of 0.1% (v/v) was obtained, which is non-
toxic to cells. 100 L of cell media was added to the reference cells and 100 L of 
differing concentrations of drug solution were added to the remaining wells. The 
plates were incubated for a further 5 days at 37 °C in an atmosphere of 5% CO2. 20 
L of 3-(4,5-dimethylthiazol-1-yl)-2,5-diphenyltetrazolium bromide (MTT) solution 
(5 mg/mL) was added to each well and incubated for a further 3 hours at 37 °C in an 
atmosphere of 5% CO2. Upon completion all solutions were removed from the wells 
via pipette, and 150 L of dimethylsulfoxide was added to each well to dissolve the 
purple formazan crystals. A Thermo Scientific Multiskan EX microplate photometer 
was used to measure the absorbance at 540 nm. Lanes containing 100% cell media 
and 100% cell solution were used as a blank and 100% cell survival respectively. 
Cell survival was determined as the absorbance of treated cells minus the blank cell 
media, divided by the absorbance of the 100% cell solution; this value was expressed 
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as a percentage. The IC50 values were determined from a plot of percentage cell 
survival against drug concentration (M), and each experiment was carried out three 
times to obtain average IC50 values. 
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Appendix: Summary of Crystallographic Data 
Compound 2.9    
Crystal system Monoclinic   
Space group P21/c   
Cell dimensions 
a = 7.6638(9) Å  = 90°  
b = 23.150(3) Å  = 90.124(5)° V = 1306.0(3) Å
3
 
c = 7.3612(8) Å  = 90°  
Z 2   
Goodness of fit 0.936   
 
Compound 2.10    
Crystal system Triclinic   
Space group P1   
Cell dimensions 
a = 8.7685(12) Å  = 118.520(7)°  
b = 10.2415(15) Å  = 95.204(7)° V = 799.0(2) Å
3
 
c = 10.5473(15) Å  = 100.907(6)°  
Z 1   
Goodness of fit 1.125   
 
Compound 3.3    
Crystal system Monoclinic   
Space group P21/c   
Cell dimensions 
a = 10.1336(8) Å  = 90°  
b = 18.1925(18) Å  = 93.819(4)° V = 2134.3(3) Å
3
 
c = 11.6027(11) Å  = 90°  
Z 4   
Goodness of fit 1.037   
 
Compound 3.4    
Crystal system Monoclinic   
Space group P21/c   
Cell dimensions 
a = 10.0953(15) Å  = 90°  
b = 7.9950(11) Å  = 103.501(6)° V = 1599.3(4) Å
3
 
c = 20.377(3) Å  = 90°  
Z 4   
Goodness of fit 1.308   
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Compound 3.7    
Crystal system Monoclinic   
Space group P21/c   
Cell dimensions 
a = 7.8704(9) Å  = 90°  
b = 12.8864(16) Å  = 103.467(5)° V = 1564.7(3) Å
3
 
c = 15.864(2) Å  = 90°  
Z 4   
Goodness of fit 1.32   
 
Compound 3.8    
Crystal system Monoclinic   
Space group P21/c   
Cell dimensions 
a = 9.9656(5) Å  = 90°  
b = 7.9319(3) Å  = 103.628(2)° V = 1542.77(12) Å
3
 
c = 20.0828(9) Å  = 90°  
Z 4   
Goodness of fit 1.084   
 
Compound 3.10    
Crystal system Monoclinic   
Space group P21/c   
Cell dimensions 
a = 15.2457(5) Å  = 90°  
b = 14.8885(5) Å  = 92.3380(10)° V = 1666.05(9) Å
3 
c = 7.3460(2) Å  = 90°  
Z 4   
Goodness of fit 1.25   
 
Compound 3.12    
Crystal system Monoclinic   
Space group P21/n   
Cell dimensions 
a = 15.0133(5) Å  = 90°  
b = 7.7940(2) Å  = 92.9020(10)° V = 1775.98(9) Å
3
 
c = 15.1970(5) Å  = 90°  
Z 4   
Goodness of fit 1.15   
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Compound 3.14    
Crystal system Orthorhombic   
Space group Pbca   
Cell dimensions 
a = 12.1237(10) Å  = 90°  
b = 17.3704(15) Å  = 90° V = 4870.2(7) Å
3
 
c = 23.126(2) Å  = 90°  
Z 8   
Goodness of fit 1.02   
 
Compound 4.12    
Crystal system Triclinic   
Space group P1   
Cell dimensions 
a = 10.8236(19) Å  = 91.890(8)°  
b = 11.4240(19) Å  = 99.060(8)° V = 1841.5(5) Å
3
 
c = 15.162(3) Å  = 95.244(8)°  
Z 2   
Goodness of fit 1.06   
 
Compound 4.13    
Crystal system Orthorhombic   
Space group P212121   
Cell dimensions 
a = 7.5069(15) Å  = 90°  
b = 11.360(2) Å  = 90° V = 2194.7(7) Å
3
 
c = 25.736(5) Å  = 90°  
Z 4   
Goodness of fit 1.078   
 
Compound 4.14    
Crystal system Monoclinic   
Space group P21/c   
Cell dimensions 
a = 8.7750(14) Å  = 90°  
b = 24.948(4) Å  = 124.722(7)° V = 2645.6(7) Å
3
 
c = 14.7032(18) Å  = 90°  
Z 4   
Goodness of fit 1.019   
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Compound 5.2    
Crystal system Triclinic   
Space group P1   
Cell dimensions 
a = 9.6847(11) Å  = 76.893(5)°  
b = 11.8387(13) Å  = 88.748(5)° V = 1290.5(3) Å
3
 
c = 12.4139(15) Å  = 68.900(5)°  
Z 2   
Goodness of fit 1.072   
 
 
